Global Clinical Development -General Medicine
QAW039 / [STUDY_ID_REMOVED]
Clinical Trial Protocol CQAW039A23 14
A 52-week, multicenter, randomized, double -blind, placebo -
controlled study to assess the
 efficac y and safety of 
QAW039 w hen added to existing asthma therapy in 
patients w ith uncontrolled severe ast hma
Authors:
Document type: Amended Protocol Version 
EUDRACT number: 2015 003172 67
Version number: v03Clean
Development phase: III
Release date: 10-Feb-2017
Property of Novartis
Confidential
May not be used, divulged, published, or otherwise disclosed 
without the consent of Novartis
Clinical Trial Protocol Template Version 2.0, November, 2013

Novartis Confidential Page 2
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Table of contents
Table of contents ................................................................................................................. 2
List of tables ........................................................................................................................ 5
List of figures ...................................................................................................................... 6
List of abbreviations ............................................................................................................ 7
Glossary  of terms ................................................................................................................. 9
10
11
11
14
Protocol summary .............................................................................................................. 15
1Introduction ....................................................................................................................... 21
1.1 Background ............................................................................................................ 21
1.2 Purpose .................................................................................................................. 22
2Study  objectives ................................................................................................................. 22
2.1 Primary  objective(s) ............................................................................................... 22
2.2 Secondary  objectives ............................................................................................. 22
23
3Investigational plan ........................................................................................................... 24
3.1 Study  design ........................................................................................................... 24
3.2 Rationale of study  design ....................................................................................... 26
3.3 Rationale of dose/regimen, route of administration and duration of treatment..... 27
3.4 Rationale for choice of comparator ....................................................................... 28
3.5 Purpose and timing of interim anal yses/design adaptations .................................. 28
3.6 Risks and benefits .................................................................................................. 28
4Population .......................................................................................................................... 32
4.1 Inclusion criteria .................................................................................................... 32
4.2 Exclusion criteria ................................................................................................... 34
5Treatment ........................................................................................................................... 37
5.1 Protocol requested treatment ................................................................................. 37
5.1.1 Investigational treatment ....................................................................... 37
5.1.2 Additional study  treatment .................................................................... 38
5.2 Treatment arms ...................................................................................................... 38
5.3 Treatment assignment, randomization ................................................................... 38
5.4 Treatment blinding ................................................................................................. 39
5.5 Treating the patient ................................................................................................ 39
5.5.1 Patient numbering ................................................................................. 39

Novartis Confidential Page 3
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
5.5.2 Dispensing the investigational treatment .............................................. 39
5.5.3 Handling of study  treatment .................................................................. 40
5.5.4 Instructions for prescribing and taking stud y treatment ........................ 40
5.5.5 Permitted dose adjustments and interruptions of study  treatment ........ 41
5.5.6 Rescue medication ................................................................................ 41
5.5.7 Background therap y .............................................................................. 42
5.5.8 Concomitant treatment .......................................................................... 42
5.5.9 Prohibited Treatment ............................................................................. 44
5.5.10 Discontinuation of study  treatment ....................................................... 44
5.5.11 Discontinuation from study ................................................................... 46
5.5.12 Withdrawal of consent .......................................................................... 46
5.5.13 Lost to follow -up................................................................................... 46
5.5.14 Emergency  breaking of assigned treatment code .................................. 46
5.5.15 Study  completion and post -study  treatment .......................................... 47
5.5.16 Early study termination ......................................................................... 47
6 Visit schedule and assessments ......................................................................................... 47
6.1 Information to be collected on screening failures and run- in failures ................... 59
6.2 Patient demogra phics/other baseline characteristics ............................................. 59
6.3 Treatment exposure and compliance ..................................................................... 60
6.4 Efficacy .................................................................................................................. 60
6.4.1 Asthma exacerbations ........................................................................... 60
6.4.2 Asthma Control Questionnaire (ACQ -5) .............................................. 60
6.4.3 Asthma Quality  of Life Questionnaire for 12 y ears and older 
(AQLQ+12) ........................................................................................... 61
62
63
63
64
6.4.8 Spirometry  (FEV1 ) ................................................................ 65
6.4.9 Appropriateness of efficacy  assessments .............................................. 65
6.5 Safety ..................................................................................................................... 65
6.5.1 Physical examination ............................................................................ 66
6.5.2 Vital signs .............................................................................................. 66
6.5.3 Height and weight ................................................................................. 67
6.5.4 Laboratory  evaluations .......................................................................... 67
6.5.5 Electrocardiogram (ECG) ..................................................................... 68
6.5.6 Pregnancy  and assessments of fertility ................................................. 68

Novartis Confidential Page 4
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
6.5.7 Appropriateness of safety  measurements .............................................. 69
6.6 Other assessments .................................................................................................. 69
69
69
70
6.6.4 Airway s hyper-reactivity test ................................................................ 70
7Safety  monitoring .............................................................................................................. 70
7.1 Adverse events ....................................................................................................... 70
7.2 Serious adverse events ........................................................................................... 72
7.2.1 Definition of SAE ................................................................................. 72
7.2.2 SAE reporting ........................................................................................ 73
7.3 Liver safety  monitoring ......................................................................................... 74
7.4 Renal safet y monitoring ......................................................................................... 75
7.5 Idios yncratic drug reactions monitoring ................................................................ 76
7.6 Pregnancy  reporting ............................................................................................... 76
8Data review and database management ............................................................................. 76
8.1 Site monitoring ...................................................................................................... 76
8.2 Database management and quality  control ............................................................ 77
8.3 Data Monitoring Committee .................................................................................. 78
8.4 Data collection....................................................................................................... 79
8.5 Adjudication Committee ........................................................................................ 79
9Data analy sis...................................................................................................................... 79
9.1 Analy sis sets .......................................................................................................... 79
9.2 Patient demographics and other baseline characteristics....................................... 80
9.3 Treatments ............................................................................................................. 80
9.4 Analy sis of the primary  variable(s) ....................................................................... 80
9.4.1 Variable(s) ............................................................................................. 80
9.4.2 Statistical model, hy pothesis, and method of anal ysis.......................... 81
9.4.3 Handling of missing values/censoring/discontinuations ....................... 83
9.4.4 Supportive analy ses............................................................................... 84
9.5 Analy sis of secondary  variables ............................................................................ 85
9.5.1 Efficacy  variables.................................................................................. 85
9.5.2 Safety variables ..................................................................................... 88
90
90
90
90

Novartis Confidential Page 5
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
9.6 Interim anal yses..................................................................................................... 90
9.7 Sample size calculation.......................................................................................... 90
10Ethical considerations ........................................................................................................ 93
10.1 Regulatory and ethical compliance ........................................................................ 93
10.2 Informed consent procedures................................................................................. 93
10.3 Responsibilities of the investigator and IRB/ IEC.................................................. 94
10.4 Publication of study  protocol and results ............................................................... 94
10.5 Quality  Control and Quality .................................................................................. 94
11Protoc ol adherence ............................................................................................................ 95
11.1 Protocol Amendments ........................................................................................... 95
12References ......................................................................................................................... 95
13Appendix 1: Clinically  notable laboratory  values and vital signs ..................................... 98
14Appendix 2: L iver event and Laboratory  trigger Definitions and Follow-up 
Requirements ..................................................................................................................... 99
15Appendix 3: L ist of IDRs for investigators ..................................................................... 102
16Appendix 4: Blood collection logs .................................................................................. 103
17Appendix 5: Spirometry  Guidance .................................................................................. 105
17.1 References for appendix ...................................................................................... 107
108
19Appendix 7: Estimated Equivalence of Inhaled Corticosteroids ..................................... 109
20Appendix 8: Asthma Control Questionnaire ................................................................... 110
21Appendix 9: Asthma Quality  of Life Questionnaire for 12 years and older 
(AQLQ+12) ..................................................................................................................... 112
118
119
List of tables
Table 5 -1 Medications allowed under certain conditions ...................................... 42
Table 5 -2 Medications to be withheld prior to spirometry .................................... 43
Table 5 -3 Prohibited medications.......................................................................... 44
Table 6 -1 Assessment schedule ............................................................................. 50
Table 7 -1 Specific Renal Alert Criteria and Actions ............................................. 75
Table 9 -1 Power for the primary  variable ............................................................. 92
Table 9 -2 Power of each dose for the anal yses of key  secondary  variables.......... 93
Table 14 -1 Liver Event and Laboratory  Trigger Definitions .................................. 99
Table 14 -2 Follow Up Requirements for L iver Events and Laboratory  Triggers ...99
Table 15 -1 Definition of potential idiosy ncratic drug reactions ............................ 102

Novartis Confidential Page 6
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Table 16 -1 Time schedule for blood sampling for safet y, Total IgE and 
RAST/I mmunoCAP test ...................................................................... 103
 
104
List of figures
Figure 3 -1 Study  design .......................................................................................... 25
Figure 9 -1 Closed testing procedure for primary  and key  secondary  objectives ....82

Novartis Confidential Page 7
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
List of ab breviations
Abbreviation: Explanation:
ACQ Asthma Control Questionnaire
AE(s) Adverse Event(s)
AHR Airway H yper-reactivity Test
ALT Alanine aminotransferase
ANCOVA Analysis of covariance
AQLQ+12 Asthma Quality of Life Questionnaire for 12 years and above
AST Aspartate aminotransferase
ATS/ERS American Thoracic Society/European Respiratory Society
AUC Area under the plasma concentration -time curve. The time interval may 
be specified e.g. AUC infmeans the interval 0 to infinity. 
b.i.d. Twice a day
BMI Body Mass Index
CFR United States Code of Federal Regulations 
CK Creatine kinase
CPO Countr y Pharma Organization
CRO Contract Research Organization
CRF Case Report/Record Form (paper or electronic)
CRTh2 Chemoattractant receptor -homologous molecule expressed on Th2
DK-PGD2 13,14- dihydro- 15-ketoprostaglandin D2
DP Prostaglandin D2 receptor
DMC Data Monitoring Committee
DS&E Drug Safety & Epidemiology
ECG Electrocardiography
EDC Electronic Data Capture
eGFR Estimated Glomerular Filtration Rate
FCT Film-coated tablet
FDA Food and Drug Administration
FEV 1 Forced Expirator y Volume in 1 second
GCP Good Clinical Practice
GINA Global Initiative for Asthma
HbA1c Hemoglobin A1c; Gly cosylated Hemoglobin
hCG Human Chorionic Gonadotropin
ICH International Conference on Harmonization of Technical Requirements 
for Registration of Pharmaceuticals for Huma n Use
ICS Inhaled Corticosteroid
IDR Idios yncratic Drug Reactions
IEC Independent Ethics Committee
IgE Immunoglobulin E
IL Interleukin

Novartis Confidential Page 8
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Abbreviation: Explanation:
ImmunoCAPRSpecific IgE test
IN Investigator Notification
IRB Institutional Review Board
IRT Interactive Response Technology
LABA Long -acting Beta -agonist
LAMA Long -acting muscarinic a ntagonist
LC-MS/MS Liquid chromatography –mass spectrometry /mass spectrometry
LFT Liver Function Test
LLOQ Lower Limit of Quantification
LTRA Leukotriene Receptor Antagonist
MedDRA Medical Dictionar y for Regulatory Activities
MDRD Modification of Diet in Renal Disease Study
MID Minimally Important Difference
MMRM Mixed Model Repeated Measures
NYHA New York Heart Association
OC/RDC Oracle Clinical/Remote Data Capture
OCS Oral corticosteroids
PGD2 Prostaglandin D2
PK Pharmacokinetic
PoC Proof of Concept
PRO Patient Reported Outcome
p.o. Oral(ly)
q.d. Quaque die /once a day
QOL Quality of life
QTcF Fridericia QT correction formula
RAST Radioallergosorbent Test
SABA Short -acting Beta -agonist
SAE(s) Serious Adverse Event(s)
SD Standard Deviation
SoC Standard of care
SUSAR Suspected Unexpected Serious Adverse Reactions
TD Treatment Discontinuation
Th2 T helper type 2 cells
UGT Uridinediphosphate glucuronosyltransferase
ULN Upper Limit of Normal

Novartis Confidential Page 9
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Glossary  of terms
Assessment A procedure used to generate data required by the study
Cohort A group of newly enrolled patients treated at a specific dose and 
regimen (i.e. treatment group) at the same time
Control drug Any drug (an active drug or an inactive drug, such as a placebo) 
which is used as a comparator to the drug being tested in the trial
Dose level The dose of drug given to the patient (total daily or weekly  etc.)
Enrollment Point/time of patient entry into the study at which informed 
consent must be obtained (i.e. prior to starting any of the 
procedures described in the protocol)
Epoch A portion of the study which serves a specific purpose. T ypical 
Epochs are: screening/recruitment, wash -out, treatment, and 
follow -up
Investigational drug The drug whose properties are being tested in the study; this 
definition is consistent with US CFR 21 Section 312.3 and is 
synony mous w ith “investigational new drug” or “investigational 
medicinal product.”
Investigational treatment All investigational drug(s) whose properties are being tested in the 
study as well as their associated treatment controls. 
This includes any placebos, any active controls, as well as 
approved drugs used outside of their indication/approved dosage 
or tested in a fixed combination. 
Investigational treatment generally does not include protocol -
specified concomitant background therapies  when these are 
standard treatments in that indication
Medication number A unique identifier on the label of each investigational/study drug 
package in studies that dispense medication using an IRT sy stem
Protocol A written account of all the procedures to be followed in a trial, 
which describes all the administrative, documentation, analytical 
and clinical processes used in the trial.
Premature subject/patient 
withdrawalPoint/time when the patient exits from the study prior to the 
planned completion of all study  treatment administration and/or 
assessments; at this time all study treatment administration is 
discontinued and no further assessments are planned, unless the 
patient will be followed for progression and/or survival
Randomization number A unique id entifier assigned to each randomized patient, 
corresponding to a specific treatment arm assignment
Study drug/ treatment Any single drug or combination of drugs administered to the 
patient as part of the required study procedures; includes 
investigational drug (s), active drug run -ins or background therapy 
Study/investigational 
treatment discontinuationPoint/time when patient permanently stops taking 
study/investigational treatment  for any reason; may or may not 
also be the point/time of premature patient withdrawal
Subject Number A num ber assigned to each patient who enrolls into the study 
Variable A measured value or assessed response that is determined in 
specific assessments and used in data analysis to evaluate the 
drug being tested in the study

Novartis Confidential Page 10
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14

Novartis Confidential Page 11
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14

Novartis Confidential Page 12
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14

Novartis Confidential Page 13
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14

Novartis Confidential Page 14
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14

Novartis Confidential Page 15
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Protocol summary
Protocol number CQA W039A2307
Title A 52-week, multicenter, randomized, double -blind, placebo -controlled 
study to assess the efficacy and safety of QAW 039 when added to 
existing asthma therapy in patients with uncontrolled severe asthma .
Brief title Study of efficacy and safety of QA W039 in m ale and female patients ( ≥12 
years) with severe asthma inadequately controlled with standard of care 
asthma treatment.
Sponsor and Clinical 
PhaseNovartis, Phase III.
Investigation type Drug .
Study type Interventional .
Purpose and rationale The overall purpose of this study  is to determine the efficacy  and safety 
of QAW039 (150 mg and 450 mg once daily), compared with placebo, 
when added to GINA steps 4 and 5 standard -of-care (SoC) asthma 
therapy (GINA 2016 ), in patients with inadequately controlled severe 
asthma and high eosinophil counts (eosinophil count at Visit 1 
≥250cells/µl).  Inadequate control isdefined as partly controlled or 
uncontrolled asthma ( GINA 2016 ).
The study will also determine the efficacy and safety of QA W039 (150 mg 
and 450 mg once daily), compared with placebo, in the overall study  
populati on.
The rationale for this approach is to determine whether QA W039 reduces 
the rate of moderate -to-severe asthma exacerbations in the subset of 
patients with severe asthma and high eosinophil counts (≥250 cells/ µ
l) as 
well as in the overall study population regardless of eosinophil counts. 
Primary Objectives In patients with severe asthma and high eosinophil counts ( ≥250 cells/µl) 
receiving SoC asthma therapy, to demonstrate the efficacy (as measured 
by rate of moderate -to-severe asthma exacerbations) of at least one dose 
level of QA W039 (150 mg or 450 mg once daily), compared with placebo, 
at the end of the 52- week active -treatment epoch.
In patients with severe asthma receiving SoC asthma therapy, to 
demonstrate the efficacy  (as measured by rate of moderate -to-severe 
asthma exacerbations) of at least one dose level of QAW 039 (150 m g or 
450 mg once daily), compared with placebo, at the end of the 52-week 
active- treatment epoch.
Secondary Objectives In patients with severe asthma and high eosinophil counts ( ≥250 cells/µl) 
receiving SoC asthma therapy:
To demon strate the efficacy of at least one dose level of QA W039 
(150 mg or 450 mg once daily), compared with placebo, with respect 
to change from baseline in Asthma Quality of Life Questionnaire 
(AQLQ+12) scores at the end of the 52-week active -treatment epoch.
To demonstrate the efficacy of at least one dose level of QA W039 
(150 mg or 450 mg once daily), compared with placebo, with respect 
to change from baseline in Asthma Control Questionnaire -5 (ACQ -5) 

Novartis Confidential Page 16
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
score at the end of the 52-week active -treatment epoch.
To demonstrate the efficacy of at least one dose level of QA W039 
(150 mg or 450 mg once daily), compared with placebo, with respect 
to change from baseline in pre -dose FEV1 at the end of the 52-week 
active- treatment epoch.
To assess the safety  of QAW 039 (150 mg and 450 mg once daily), 
compared with placebo, with respect to adverse events, 
electrocardiograms (ECGs), vitals sign, laboratory tests and 
hypersensitivity reactions.
In all patients with severe asthma receiving SoC asthma therapy:
To demonstrate the e fficacy of at least one dose level of QA W039 
(150 mg or 450 mg once daily), compared with placebo, with respect 
to change from baseline in Asthma Quality of Life Questionnaire 
(AQLQ+12) scores at the end of the 52-week active -treatment epoch.
To demonstrat e the efficacy of at least one dose level of QA W039 
(150 mg or 450 mg once daily), compared with placebo, with respect 
to change from baseline in Asthma Control Questionnaire -5 (ACQ -5) 
score at the end of the 52-week active -treatment epoch.
To demonstrate the efficacy of at least one dose level of QA W039 
(150 mg or 450 mg once daily), compared with placebo, with respect 
to change from baseline in pre -dose FEV1 at the end of the 52-week 
active- treatment epoch.
To assess the safety  of QAW 039 (1 50 mg and 450 mg once daily), 
compared with placebo, with respect to adverse events, 
electrocardiograms (ECGs), vitals sign, laboratory tests and 
hypersensitivity reactions.
Study design This study uses a randomized, multicenter, double -blind, placebo -
controlled parallel -group study design in which QAW 039 or placebo is 
added to GINA steps 4 and 5 asthma therapy .
The study will include: 
a Screening epoch of up to 2 weeks to assess eligibility; 
a Run -in epoch of approximately 2 weeks and a maxim um of 6 
weeks to collect baseline data for efficacy  variables and compliance 
with the Electronic Peak Flow/ eDiar y device (if a patient experiences 
an asthma exacerbation during the run -in epoch, the run -in epoch 
must be extended to 6 weeks to permit for r esolution of the asthma 
exacerbation before randomization.  The run -in epoch should only be 
extended beyond 2 weeks (+/ -5 day s) for an asthma exacerbation.);
a Treatment epoch of 52 weeks; 
a Follow -up epoch of 4 weeks, investigational and drug -free, 
following the last dose of study drug.
Population The study population will include approximately 846males and females 
aged ≥12 years with inadequately controlled severe asthma (partly 
controlled or uncontrolled asthma on treatment at GINA steps 4 and 5).
Approximately 15% of the patients will be adolescents (aged ≥12 to <18 
years).
Approximately two thirds of random ized patients will have a blood 
eosinophil count ≥ 250 cells/µl and one third a blood eosinophil count < 
250 cells/µl.
Inclusion criteriaWritten informed consent and assent (if applicable) must be obtained 
within 14 days prior to or at Visit 1 before any assessment is 

Novartis Confidential Page 17
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
performed including any adjustment to asthma medication.
Male and female patients aged ≥12 y ears (or ≥ lower age limit 
allow ed by  health authority and/or ethics committee/institutional 
review board approvals).   
Patients must have a diagnosis of asthma (according to GINA 2016) 
for a period of at least 24 months prior to Visit 1.
Patients have been treated with:
Medium or h igh-dose inhaled corticosteroids (ICS) plus long -
acting beta agonist (LABA), or 
Medium or h igh-dose ICSplus leukotriene receptor antagonist 
(LTRA), or
Medium or h igh-dose ICSplus theophylline, or
Medium or h igh-dose ICSplus Long -acting muscarinic 
antagonist (LAMA) , or
Medium or high-dose ICSplus LABA plus LAMA , or
Medium or h igh-dose ICS plus LABA plus LTRA , or
Medium or high -dose ICS plus LABA plus theophylline,
withor without maintenance oral corticosteroids for at least 3 months 
prior to Visit 1. The doses must have been stable for at least 4 
weeks prior to Visit 1. 
See GINA 2016 for the definition of medium  and high-dose 
ICS (Appendix 7contains the estimated equivalence of 
inhaled corticosteroids per GINA 2016 ).
For patients aged ≥18 y ears, FEV1 of 
≤80% of the predicted normal 
value for the patient, after withholding bronchodilators at Visit 1 and 
Visit 101.
For patients aged 12 to <18 years, FEV1 of ≤90% of the predicted 
normal value for the patient, after withholding bronchodilators at Visit 
1 and Visit 101.
Demonstration of inadequate control of asthma based on an ACQ 
score ≥1.5 at Visit 1.
A history of 2 or more asthma exacerbations within the 12 months 
prior to Visit 1 that required either:
Treatment with s ystemic corticosteroids (tablets, suspension or 
injection) 
OR
Hospitalization (defined as an inpatient stay or >24 -hour stay in 
an observation area in the emergency  room of other equivalent 
facility.
A clinical diagnosis of asthma supported by at least one of the 
following: 
An increase of ≥12% and ≥200 ml in FEV 1approximately 10 to 
15 minutes after administration of 400 mcg of 
salbutamol/albuterol (or equivalent dose) prior to randomization.   
Spacer devices are not permitted during reversibility testing.  All 
patients must perform a reversibility test at Visit 1.  If reversibility 
is not demonstrated at Visit 1*, the following historical 
information may  be used:
Documented evidence of reversibility that was performed 
according to ATS/ERS guidelines ( ATS/ERS 2005 ) with in
the 2 years prior to Visit 1.  W here a patient is assessed as 

Novartis Confidential Page 18
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
eligible based on historical evidence of reversibility, a copy 
of the original printed spirometry report with relevant 
spirometry  tracings must be available as source 
documentation.
Documented evidence of a positive airway s hyper-reactivity 
(AHR) test result within the 2 years prior to or at Visit 101, 
defined as a provoked fall in FEV1 of 20% by methacholine 
at ≤8 mg/ml (or histamine ≤10 mg/ml or acetylcholine <20 
mg/mL) when not on ICS or ≤16 mg/ml or histamine ≤20 
mg/ml or acetylcholine <40 mg/mL) on ICS therapy 
performed according to ATS/ERS guidelines .
*NOTE: If reversibility is not demonstrated at Visit 1 and 
documented evidence for one of the other criteria for a clinical 
diagnosi s of asthma is not met, then the reversibility test may 
be repeated at Visit 101.
Key exclusion criteriaUse of other investigational drugs within 5 half -lives of enrollment, or 
within 30 days until the expected pharmacodynamic effect has 
returned to baseline , whichever is longer.
Patients who have participated in another trial of QA W039 (i.e. 
patient received study medication [active (QA W039), placebo or 
other].
Patients with a resting QTcF (Fridericia) ≥450 msec (male) or ≥460 
msec (female) at Visit 1 or at Visit 101 .
Patients with a histor y of malignancy of any organ, treated or 
untreated, whether or not there is evidence of local recurrence of 
metastases, with the exception of local basal cell carcinoma of the 
skin.
Pregnant or nursing (lactating) w omen, where pregnancy  is defined 
as the state of a female after conception and until the termination of 
gestation, confirmed by a positive hCG laboratory test.
Women of child- bearing potential, defined as all women 
physiologically capable of becoming pregn ant, unless they are using 
effective methods of contraception during dosing of study treatment. 
Patients who have a clinically significant laboratory abnormality at the 
Visit 1 laborator y test.
Patients with serious co -morbidities including, but not limi ted to, 
neurodegenerative diseases, rheumatoid arthritis and other 
autoimmune diseases.
Patients on >20 mg of simvastatin, > 40 mg of atorvastatin, >40 mg 
of pravastatin, or>2 m g of pitavastatin.  Statin doses less than or 
equal to these doses as well as other statins will be permitted during 
the study.
Patients on any statin therapy with a CK level >2 X ULN at Visit 1.
Patients with a histor y of conditions other than asthma that could 
result in elevated eosinophils (e.g., hypereosinophilic syndromes, 
Churg -Strauss Syndrome, eosinophilic esophagitis).  Patients with 
known parasitic infestation within 6 months prior to Visit 1 are also 
excluded.
Investigational and 
reference therapyQAW039 150 mg once daily
QAW039 450 mg once daily
Placebo to QAW 039once daily

Novartis Confidential Page 19
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Efficacy  assessmentsAsthma exacerbations
Asthma Quality of Life Questionnaire for 12 years and older 
(AQLQ+12)
Asthma Control Questionnaire (ACQ -5)
Spirometry  (Pre -dose FEV1)
Safety assessmentsHistory and physical examination
Vital signs
Hematology
Blood chemistry  including liver function tests, metabolic panels, 
amylase, lipase and hsCRP.
CK-MB and Troponin I (in response to CK results outside of the 
normal range)
HbA1c (collected at screening only )
Urinalysis
Pregnancy test (females of c hildbearing potential)
ECG
Adverse events including serious adverse events
Data analysis The primary variable for this study is the number of moderate -to-severe 
asthma exacerbations experienced by each patient per patient year of 
follow -up. The primary variable will be analyzed using a negative binomial 
regression model with the natural logarithm of the duration of follow -up as 
an offset variable, treatment group, randomization strata and region as 
fixed class effects, as well as the natural logarithm of the number of 
asthma exacerbations in the 12 months prior to screening and the 
baseline pre -dose FEV1 as continuous linear covariate s. Missing data will 
be imputed assuming no further treatment effect versus placebo for 
QAW039 patients that discontinue treatment and are lost to follow -up due 
to (or following a treatment discontinuation due to) lack of efficacy , 
adverse events or death. In contrast a continued treatment effect for 
QAW039 patients being lost to foll ow-up for reasons likely to be unrelated 
to study  treatment (e.g. lost to follow -up, withdrew consent) will be 
imputed.
The superiority of QAW039 over placebo will be considered confirmed if 
at least one of the four primary  null hypotheses regarding the 
exacerbation rates is rejected in favor of the respective two-sided 
superiority alternative hypothesis. 
The familywise type I error rate will be controlled at the two -sided 5% 
level across the primary  and key secondary null hypotheses using a 
closed testing procedure. In this closed testing procedure the primary null 
hypotheses about exacerbations for each dose and population act as 
gatekeepers for the key secondar y null hypotheses for the same dose 
and population.
188patients per arm in the subpopulation with blood eosinophils ≥ 250 
cells/μl and 282 patients per arm in the overall population corresponding 

Novartis Confidential Page 20
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
to a total sample size of 846 patients provide greater than 80% power for
demonstrating the superiority ofeach dose of QAW 039 compared to 
placebo in the subpopulation with blood eosinophils ≥ 250 cells/ μland 
overall population. Treatment discontinuation rate of 15% by 1 year is 
assumed in the active treatment groups and the placebo group. No 
further treatment effect versus p lacebo has been assumed during the off-
treatment period. Additionally, the planned sample size will give 80% 
power for FEV1 for each dose in the subpopulation at the resulting local 
two-sided significance level of 1.625% and 90% power for each dose in 
the overall population at the resulting local two-sided significance level of 
0.698% once the respective primary null hypothesis has been rejected . It 
was assumed that QAW 039 achieves a difference of 150 mL against 
placebo in FEV1 after 52 weeks for patients that remain on treatment. A 
SD of 380 mL was assumed for FEV1.
The key secondar y variables of this trial are AQLQ+12, ACQ -5 and 
average of the two pre-dose FEV1 assessments at the end of the 52 
week treatment period. 
For each key secondar y variable, QAW 039 dose and population the null 
hypothesis that the difference to placebo at week 52 is zero will be tested 
versus the two-sided alternative hypothesis that the treatment difference 
at week 52 ≠0 using analy sis of covariance. Prior to analysis, missing 
values for key  secondary  variables will be imputed in a similar manner as 
for the primary  variable.
Safety summaries will be primarily based on on-treatment data for the 
safety set with selected tables also presented for the all data after the first 
intake of study drug, while all databased safety data will be listed.
Key words Efficacy  and safety of QA W039, placebo -controlled, add -on to standard 
of care, uncontrolled severe asthma, female and male patients ≥12 y ears

Novartis Confidential Page 21
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
1 Introduction
1.1 Background
Asthma presents a major global health burden. Despite existing therapies, there is still 
significant unmet medical need in asthma, with an estimated 300 million people affected 
worldwide. The World Health Organization estimates that 15 million disability–adjusted life 
years are lost annuall y due to asthma, representing 1% of the total global burden. Annual 
worldwide deaths have been estimated at 250,000 (Masoli, et al 2004 ) . Uncontrolled asthma 
has a prevalence of greater than 6 million patients worldwide. 
Severe asthma is defined as asthma that requires treatment with high dose inhaled 
corticosteroids (ICS) plus a second controller and/or systemic corticosteroids to prevent it 
from becoming "uncontrolled" or that remains "uncontrolled" despite this therapy . Severe 
asthma is a heterogeneous condition consisting of phenot ypes such as eosinophilic asthma 
(Chung, et al 2014 ). This subgroup has also been defined as "refractory " asthma (Proceedings 
of the ATS workshop on refractory  asthma 2000 ).
Recurrent exacerbations are a major problem 
in some patients with severe asthma and can 
predominate in the subgroup with eosinophilic airway  inflammation ( Haldar, et al 2009 ). A 
number of therapeutic interventions impact on eosinophilic airway  inflammation as measured 
by sputum eosinophilia. These include inhaled and oral corticostero ids and a number of 
biologic therapies (including anti-IL-5, anti-IL-5R, anti-IgE,and anti-IL-4Rα therapies ). 
Generally , when a therapeutic agent hassuccessfully  suppress edsputum eosinophil level s, 
evidence of efficacy ,as measured bya reduction in asthma exacerbation s,has also been 
demonstrated (Pavord, et al 2012 ; Nowak, et al 2015 ; Wenzel, et al 2013 ; Takaku, et al 2013 ). 
In more severe asthma, inhaled andoral corticosteroids may not be as effective in reducing 
sputum eosinophilia as they are in milder disease (Wenzel, et al 2005 ; Nair, et al 2009 ). 
Consequently , there remains a need for well tolerated , easily-administered ,anti-inflammatory 
therapies with the capability  of suppressing sputum eosinophilia and reducing asthma 
exacerbations, particularly , for those patients appear ingto be steroid resistant.
Chemoattractant receptor -homologous molecule expressed on Th2 cells (CRTh2) is a receptor 
for prostaglandin D2 (PDG 2) which is one of the major prostanoid inflammatory  mediators 
identified in asthma .  QAW039 is a CRTh2 antagonist expected to provide benefit in asthma 
by binding to CRTh2 receptors on eosinophils , basophils, and T ly mphocy tes in the blood and 
tissues ;thus, inhibiting migration and activation of these cells into the airway  tissues and 
blocking the PGD 2-driven release of Th2 cytokines (Chevalier, et al 2005 ). Since these are 
the 
major effector cells and soluble factors driving airway  inflammation in asthma, treatment 
with QAW039 should result in a decrease in these parameters of airway  inflammation as well 
as a clinical improvement in asthma.  In support of this premise are theresults of Study 
CQAW039 A2208: a randomized, placebo -controlled, 12-week sputum study of QAW039 
(225 mg BID), compared with placebo, in patients with severe eosinophilic asthma.  In this 
study , QAW039 demonstrated a fall in sputum eosinophils of 71% (geometric mean) after 12 
weeks treatment .  
Given published results with other asthma therapies in which a reduction in sputum 
eosinophils is associated with a reduction in asthma exacerbations (Haldar, et al 2009 ; Pavord, 

Novartis Confidential Page 22
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
et al 2012) , and the observed reduct ion in sputum eosinophils in Study  CQAW039A2208 , it is 
postulated QAW039 will reduce the rate of asthma exacerbations.
1.2 Purpose 
The overall purpose of this study  is to determine the efficacy  and safety  of QAW039 (150 mg 
and 450 mg once dail y), compared with placebo, when added to GINA steps 4 and 5 standard -
of-care (SoC) asthma therapy  (GINA 2016 )†, inpatients with inadequately  controlled severe 
asthma and high eosinophil counts (eosinophil count at Visit 1 ≥250 cells/ µl).  Inadequate 
control is defined as partly controlled or uncontrolled asthma ( GINA 2016 ).
The study  will also determine the efficacy  and safety  of QAW039 (150 mg and 450 mg once 
daily ), compared with placebo, in the overall study  population.  
This approach will permit the determination of the effect of QAW039 in reducing asthma 
exacerbations i
nthe subset of patients with severe asthma and high eosinophil counts as well 
as in the overall study  population regardless of eosinophil counts. 
†Medium or high-dose ICSplus a second controller and/or s ystemic corticosteroids.
2 Study  objectives
2.1 Primary  objective(s)
In patients with severe asthma andhigh eosinophil counts (≥250 cells/µl) receiving SoC 
asthma therap y, to demonstrate the efficacy  (as measured b y rate of moderate -to-severe 
asthma exacerbations) of at least one dose level of QAW039 (150 mg o r 450 mg once 
daily ), compared with placebo, at the end of the 52-week active -treatment epoch.
In all patients with severe asthma receiving SoC asthma therap y, to demonstrate the 
efficacy  (as measured b y rate of moderate -to-severe asthma exacerbations) of at least one 
dose level of QAW039 (150 mg or 450 mg once daily ), compared with placebo, at the end 
of the 52-week active -treatment epoch.
2.2 Secondary  objectives
In patients with severe asthma and high eosin ophil counts (≥250 cells/µl) receiving SoC 
asthma therap y:
To demonstrate the efficacy  of at least one dose level of QAW039 (150 mg or 450 mg 
once dail y), compared with placebo, with respect to change from baseline in Asthma 
Quality  of Life Questionnaire ( AQLQ+12) scores at the end of the 52 -week active -
treatment epoch.
To demonstrate the efficacy  of at least one dose level of QAW039 (150 mg or 450 mg 
once dail y), compared with placebo, with respect to change from baseline in Asthma 
Control Questionnaire-5 (ACQ- 5) score at the end of the 52 -week active -treatment epoch.
To demonstrate the efficacy  of at least one dose level of QAW039 (150 mg or 450 mg 
once dail y), compared with placebo, with respect to change from baseline in pre -dose   
FEV1 at the end of the 52-week active -treatment epoch.

Novartis Confidential Page 23
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
To assess the safety  of QAW039 (150 mg and 450 mg once daily ), compared with placebo, 
with respect to adverse events, electrocardiograms (ECGs), vitals sign, laboratory  tests 
and hy persensitivity  reactions.
In all patients with severe asthma receiving SoC asthma therap y:
To demonstrate the efficacy  of at least one dose level of QAW039 (150 mg or 450 mg 
once dail y), compared with placebo, with respect to change from baseline in Asthma 
Quality  of Life Questionnaire (AQLQ+12) scores at the end of the 52 -week active -
treatment epoch.
To demonstrate the efficacy  of at least one dose level of QAW039 (150 mg or 450 mg 
once dail y), compared with placebo, with respect to change from baseline in Asthma 
Control Questionnaire-5 (ACQ-5) sc ore at the end of the 52 -week active -treatment epoch.
To demonstrate the efficacy  of at least one dose level of QAW039 (150 mg or 450 mg 
once dail y), compared with placebo, with respect to change from baseline in pre -dose 
FEV1 at the end of the 52-week a ctive -treatment epoch.
To assess the safety  of QAW039 (150 mg and 450 mg once daily ), compared with placebo, 
with respect to adverse events, electrocardiograms ( ECGs) , vitals sign, laboratory  tests 
and hy persensitivity  reactions.

Novartis Confidential Page 24
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
3 Investigational plan
3.1 Stud y design
This study  uses a randomized, multicenter, double -blind, placebo -controlled parallel -group 
study  design in which QAW039 orplacebo is added to GINA steps 4 and 5 asthma therap y 
(Figure 3 -1).  
Within 14 days prior toor at Visit 1, an informed consent will be obtained from patients 
before any study  related assessments or pro cedures are performed. All patients signing 
informed consent must be registered in the Interactive Response Technology  (IRT). Asthma 
and other medications and eligibility  criteria will be reviewed. Patients will be instructed 
regarding medications to be withheld prior to spirometry for Visit 101 (See Section 5.5.8 ).
Approximately 2400 patients will be screened to randomize 846patients into this study .
The study  will include: 
a Screening epoch of up to 2 weeks to assess eligibility ;
a Run- in epoch of approximately 2weeks and a maximum of 6 weeks to collect baseline 
data for efficacy  variables and compliance with the Electronic Peak Flow/ eDiary  device
(if a patient experiences an asthma exacerbation du ring the run -in epoch, the run- in epoch 
must be extended to 6 weeks to permit for resolution of the asthma exacerbation before 
randomization.  The run -in epoch should only be extended bey ond 2 weeks (+/- 5days) 
for an asthma exacerbation.);
a Treatment ep och of 52 weeks;
a Follow- up epoch of 4 weeks, investigational and drug -free, following the last dose of 
study  drug. Note :the follow- up epoch applies to all patients except those patients who 
enter the safet y study directly  after Visit 299.

Novartis Confidential Page 25
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Figure 3-1 Study  design
Upon completion of the run-in epoch, all patients who met the eligibility  criteria will be 
randomized to 1 of 3 treatments (QAW039 [150 mg or 450 mg once daily ] or placebo once 
daily )in a ratio of 1:1:1 .  Randomized patients will stratified according totheir peripheral 
blood eosinophil counts (<250 cells/ l or ≥250 cells/ l), patient age (<18 years or ≥18 years),
andtheir baseline use or non-use of oral corticosteroids as part of their SoC asthma therapy at 
Visit 1 .  Clinic visits will be scheduled approximately  4weeks after randomization and then at 
approximately  8-week intervals during the active -treatment epoch.  Phone calls will occur at 
specifi ed time points between visits occurring at 8-week intervals (see schedule of 
assessments Table 6-1).  A follow -up visit will occur approximately  4 weeks (i.e., 
approximately  30 days) following the last dose of study  therap yto complete safet y 
assessments and pregnancy  testing (if applicable) . Please refer to the assessment schedule 
(Section 6 ) for a list of procedures to be conducted at each visit.
A Safety  
Study of QAW039 is planned.  At sites participating in the Safet y Study , patients 
who successfully  complete 52 weeks of treatment in this study  (Study  A2307) may be offered 
participation in the Safety  Study; patient participation in the Safety  Study will be optional. 
The study  design and procedures for the S afety Study will be described in a separate protocol.
Note: 
Patients experiencing an asthma exacerbation during the run-in epoch should receive 
treatment for their exacerbation, and remain in therun-in epoch until the subject has returned 
to their baseline asthma status for at least 2week s (2 weeks=14 day s). If patients do not return 
to their baseline status for at least 2 weeks prior to Visit 199, patients will not be eligible for 
randomization and will be designated a run-in failure .
In addition to periodic unblinded safety  reviews by an independent Data Monitoring 
Committee, a single futility  interim anal ysis is planned as described in Section 3.5 .

Novartis Confidential Page 26
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
3.2 Rationale of study  design
This randomized, double -blind, parallel- group, placebo -controlled, design supports the 
assessment of efficacy  as well as safety  of QAW039 as add-on treatment for patients with 
inadequatel y controlled severe asthma otherwise treated according to GINA 2016 (steps 4and 
5) guidelines. According to GI NA guidelines, the goals of asthma therapy  are to attain asthma 
control and reduce future risk of asthma worsening while maintaining minimal side effects of 
therap y.  By maintaining good asthma control in patients with appropriate use of therapies, 
potential future risk to patients may be reduced. The endpoints included inthis study  measure 
symptomatic and objective parameters of asthma control (symptomatic parameters: daytime 
and nighttime asthma symptoms, SABA use, quality  of life, Asthma Control Questionnaire 
[ACQ] scores; objective: lung function [FEV1, peak flow]) and future risk (moderate -to-
severe asthma exacerbations, longitudinal lung function) in patients at the end of 52 weeks of 
therap y.  
Patient population 
The overall purpose o f this study  is to determine the efficacy  and safety  of QAW039 (150 mg 
and 450 mg once dail y), compared with placebo, when added to GINA steps 4 and 5 standard -
of-care (SoC) asthma therapy  (GINA 2016 ), in patients with inadequately  controlled severe 
asthma and high eosinophil counts (eosinophil count at Visit 1 ≥250 
cells/µl).  The study  will 
also determine the efficacy  and safet y of QAW039 (150 mg and 450 mg once daily), 
compared with placebo, in the overall stud y population.
A prior study  of QAW039 (Study  CQAW039A2208) demonstrated QAW039 (225 mg BID), 
compared with placebo, caused a reduction in sputum eosinophils in patients with severe 
eosinophilic asthma.  Given published results with other asthma therapies in which a 
reduction in sputum eosinophils is associated with a reduction in asthma exacerbations 
(Haldar, et al 2009 ;Pavord, et al 2012 ), and the observed reduction in sputu m eosinophils in 
Study  CQAW039A2208, it is postulated QAW039 will reduce the rate of asthma 
exacerbations.  Further, recent published results of the MENSA study (Ortega, et 
al 2014 ) , in 
which the included patient population issimilar to that proposed for the current study of 
QAW039 , suggest patients with severe asthma , particularly  those with severe eosinophilic 
asthma, are at risk forrecurrent asthma exacerbations .  Taken together, the patient population 
for the current study  is appropriate to evaluate the effect of QAW039 on reduction in rate of 
asthma exacerbations when patients stratified by eosinophil counts .
Screening epoch 
The screening epoch allows for assessment of patient entry  criteria and for patien ts to become 
familiar with spirometry measurement and daily  eDiary entry prior to the collection of 
baseline values. 
Run-in epoch 
Therun-in epoch allows for patients to become familiar with administration of investigational 
treatment, to determine patie nt’slevel of asthma control based on ACQ score (for eligibility ),
and to collect baseline data for all efficacy  variables.  This epoch will also assess patients’ 
compliance with an Electronic Peak Flow/ eD iary device and treatment . 

Novartis Confidential Page 27
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Treatment epoch 
During this epoch oral QAW039 (150 mg and 450 mg) or placebo (1:1:1) will be 
administered once daily for 52 weeks, with the last dose given at Week 52 and final 
assessment for the treatment period at week 52. A 52-week study  duration is necessary  to 
minimize the impact of the seasonal variation onthe primary  endpoint, the rate of asthma 
exacerbations. Since one of the secondary  endpoints is predose FEV1, patients will receive 
witnessed dosesof study  drug at clinic visits after spirometry  is performed for the FEV1 
assessment.  This will allow for appropriate assessment of predose FEV1 prior to dosing.
Follow -upepoch 
The 4 week wash out epoch will monitor the safety  and tolerability  profile after the last dose 
of study  drug. Note :the follow -up epoch applies to all patients except those patients who 
enter the safet y stud y directly after Visit 299.
3.3 Rationale of dose/regimen, route of administration and duration 
of treatment
QAW039 will be administered at doses of 150 mg and 450 mg once daily as oral film-coated 
tablets (FCTs) in this study . 
A 450 mg once dail y dose was selected for inclusion in the study  based on the following:
At a dose of 450 mg once daily , >98% receptor occupancy  is expected for the entire 
dosing interval in a “t ypical patient” at stead y state allowing inhibition of eosinophil 
migration over the entire treatment interval.
A 500 mg once dail y dose of QAW039 was efficacious on the endpoint of pre-dose FEV1 
in a sub -set of patients with percent predicted FEV1 <70% at baseline in Study  
CQAW039 A2201 (proof -of-concept study ). A 450 mg total dail y dose was also 
efficacious on the endpoint of pre -dose FEV1 instudy  CQAW039 A2206.
A total daily  dose of 450 mg (225 mg twice daily ) was evaluated in Study  
CQAW039 A2208 in patients with severe asthma as add- on to SoC asthma therap y.  In this 
study , QAW039 caused significant reduction of sputum eosinophilia in patients with 
severe eosinophilic asthma.  The reduction in sputum eosinophils was comparable to that 
observed with the an ti-IL5 antibodies, Mepolizumab ( Pavord, et al 2012 ) and Reslizumab 
(Castro, et al 2011 and 2015 ).  An association between reduction of eosinophilic airway  
inflammation and frequency  of exacerbations has been reported in the literature ( Haldar, et 
al 2009 ; Pavord, et al 2012 ; Nowak, et al 2012 ; Wenzel, et al 2013 ; Takaku, et al 2013 ), 
suggesting QAW039 may  also cause a reduction in the frequency  of asthma exacerbations 
inpatients with severe refractory  eosinophilic asthma.
The dose of 150 mg once daily  was selected for inclusion in the study  because it was the 
lowest dose of QAW039 with “maximal efficacy” on the endpoint of FEV1 in a prior dose -
ranging study  (Study  CQAW0 39A2206) in patients with moderate -to-severe asthma (GINA 
treatment steps 
4 and 5) as add-on to low -dose ICS.  This dose is ½ log lower than highest 
dose. 
Since the QAW039 dose of 150 mg was considered the optimal dose (i.e., lowest dose 
providing maximal efficacy ) ina prior dose-ranging study , doses lower than 150 mg will not 
be included in this study .

Novartis Confidential Page 28
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
3.4 Rationale for choice of comparator
All patients in this study  will continue to receive their asthma medications as background 
treatment. QAW039 or placebo will be administered as add- on therapy .
The use of placebo will permit the assessment of improvement in terms of incidence of 
moderate -to-severe asthma exacerbations for patients with uncontrolled disease who are 
treated with QAW039, in comparison to those continuing solely  on existing SoC asthma 
therap y.  Additionally , the use of placebo will permit a controlled evaluation of the safet y of 
QAW039 in these patients.
This study  does not include an active comparator since QAW039 will be given as add-on 
thera py to standard of care asthma therap y in patients with severe asthma (GINA treatment 
steps 4 and 5).
3.5 Purpose and timing of interim analy ses/design adaptations
An independent Data Monitoring Committee (see Section 8.3 ) will conduct periodic 
unblinded safety  reviews of the accumulating data (including specific safet y summaries for 
adolescent participants) from this trial and other Phase III trials 
ofthe QAW 039 asthma 
development program to ensure safet y of trial participants. 
In addition, a single interim analy sis for futility  will be conducted to assess whether the study 
should be stopped for futility  or safet y, or whether treatment in one or more QAW039 dose 
groups should be discontinued for safet y reasons. There will be no stopping for demonstrated 
efficacy  prior to the completion of the study  at either the unblinded safety  reviews or the 
futility  interim analysis, because a sufficiently  large safet y dataset is needed in addition to 
efficacy  data.  Therefore, no statistical adjustment will be made to the final anal ysis.
This interim analy sis for futility  will occur when approximately  200 patient -years of follow -
up data have accumulated.  The timing of the futility  interim analysis may be modified based 
on the progress of recruitment, the logistics of arranging DMC meetings, the data accrual in 
other QAW039 asthma Phase III trials and additional external data that might become 
available. 
3.6 Risks and benefits
QAW039 is a potent and highl y selective oral CRTh2 receptor antagonist being developed as 
a potential therap y treatment forpatients with severe asthma.  CRTh2 is a receptor for PGD 2
which mediates the activation and migration of Th-2 cells and eosinophil s, some of the key 
inflammatory  cell types in asthma.  Recruitment of these cells into the lung is partly  
responsible for the intermittent airway obstruction which leads to wheezing and shortness of 
breath characteristic of asthma.
QAW039 is at least 300-f old selective for the CRTh2 receptor compared to other available 
prostanoid receptors and to cycloox ygenase -1 and cycloox ygenase -2, and it has been 
demonstrated to be a potent in vitro inhibitor of human whole blood eosinophil activation and 
induction of Th-2 cytokines. After oral dosing in rats, QAW039 inhibited pulmonary 
eosinophilia induced by  the PGD 2metabolite DK -PGD 2. 
The potential benefits of QAW039 therapy  need to be balanced against its potential risks. The 
risk to patients in this study  will be minimized by compliance with the inclusion/exclusion 

Novartis Confidential Page 29
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
criteria and close clinical monitoring. All patients will remain on the background SoC asthma 
therap y they were taking at screening throughout the study .  Furthermore, patients will be 
instructed how to react to worsening of asthma symptoms so patients can be managed 
appropriatel y.
The overall clinical experience with QAW039 includes 12 studies: 10 (6 in healthy volunteers 
and 4 in patients) have completed and 2 (in patients) are ongoing. The completed phase 2 
studies consist of 3 in patients with asthma and 1 in patients with allergic rhinitis. The 
ongoing phase 2 studies include one study  in patients with asthma (CQAW039A2214) and 1 
study  in patients with atopic dermatitis (CQAW039X2201). 
As of January  2015, over 1300 subjects have been exposed to QAW039 in the clinical 
program. In the completed studies of QAW039, 1239 subjects (175 healthy  volunteers and 
1064 patients with asthma or allergic rhinitis) received QAW039, 342 subjects received 
placebo, and 359 subjects received other treatment (rosuvastatin, simvastatin or montelukast).
QAW039 has been well tolerated in populations studied to date at total daily  doses up to 500 
mg given for up to 12 weeks. In the 10 completed studies, 16 patients reporte d 17 serious 
adverse events (SAEs), no deaths due to SAEs were reported, and 5 discontinuations due to 
SAEs were reported. Of the 16 patients reporting SAEs, 12 patients reported 13 events, 2 
patients reported 2 events and 2 patients reported 2 events in the QAW039, placebo, and 
montelukast treatment groups, respectively .There were no SAEs with a suspected causal 
relationship to QAW039. There have been no adverse events of idiopathic drug reactions. 
Overall, the safet y profile of QAW039 has been favora ble across studies.
Three Phase 2 studies in patients with asthma demonstrated the effect of QAW039 across the 
range of asthma severities (mild to severe). Below is a summary  of efficacy  data from these 3 
completed studies in asthma. For detailed informati on on the studies described below, please 
refer to the Investigators Brochure.
Study A2201 (proof -of-concept [PoC] study) 
Study  A2201 was a PoC study  in 170 corticosteroid -free, atopic, asthmatic patients 
uncontrolled on as needed β-agonist medication who were randomized (1:1) to receive 
QAW039 500 mg or matching placebo for 28 days.  The primary  objective was to assess the 
efficacy  of QAW039, compared with placebo, as measured by trough FEV1 after 28 days of 
treatment. Overall benefit for QAW039 treatment was not demonstrated in the entire study 
population (patients with percent predicted FEV 1of 60% to 85% at baseline) compa red with 
placebo treatment. Benefit occurred only in those patients with more severe baseline airflow 
obstruction (FEV 1< 70% predicted). Results from Study  A2201 demonstrated 4 weeks of 
treatment with QAW039 (500 mg q.d.) improved both lung function (FEV 1: 207 ml > placebo 
group, p=0.002, 1-sided test) and control of asthma symptoms (ACQ: 0.41 points < placebo 
group, p=0.009, 1-sided test) in the subset of patients with moderate airflow obstruction at 
baseline (FEV 1< 70% predicted) who were inadequatel y controlled on reliever medication 
alone.
Study A2206 (dose -ranging study) 
Study  A2206 was a randomized, placebo -controlled, multi -center, dose-ranging study  in 
patients with moderate -to-severe allergic asthma inadequatel y controlled by ICS therapy .  

Novartis Confidential Page 30
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Patien ts who satisfied selection criteria were randomized to 1 of 15 treatment arms (13 
QAW039 treatment arms, 1 montelukast positive control arm and 1 placebo arm) for 12 
weeks followed by a  s ingle -blind, placebo wash -out period for 4 weeks. The primary 
objecti ve of the study  was to assess the efficacy  of QAW039, compared with placebo, as 
measured by trough FEV1 after 12 weeks of treatment.  A  t otal 1058 patients were 
randomized to the following treatment groups: 139 patients to montelukast, 137 patients to 
placebo and 782 patients to QAW039.  The study  achieved its primary  endpoint by 
demonstrating a clinically  and statistically  significant improvement (0.112 L; p=0.0035) in 
trough FEV1 after 12 weeks therapy  with QAW039, compared with placebo, in a population 
of moderate -to-severe, persistent, atopic asthmatics with a predicted baseline, pre-
bronchodilator FEV1 of 40% to 80% of the predicted value who were uncontrolled on low 
dose I CS.
Results showed the greatest differences from placebo occurred at doses of 75 mg twice daily 
and 150 mg once daily . These doses were towards the middle of the 1mg to 450 mg dose 
range tested. There appeared to be little difference between once daily  and twice daily  dosing.  
There were no significant changes compared with placebo inACQ, AQLQ or Juniper asthma 
control diary  scores across the study  population either for QAW039 or the positive control, 
montelukast.  Examination of sub-groups did not provide evidence of increased efficacy  for 
QAW039, compared with placebo, in terms of F EV1.
Study A2208 
Study  A2208 was a single site, double -blind, placebo -controlled study  to determine whether, 
in patients with sputum eosinophilia (≥ 2%) and persistent, moderate -to-severe asthma, 12 
weeks of treatment with QAW039 at a dose of 225 mg twice daily, compared with placebo, 
on top of SoC asthma treatment would reduce levels of eosinophils in induced sputum.  In 
addition to measurements of changes in sputum eosinophilia (primary  endpoint) and ACQ 
(secondary  endpoint), a very wide range of lung function, patient reported outcome, imaging, 
histological, proteomic and transcriptional endpoints were also measured.
A total of 61 patients were randomized and 55 patients completed their assigned double -blind 
treatment period.  The primary  endpoint of thestudy  was achieved. The level of sputum 
eosinophilia decreased by  71% (geometric mean) from baseline after 12 weeks treatment with 
QAW039.  This fall was significantl y different from the change observed in placebo -treated 
patients (p=0.0007).  QAW039 led to clinically and statistically  relevant asthma control (as 
measured b y the ACQ test) in patients uncontrolled at baseline (i.e. baseline ACQ7 ≥1.5), with 
the ACQ7 improving by 0.58 points (p=0.0473) in the per-protocol population. In the overall 
population , the ACQ7 score improved by 0.40 points (p=0.0843). There was a clinically  (0.5 
point) and statisticall y significant improvement in QoL, as measured by the AQLQ overall 
score, after 12 weeks treatment with QAW039 in comparison to placebo (treatment differ ence 
= 0.593 point; p=0.0080). The proportion of patients experiencing a moderate or severe 
asthma exacerbation was similar across the two treatment groups (7 in the QAW039 group 
and 6 in the placebo group).  This finding was not surprising given the study was small and of 
limited duration and, therefore, was not designed to detect an effect on this endpoint.  
Numerical increases were seen in pre-bronchodilator FEV1 in QAW039 -treated patients 
regardless of whether absolute volume or % change was considered. The greatest increases 
were observed in those per protocol -treated patients whose predicted FEV1 was <70% at 
baseline (190 mL and 13.409% for volume and % change, respectivel y). However, none of 

Novartis Confidential Page 31
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
these results were statistically  significant.  Given the results with other therapies (a reduction 
in sputum eosinophils is associated with a reduction in asthma exacerbations), and the 
observed reduction in sputum eosinophil numbers in the prior study  of QAW039, it is 
postulated QAW039 will reduce the rate of asthma exacerbations in the current study.  
Therefore, the main purpose of the current study  is to definitively  demonstrate the effect of 
QAW039 on reduction in the rate of moderate -to-severe asthma exacerbations. 
Cardiovascular risks:
Transient, increases in heart rate were observed in a cardiovascular safet y pharmacology stud y 
in dogs. These changes were not associated with any significant alterations in blood pressure, 
ECG interval duration, morphology  or rhy thm or any  structural changes in cardiac tissues.   No 
cardiac findings have been identified in the healthy  volunteer and patient studies completed to 
date apart from an observed imbalance in the frequency  of post -randomization cardiac adverse 
events in study  CQAW039A2206 with a higher incidence in the QAW039 treatment group 
(1.7%) compared with either placebo (0.7%) or montelukast (0%) treated patients. The cardiac 
events comprised a number of different non- serious arrhythmias and one serious adverse 
event of pericarditis not suspected to be related to study drug by the investigator. Three of the 
events in the QAW039 treatment groups occurred during the washout period and 9 resolved 
on treatment. Based on the inability  to identify discernable trends with QAW039 dose, 
regimen, time-of-onset, patient age and gender, concomitant medication, event type and 
following detail ECG review, it was considered that these were most probably  coincidental 
events without a causal association to study  drug.
Aformal QTc study  has not been completed for QAW039. Monitoring for changes in vital 
signs, ECGs and biochemical parameters will be conducted.
Liver toxicity :
Dose -dependent increases in liver weights with concomitant hepatocellular hypertrophy  were 
the primary  findings during 2-and 13-week toxicity  studies in mice. These changes were 
considered to be a species -specific adaptive metabolic response with no relevance for humans.
Liver toxicity  findings have not been identified in the healthy  volunteer and patient studies 
completed to date.  Monitoring of liver function tests will be conducted as described in 
Appendix 2 of this protocol .
Potential risk of idiosyncratic drug reactions
CCN362 is an acylglucuronide metabolite of QAW039 and its potential to covalentl y bind to 
plasma protein s, such asalbumin ,was demonstrated in the human ADME (Absorption, 
distribution, metabolism, and excretion) study of QAW039 (CQAW039A2104). In the 
literature, in vivo binding of acyl glucuronide sto proteins has been reported to be associ ated 
with rare idiosy ncratic drug reactions (IDRs) ,although a causal connection of protein 
adduction to IDRs remains uncertain (Regan, et al 2010 ) .  There have been no IDRs observed 
with QAW039 treatment in completed clinical trials.  S urveillance of adverse events for 
identification of IDRs will be conducted.

Novartis Confidential Page 32
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Drug -drug interactions
QAW039 and CCN362 did not show any relevant inhibition or induction of the cytochrome 
P450 isoenzy mes or inhibition of ubiquitous efflux transporters. The most potent in vitro 
inhibition by QAW039 was found for OATP1B1, but clinically  only a small impact was 
observed at 450 mg/day (~2-fold increase in Cmax of simvastatin acid and rosuvastatin 
without change in AUC) .  Based on these data ,as well as recommendations in the simvastatin 
label, simvastatin doses of > 20 mg per day should not be co-administered with QAW039; no 
relevant impact on the disposition of other co-medicatio nsare expected with QAW039 dosed 
up to 450 mg/day .   Patients on doses of simvastatin >20 mg, doses of atorvastatin >40 mg,
doses of pravastatin >40mg, ordoses of pitavastatin >2 mg per day(Elsby et al 2012 , Deng et 
al 2008 , Noe et 
al 2007 , and Kalliokoski et al 2009 ),as well as patients on any statins with 
high CK levels (>2 X ULN) at screening (Visit 1) will be excluded from the study  (see 
Section 4.2 ). Furthermore, patients on statin medication who are included in the study  will 
have regula r monitoring for relevant symptoms and be subject to discontinuation based on 
persistent my algia and blood CK levels (Jacobson 2008 ) as described in Section 5.5 .10.
4 Population
The study  population will include approximately  846 males and females aged ≥12 years with 
inadequatel y controlled severe asthma (partl y controlled or uncontrolled asthma on treatment 
at GINA steps 4 and 5).Approximately  15% of the patients willbe adolescents (aged ≥12 to 
<18years).
Patients will be stratified based on blood eosinophil counts at Visit 1, so that approximatel y
two thirds of randomized patients will have a blood eosinophil count ≥ 250 cells/µl and one 
third a blood eosinophil count < 250 cells/µl at Visit 1.It is anticipated at least 2400 patients 
will need to be screened to randomize approximately  846 patients into the study . It is 
estimated that approximately  15% of patients will discontinue their investigational treatment
during the treatment epoch ; these patients will not be replaced. 
4.1 Inclusion criteria
Patients eligible for inclusion in this study have to fulfill allof the following criteria:
1.Written informed consent and assent (if applicable) must be obtained within 14 day s prior 
to or at Visit 1 before any  assessment is performed including an y adjustment to asthma 
medication.
2.Male and female patients aged ≥12 years (or ≥ lower age limit allowed by health authorit y
and/or ethics committee/institutional review board approvals ).   
3. Patients must have a diagnosis of asthma (according to GINA 2016 ) for a period of at least 
24 months prior to Visit 1.
4.Patients have been treated 
with:
Medium or h igh-dose ICSplus long- acting beta agonist ( LABA ), or
Medium or h igh-dose ICSplus leukotriene receptor antagon ist(LTRA), or
Medium or h igh-dose ICSplus theophy lline, or
Medium or h igh-dose ICSplus long- acting muscarinic an tagonist (LAMA) , or
Medium or h igh-dose ICS plus LABA plus LAMA , or

Novartis Confidential Page 33
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Medium or h igh-dose ICS plus LABA plus LTRA , or 
Medium or high-dose ICS plus LABA plus theophy lline,
with or without maintenance oral corticosteroids for at least 3 months prior to Visit 1. The 
doses must have been stable for at least 4 weeks prior to Visit 1.
See GINA 2016 for the definition of medium and high-dose ICS (Appendix 7
contains the estimated equivalence of inhaled corticosteroids per GINA 2016 ).
5.For patients aged ≥18 y ears, FEV1 of ≤80% of the predicted normal value for the patient, 
after withholding bronchodilators at Visit 1 andVisit 
101. For patients aged 12 to <18 
years, FEV1 of ≤90% of the predicted normal value for the patient, after withholding 
bronchodilators at Visit 1 and Visit 101.
NOTE: Withholding of bronchodilators prior to spirometry : 
SABAs ≥ 6 hours; 
LABAs given twice daily ≥ 12 hours;
LABAs given once daily  ≥ 24 hours; 
Fixed dose combinations of LABA and ICS given twice dail y ≥ 12 hours; 
Fixed dose combinations of LABA and ICS given once dail y ≥ 24 hours;
LAMAs ≥ 24 hours. 
6.Demonstrat ion of inadequate control of asthma based on an ACQ score ≥ 1.5at Visit 1.
7.A history  of 2 or more asthma exacerbation swithin the 12 months prior to Visit 1 that 
required either:
Treatment with s ystemic corticosteroids (tablets, suspension or injection) .
OR
Hospitalization (defined as an inpatient stay  or >24 -hour stay  in an observation area in 
the emergency  room of other equivalent facility .
NOTE S:
For subjects receiving maintenance OCS, the OCS treatment for exacerbations must 
have been at least a 2 -foldor greater increase in the dose of OCS.  
The start of the second exacerbation episode must have been at least 7 days after the 
end of the first exacerbation episode.
Investigators must use appropriate means to ensure the accuracy  of the patient’s 
exacerb ation history   (patient history  at Visit 1 documented in source notes, pharmacy  
records, hospital records, or chart records are acceptable ).
8.A clinical diagnosis of asthma supported by  at least one of the following: 
An increase of ≥12% and ≥200 ml in FEV 1approximately 10 to 15 minutes after 
administration of 400 mcg of salbutamol/albuterol (or equivalent dose) prior to 
randomization.   Spacer devices are not permitted during reversibility  testing.  All 
patients must perform a reversibility  test at Visit 1.   If reversibility  is not demonstrated 
at Visit 1*, the following historical information may  be used:
Documented evidence of reversibility  that was performed according to 
ATS/ERS guidelines (ATS/ERS 200 5) withinthe 2 years prior to Visit 1.  
Where a patient is assessed as eligible based on historical evidence of 

Novartis Confidential Page 34
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
reversibility , a copy  of the original printed spirometry  report with relevant 
spirometry  tracings must be available as source documentation.
Documented evidence of a positive airway s hyper-reactivity  (AHR) test result 
within the 2 y ears prior to or at Visit 101, defined as a provoked fall in FEV 1of 
20% by  methacholine at ≤8 mg/ml (or histamine ≤10 mg/ml or acety lcholine 
<20 mg/mL) when not on I CS or ≤16 mg/ml or histamine ≤20 mg/ml or 
acetylcholine <40 mg/mL) on ICS therapy  performed according to ATS/ERS 
guidelines.
*NOTE: If reversibility  is not demonstrated at Visit 1 and documented evidence for 
one of the other criteria for a clinical diagnosis of asthma is not met, then the 
reversibility  test may  be repeated at Visit 101 .
4.2 Exclusion criteria
Patients fulfilling anyof the following criteria are not eligible for inclusion in this study . No 
additional exclusions may be applied by the investigator, in order to ensure that the study 
population will be representative of all eligible patients.
1. Use of other investigational drugs within 5 half- lives of enrollment, or within 30 day s until 
the expected pharmacodynamic effect has returned to baseline, whichever is longer.
2.Patients who have participated in another trial of QAW039 (i.e. patient received study  
medication [active (Q AW039), placebo or other].
3.History  of hypersensitivity  to any  ingredients of the study  drugs or to drugs related to 
QAW039 .
4.Patients who, in the judgment of the investigator have a clinically  significant ECG 
abnormality  such as (but not limited to) sustai ned ventricular tach ycardia, or clinically 
significant second or third degree AV block without a pacemaker.
5.Patients with a history  of familial long QT s yndrome or known famil y history of Torsades 
de Pointes.
6.Patients with a r esting QTcF (Fridericia) ≥450 msec (male) or ≥460 msec (female) at Visit 
1 or at Visit 101.
7.Patients receiving an y medications or other agents known to prolong the QT interval .
8.Patients with a history of malignancy  of an y organ , treated or untreated, whether or not 
there is evidence of local recurrence of metastases, with the exception of local basal cell 
carcinoma of the skin .
9.Pregnant or nursing (lactating) women, where pregnancy  is defined as the state of a female 
after conce ption and until the termination of gestation, confirmed by  a positive hCG 
laboratory  test.
10.Women of child -bearing potential, defined as all women physiologicall y capable of 
becoming pregnant, unless they  are using effective methods of contraception during 
dosing of stud y treatment. Effective contraception methods include:
Total abstinence (when this is in line with the preferred and usual lifest yle of the 
subject ) if allowed as effective method of contraception by  local regulations . Periodic 
abstinence (e.g ., calendar, ovulation, sy mptothermal, post -ovulation methods) and 
withdrawal are not acceptable methods of contraception

Novartis Confidential Page 35
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterectom y) or tubal ligation at least six weeks befo re taking stud y treatment.  I n 
case of oophorectom y alone, only  when the reproductive status of the woman has been 
confirmed b y follow up hormone level assessment
Male sterilization (at least 6 months prior to screening). For female subjects on the 
study , the vasectomized male partner should be the sole partner for that subject
Barrier methods of contraception: Condom or Occlusive cap (diaphragm or 
cervical/vault caps) if allowed as effective method of contraception by  local 
regulations. For UK: with spermi cidal foam/gel/film/cream/ vaginal suppository  
Use of oral, injected or implanted hormonal methods of contraception or other forms 
of hormonal contraception that have comparable efficacy  (failure rate <1%), for 
example hormone vaginal ring or transdermal hormone contraception
Placement of an intrauterine device (IUD) or intrauterine s ystem (IUS)
In case of use of oral contraception women should have been stable on the same pill for a 
minimum of 3 months before taking stud y treatment.
Women are considered post-menopausal and not of child bearing potential if they have 
had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile 
(e.g. age appropriate, history  of vasomotor symptoms) or have had surgical bilateral 
oophorectom y (with orwithout hysterectom y) or tubal ligation at least six weeks ago. In 
the case of oophorectomy  alone, only  when the reproductive status of the woman has been 
confirmed by follow up hormone level assessment is she considered not of child bearing 
potential. 
11. Patients who have smoked or inhaled any substance other than asthma medications within 
the 6 month period prior to Visit 1 , or who have a smoking history of greater than 10 pack 
years (Note:10 pack years = 1 pack /day x 10 yrs., or ½ pack/day x 20 yrs.) .
12.Patients who have had an asthma attack/exacerbation requiring s ystemic cortico steroids 
hospitalization or emergency  room visit within 6 weeks prior to Visit 1.  If patients 
experience an asthma attack/exacerbation requiring s ystemic corticosteroids, 
hospital ization or emergency room visit during screening, they may be rescreened once, 6 
weeks after recovery  from the exacerbation.
13.Patients who have had a respiratory  tract infection or asthma worsening within 4 weeks of 
Visit 1.   Patients who experience a resp iratory  tract infection of asthma worsening during 
screening may be re -screened after 4 weeks after recovery  from their respiratory  tract 
infection or asthma worsening.
14.Patients with any  chronic condition of the respiratory  tract which in the opinion of the 
investigator may  interfere with study  evaluation or optimal participation in the study .
15.Patients with a history  of chronic lung disease other than asthma, including (but not 
limited to) chronic obstructive pulmonary  disease, bronchiectasis, (non -clinic ally 
significant bronchiectasis may  be allowed provided recent [within 3 months prior to Visit 
101] CT scan proof is available), sarcoidosis, interstitial lung disease, cy stic fibrosis, and 
tuberculosis .
16.Patients with uncontrolled diabetes having an HbA1c test result ≥8% at the Visit 1 
laboratory  test.

Novartis Confidential Page 36
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
17.Patients who have a clinically  significant laboratory  abnormalit y at the Visit 1 laboratory  
testincluding (but not limited to):
Total white blood cell count <2500 cells/µL  
AST or ALT>2.0 X ULN or total bil irubin >1.3 X ULN 
Estimated Glomerular Filtration Rate (eGFR) b y the Modification of Diet in Renal 
Disease ( MDRD ) equation or Bedside Schwartz equation <55 mL /minute/1.73 m2 
18.Patients who in the judgment of the investigator have a clinically  significant c ondition 
such as (but not limited to) unstable ischemic heart disease, NYHA Class III/IV left 
ventricular failure ,arrhy thmia, uncontrolled hy pertension, cerebrovascular disease, 
neurodegenerative diseases, or other neurological disease,  uncontrolled h ypo-and 
hyperthy roidism and other autoimmune diseases, hy pokalemia, hy peradrenergic state, or 
ophthalmologic disorder or patients with a medical condition that might compromise 
patient safet y or compliance, interfere with evaluation, or preclude completion o f the 
study .
19.Patients with a history  of my ocardial infarction within 12 months of Visit 1.
20. Patients with serious co- morbidities including, but not limited to, neurodegenerative 
diseases, rheumatoid arthritis and other autoimmune diseases.
21.Patients with a h istory  of alcohol or drug abuse within 12 months prior to Visit 1.
22.Patients with a weight <30 kg.
23.Patients receiving an y medications in the classes listed in Table 5 -3should be excluded 
unless they meet the criteria as specified in Table 5 -3.
24. Patients receiving medications in the classes listed in Table 5 -1should be excluded unless 
the medication has been stabilized for the specified period and the stated conditions have 
been met.
25.Patients who started immunotherap y or desensitization for allergies, within 3 months prior 
to Visit 1, or where the maintenance dose is expected to change duri ng the study . 
26.Patients with a known history  of non -compliance to medication or who are unable or 
unwilling to complete an electronic patient diary  or who are unable or unwilling to use 
Electronic Peak Flow with e Diary device or who are unable to demonstra te good eDiary  
compliance (defined as > 75% for eDiary  compliance) during the run -in epoch.
27.Inability  to compl y with all study requirements and demonstrate good medication 
compliance (>=80% compliance rate) during the treatment run -in epoch .
28.Patients with a ny medical or psy chological condition that, in the investigators opinion, 
renders the patient unable to understand the nature, scope, and possible consequences of 
the study .
29.Patients with a history  of being unable to swallow tablets .
30.Patients who have received methotrexate, oral gold, troleandomy cin, cy closporine 
azathioprine or an y experimental anti -inflammatory  therapies within 6 months of Visit 101.
31.Patients with r egular use of oral or s ystemic cortico steroid sfor diseases other than asthma 
within the 12 months or any  intra -articular or short -acting, intramuscular corticosteroid 
within 1 month or intramuscular, long acting depot corticosteroids within 3 months of 
Visit 101.
32.Patients who have a hi story  of or current treatment for hepatic disease i ncluding but not 
limited to acute or chronic hepatitis, cirrhosis or hepatic failure.

Novartis Confidential Page 37
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
33.Patients with a history  of immunodeficiency  disease or hepatitis B or hepatitis C.
34.Patients on >20 mg of simvastatin, >40 mg of atorvastatin , >40 mg of pravastatin , or >2 
mg of pitavastatin. Statin doses less than or equal to these dose s as well as other statins 
will be permitted during the study .
35.Patients on any  statin therapy  with a CK level >2 X ULN at Visit 1.
36.Patients on rifampin, probenecid, ritonavir and valproic acid (i.e. medications blocking 
several pathway s important for the elimination of QAW039 [broad range UGT inhibition 
and/or inhibition of OAT3, OATP1B3, MXR and P -gp]).
37.No person directly  associated with the administration of the study  is all owed to participate 
as a study subject .
38.No family  member of the investigational study  staff is allowed to participate in this study .
39.History  of lactose or milk sensitivity .
40.Patients with a history  of conditions other than asthma that could result in elevat ed 
eosinophils (e.g., h ypereosinophilic sy ndromes, Churg -Strauss Sy ndrome, eosinophilic 
esophagitis).  Patients with known parasitic infestation within 6 months prior to Visit 1 are 
also excluded.
41.Patients aged 12 to <18 years below the 3rdpercentile for weight b y age (based on local 
growth charts or the United States Center for Disease Control growth charts (Center for 
Disease Control and Prevention, 2000 ) if local growth charts are not available).
No additional exclusions may be applied by the investigator, in order to ensure that the study  
population will be representative of all eligible patients
.
5 Treatment
5.1 Protocol requested treatment
5.1.1 Investigational treatment
The following investigational treatment will be supplied by  Novartis to the study  sites:
Name: QAW039
Formulation: tablet
Unit dose: 2 strengths: 150 mg and 450 mg
Please refer to the Investigator’s Brochure for composition of the QAW039 tablets.
Name: QAW039 placebo
Formulation: tablet
Unit dose: matching placebo to QAW039 150 mg, matching placebo to QAW039 450 mg
Please refer to the Investigator’s Brochure for composition of the placebo tablets.
The investigational treatment (tablets) will be supplied in bottles. The matching placebos for 
QAW039 will be identical in appearance to their active counterparts and will be identicall y 
packaged. 

Novartis Confidential Page 38
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
5.1.2 Additional study treatment
No additional maintenance asthma treatment beyond investigational treatment is requested for 
this trial.
All patients will be provided with short -acting β2-agonists (SABAs)
(salbutamol/albuterol/other SABA) which they will be instructed to use throughout the study 
as rescue medication on an ‘as needed basis.’
Short -acting β2-agonists will either be supplied to the investigator sites locally  by Novartis or 
be provided b y the stud y center and reimbursed b y Novartis.
5.2 Treatment arms
During the run-in epoch, all patients will receive placebo to QAW039 once daily  (one tablet 
blinded placebo to QAW039 150 mg and one tablet blinded placebo to QAW039 450 mg).
Patients will be assigned to one of three treatment arms as follows in a 1:1:1 ratio in the 
treatment epoch :
QAW039 150 mg once daily  (one tablet of blinded QAW 039at 150 mg dosage 
strength to be given together with one tablet blinded placebo to QAW039 450 mg )
QAW039 450 mg once daily  (one tablet of blinded QAW 039at 450 mg dosage 
strength to be given together with one tablet blinded placebo to QAW039 150 mg )
Placebo to QAW039 once daily  (one tablet blinded placebo to QAW039 150 mg and 
one tablet blinded placebo to QAW039 450 mg)
Patients will be instructed to take their investigational treatment (QAW039 or placebo) once 
daily in the morning without regard to time of food intake .
5.3 Treatment assignment, randomization
At Visit 201, all eligible patients will be randomized via Interactive Response Technology 
(IRT) to 1 of the 3 treatment arms (QAW039 150 mg or 450 mg once daily  or placebo once 
daily ) in a 1:1:1 fashion within each of the randomization strata (peripheral blood eosinophil 
coun ts at Visit 1(<250 cells/l or ≥250 cells/l), patient age (<18 years or≥18 years), and 
their use or non-use of oral corticosteroids as part of their SoC asthma therap y) by IRT. The 
investigator or his/her delegate will contact the I RT after confirming that the patient fulfills all 
the inclusion/exclusion criteria. The IRT will assign a randomization number to the patient, 
which will be used to link the patient to a treatment arm and will specify  a unique medication 
number for the package sof investigati onal treatment to be dispensed to the patient. The 
randomization number will not be communicated to the caller.
The randomization numbers will be generated using the following procedure to ensure that 
treatment assignment is unbiased and concealed from patients and investigator staff. A patient 
randomization list will be produced by the IRT provider using a validated system that 
automates the random assignment of patient numbers to randomization numbers. These 
randomization numbers are linked to the differe nt treatment arms, which in turn are linked to 
medication numbers. A separate medication list will be produced by or under the 
responsibility  of Novartis Drug Suppl y Management using a validated system that automates 
the random assignment of medication num bers to packs containing the investigational drug(s). 

Novartis Confidential Page 39
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Randomization will be stratified by peripheral blood eosinophil counts at Visit 1 (<250 
cells/l or ≥250 cells/l), patient age (<18 years or≥18 years), and patient use or non- use of 
oral corticostero ids as part of their SoC asthma therap y.Treatment randomization will be 
stratified at the regional level.
Note : Enrollment to patient strata may be restricted by the Sponsor prior to the end of overall 
recruitment in order to achieve the desired distribu tion in the trial population.
The randomization scheme for patients will be reviewed and approved by a member of the 
Novartis Randomization Group.
5.4 Treatment blinding
This study  consists of a single -blind run-in epoch (i.e., only patients will be blinded tothe 
identity  of the treatment) followed by  a double -blind randomized treatment epoch. 
Patients, investigator staff, persons performing the assessments, and data analy sts will remain 
blind to the identity  of the treatment from the time of randomization un til database lock, using 
the following methods: (1) Randomization data are kept strictly  confidential until the time of 
unblinding, and will not be accessible by anyone involved in the study   
 
 
 
 (2) For each dose level, the identit y of the 
treatments will be concealed by the use of placebos identical in packaging, labeling, schedule 
of administration, appearance, taste, and odor to QAW039. Across the doses, a double -
dummy  design will be used.
Unblinding should only occur in the case of patient emergencies and at the conclusion of the 
study . In addition, the independent DMC will be unblinded for the purpose of safet y reviews 
and at the time of the futility  interim anal ysis.
5.5 Treating the patient 
5.5.1 Patient numbering 
Each patient is uniquely  identified by a Subject Number which is composed by the site 
number assigned by Novartis and a sequential number assigned by the investigator . Once 
assigned to a patient, the Subject Number will not be reused.  If a patient is re-screened they 
will be assigned a new subject number.
Upon signing the informed consent form, the patient is assigned the next sequential number 
by the investigator. The investigator or his/her staff will contact the IRT and provide the 
requested identify ing information for the patient to register them into the IRT. The site should 
select the CRF book with a matching Subject Number from the EDC sy stem to enter data. 
If the patient fails to be treated for any reason, the IRT must be notified within 2 day s that the 
patient was not treated. The reason for not being treated will be entered on the Screening 
Epoch Study  Disposition CRF.
5.5.2 Dispensing the investigational treatment

Novartis Confidential Page 40
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Each study  site will be supplied by Novartis with investigational treatment in packaging of 
identical appearance.
The investigational treatment packaging has a 2 -part label. 
A unique randomization medication number is printed on each part of this label which 
corresponds to the stud y epoch and/or treatment arm the patient is assigned to.
Investigator staff will identify  the investigational treatment package(s) to dispense to the 
patient by contacting the IRT and obtaining the medication number(s). Immedia tely before 
dispensing the package to the patient, investigator staff will detach the outer part of the label 
from the packaging and affix it to the source document (Drug Label Form) for that patient’s 
unique subject number. 
5.5.3 Handling of study  treatment 
5.5.3.1 Handling of investigational treatment
The investigational treatment must be received by a  d esignated person at the study  site, 
handled and stored safely  and properl y, and kept in a secured location to which only the 
investigator and designees have access. Upon receipt, all investigational treatment should be 
stored according to the instructions specified on the labels. Clinical supplies are to be 
dispensed only  in accordance with the protocol. Technical complaints are to be reported to the 
respective Novarti s CPO Quality  Assurance.
Medication labels will be in the local language and comply  with the legal requirements of 
each country . They  will include storage conditions for the investigational treatment but no 
information about the patient except for the medi cation number .
The investigator must maintain an accurate record of the shipment and dispensing of 
investigational treatment in a drug accountability log. Monitoring of drug accountability  will 
be performed by the field monitor during site visits and at the completion of the trial. Patients 
will be asked to return all unused investigational treatment and packaging at the end of the 
study  or at the time of discontinuation of investigational treatment. 
At the conclusion of the study , and as appropriate durin g the course of the study , the 
investigator will return all unused investigational treatment, packaging, drug labels, and a 
copy  of the completed drug accountability  log to the Novartis monitor or to the Novartis 
address provided in the investigator folder at each site.
5.5.3.2 Handling of other study  treatment 
No applicable.
5.5.4 Instructions for prescribing and taking study treatment
Study  treatment will be single -blind during the run-in and double -blind, double -dummy ,and 
placebo -controlled after randomization. At clinic visits, patients will receive a witnessed dose 
of study  medication.  These in-clinic witnessed doses will be given after the completion of all 
pre-dose assessments (see Section 6 ) and should be given at approximately  the same time at 
each clinic visit.  Between clinic visits, patients will take study  medication once daily  in the 

Novartis Confidential Page 41
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
morning.  Patients will be instructed to take their study  medication at approximately  the same 
time each morning.
At Vis it 101, all eligible patients will be given oral placebo to QAW039 for a run-in epoch of 
2 weeks and will be instructed on the intake of the investigational treatment. In order to 
maintain the blind from the patient’s point of view, investigators should not divulge 
information regarding the fact that all individuals will be assigned to placebo during the 
run- in epoch . If a patient experiences an asthma exacerbation during the run-in epoch, the 
run-in epoch must be extended up to 6 weeks to permit for resolution of the asthma 
exacerbation before randomization. The run -in epoch should only be extended beyond 2 
weeks (+/-5 days) for an asthma exacerbation . At Visit 201, patients will be randomized and 
stratified according to their peripheral blood eosinophil counts (<250 cells/ l or ≥250 cells/ l), 
patient age (<18 years or ≥18 years), and their baseline use or non-use of oral corticosteroids 
as part of their SoC asthma therap yat Visit 1. Each randomized patient will then enter a 52-
week treatment epoch wher e they  will receive one of the following 3 treatments:  (i) QAW039 
150 mg once dail yor (ii) QAW039 450 mg once daily or(iii) placebo once dail ygiven on top 
of their individual background asthma treatment .The investigational treatment will be 
dispensed in medication packs (bottles) at each site visit during the treatment epoch to cover 
the treatment period between patient visits and to allow for late visits and other unforeseen 
events . All dosages prescribed and dispensed to the patient and all dose changes during the 
study  must be recorded on the Dosage Administration Record CRF
All kits of investigational treatment assigned b y IRTwill be recorded/databased in the IRT. 
The investigator should instruct the patient to take theinvestigational treatment exactly  as 
prescribed in order to ensure compliance .The patient should be instructed to contact the 
investigator if he/she is unable for any reason to take the investigational treatment as 
prescribed. 
5.5.5 Permitted dose adjustments and interruptions of study treatment
QAW039 treatment dose adjustments are not permitted.
QAW039 treatment interruption is only  permitted in the following situations:
A positive urine pregnancy  test requires immediate interruption of study  medication 
until serum β- hCG is performed and found to be negative. 
An investigator considers an interruption is necessary  for the treatment of an adverse 
event. 
Interruption to treatment must be recorded on the Dosage Administration Record CRF.
5.5.6 Rescue medication
At Visit 1 all patients will be provided with a SABA (such as salbutamol [100 mcg or 
albuterol 90 mcg]) which they will be instructed to use throughout the study  as rescue 
medication on an ‘as needed basis’. Patients will be advised that between visits they can take 
their rescue medication for symptoms of asthma. Rescue medication (i.e., SABAs )will either
be supplied to the investigator sites locall y by the Novartis CPO or provided by the study 
center and reimbursed b y Novartis.
Nebulized salbutamol/albuterol is not allowed as rescue medication and will not be supplied.

Novartis Confidential Page 42
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
To standardize measurements, patient s will be instructed not to use their rescue medication 
upon rising in the morning on days requiring spirometric assessments indicated in Table 6-1, 
unless absolutely  necessary .  If rescue medication istaken within 6 hours prior to spirometry , 
this information will be recorded by the study  site staff using the equipment provided by the 
central spirometry  vendor.  Additionally , if rescue medication is taken within 6 hours prior to 
spirometry  at any of the scheduled visits, the visit should be rescheduled to the next possible 
day.
Daily  use of rescue medication (the number of puffs taken in the previous 12 hours )will be 
recorded (once in the morning and once in the evening) b y the patient using / eDia ry.
Unless clinically  indicated, the type of rescue medication (i.e.,SABA) a patient uses, the 
device used to deliver the medication (e.g. dry  powder or HFA) and the way  it is administered 
(e.g. with a spacer device) should not be adjusted. Any changes relating to the above must be 
recorded on the Concomitant medications CRF after the start of stud y drug.
5.5.7 Background therapy
All patients will remain on the incoming SoC asthma therapy  they were taking at the 
screening visit (Visit 1) throughout the study . Nodosage adjustments of the patient’s 
incoming SoC therap y will be permitted during the study .Short bursts of rescue systemic 
corticosteroids are allowed for treatment of asthma exacerbations, as clinically  indicated (see 
Section 6.4.1 ).  The duration of a burst of rescue systemic corticosteroids should be 
approximately  3 to 10 day s, and be of the shortest time needed to allow s ymptom control.
5.5.8 Concomitant treatment 
The medications in Table 5
-1are only permitted under the circumstances given.  This table is 
not considered all-inclusive. Medications should be assessed for adherence to the indication 
and other inclusion/exclusion criter ia.
Table 5-1 Medications allo wed under certain conditions
Class of medication Condition
Inhaled corticosteroids (ICS) ** Medium or high-dose* daily or equivalent. Used for 
at least 3 months prior to Visit 1 and stable for at 
least 4 weeks prior to Visit 1.Must be taken with a 
LABA or an alternate therapy (LTRA or theophylline
or LAMA )or with LABA/LAMA or with LABA/LTRA
or with LABA/theophylline .
Long -acting inhaled β -2 agonists (LABA s)**Used for at least 3 months prior to Visit 1 and 
stable for at least 4 weeks prior to Visit 1.
Must be taken with medium or high-dose* ICS .
Fixed dose combinations of ICS and LABA 
(FDC) **Used for at least 3 months prior to Visit 1 and 
stable for at least 4 weeks prior to Visit 1.
Leukotriene receptor antagonists 
(LTRAs )**Used for at least 3months prior to Visit 1and 
stable for at least 4 weeks prior to Visit 1.
Must be taken with medium or high-dose* ICS .
Theophylline ** Used for at least 3months prior to Visit 1and 
stable for at least 4 weeks prior to Visit 1.

Novartis Confidential Page 43
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Table 5-2indicates the wash -out periods for allowed asthma medications prior to spirometry  
assessments. See Appendix Spirometry  Guidance for more details. 
Table 5-2 Medications to be withheld prior to spirometry
Class of medication Last dose prior to spirometry
Short -acting β 2-agonist s ≥ 6 hours
Long -acting β 2-agonist s(LABAs) given twice daily ≥ 12 hours
LABAs given once daily ≥ 24 hours
Fixed dose combinations of LABA and inhaled 
corticosteroid ( ICS) given twice daily≥ 12 hours
Fixed- dose combinations of LABA and ICS given 
once daily≥ 24 hours
Long -acting muscarinic antagonists (LAMAs) ≥ 24 hoursMust be taken with medium or high-dose* ICS .
Long -acting muscarinic antagonist s
(LAMAs) **Used for at least 3 months prior to Visit 1 and 
stable for at least 4 weeks prior to Visit 1.
Must be taken with medium or high-dose* ICS .
Maintenance oral corticosteroids for 
treatment of asthmaUsed for at least 3months prior to Visit 1 and 
stable for at least 4 weeks prior to Visit 1.
Short bursts of rescue sy stemic corticosteroids are 
allowed for treatment of asthma exacerbations, as 
clinically indicated.  The duration of a burst of 
rescue sy stemic corticosteroids should be 
approximately 3 to 10 days, and be of the shortest 
time needed to allow sy mptom control.
Short -acting β 2-agonist (SABAs) Rescue medication to be taken as needed.
Maintenance immunotherapy for allergies Stable dose for at least 3 months prior to screening 
and the dose remains stable throughout the study.
Inactivated influenza vaccine, 
pneum ococcal vaccination or any other 
inactivated vaccineNot administered within 48 h prior to a study visit.
Topical corticosteroids for treatment of 
eczemaRecommended doses and dosage regimens
Antihistamines (e.g., lora tadine, cetirizine) Recommended doses and dosage regimens
Nasal anticholinergics
Treatment regimen has been stable for at least 1 
month prior to screening (Visit 1).
In the case of as needed use, providing an 
established pattern of use has been document ed.Nasal corticosteroids
Nasal or ophthalmological preparations of 
nedocromil
Nasal or ophthalmological preparations of 
antihistamines
*See GINA 2016 for definition of medium  and high-dose ICS .
**See Section 4.1 (inclusion criterion 4)for permitted combinations of therapy .

Novartis Confidential Page 44
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
The investigator should instruct the patient to notify  the study  site about any new medications 
he/she takes after the patient was enrolled into the study . All medications, procedures and 
significant non-drug therapies (including physical therapy  and blood transfusions) 
administered after the patient was enrolled into the study  must be recorded in the eCRF.
5.5.9 Prohibited Treatment
Use of the treatments display ed in Table 5-3is NOT allowed after the start of study (i.e., after 
Visit 101). Each concomitant drug must be individually  assessed against all exclusion criteria 
and the tables below to see if it is allowed. If in doubt, the investigator should contact the 
Novartis medical monitor or designee before randomizing a patient or allowin g a new 
medication to be started. This table is not considered all-inclusive. Medications should be 
assessed for adherence to the indication and other inclusion/exclusion criteria .
These medications are also prohibited if administered for other indications .
Table 5-3 Prohibited medications
Class of medication Minimum cessation prior to run -in (Visit 101)
Other investigational drugs 30 days or 5 half -lives, whichever is longer 
Live attenuated vaccine 30 days
Other CRT h2antagonists (e.g., ramatroban) 7days or 5 half -lives whichever is longer
Short -acting anticholinergics 8 hours
Fixed combinations of short -acting β 2agonists 
and short -acting anticholinergics8 hours
Systemic mast cell stabilizers (e.g. 
cromoglycate, nedocromil, ketotifen)7 days
Monoclonal antibodies , investigational or 
approved, for the treatment of asthma (e.g. ,
omalizum ab)5months
Simvastatin >20 mg,atorvastatin >40 mg, 
pravastatin >40 mg, orpitavastatin >2 mg
total daily dose7 days
Rifampin, probenecid, ritonavir and valproic 
acid (i.e. medications blocking several 
pathways important for the elimination of 
QAW039 (broad range UGT inhibition and/or 
inhibition of OAT3, OATP1B3, MXR and P -
gp)).7 days
Methotrexate, gold salts, cyclospo rine, 
troleandom ycin, azathioprine, other 
immunomodulator drugs or 
immunomodulator y monoclonal antibodies6 months
5.5.10 Discontinuation of study treatment
Patients may voluntarily  discontinue active study  medication (refuse study  treatment but 
continue with study  participation) at any time. Patients who wish to discontinue active 
study medication will be asked to remain in the study and complete all study visits .  
Patients withdrawn from study treatment will receive SoC asthma therapy according to 
investigator judgement. 

Novartis Confidential Page 45
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
The investigator should discontinue study  treatment for a given patient if, on balance, he/she 
believes that continuation of study  treatment would be detrimental to the patient’s well -being.  
Study  treatment must be discontinued under the following circumstances: 
Withdrawal of informed consent (and the investigator must prematurel y withdraw the 
patient from the study );
Pregnancy ;
Female subjects non -compliant with the chosen effective method o f contraception during 
the study : The investigator must provide appropriate advice on the continued use of 
effective contraception for at least one week (at least 5 half -lives of QAW039 ) after stud y 
drug discontinuation and follow up with the subject as appropriate at least to the end of 
this period;
Any protocol deviation that results in a significant risk to the patient’s safety ;
Liver laboratory  test abnormality  / event (see Appendix 2 ):
Abnormal live r laboratory  results requiring discontinuation –refer to Table 14-2;
If the investigator consider s it appropriate after the confirmation of a liver safet y 
monitoring signal :
ALT or AST ≥5xUL N, or
ALT or AST ≥2.5xUL N andtotal bilirubin   ≥1.5xULN ( Appendix 2 );
Premature unblinding of study  treatment for a patient for any reason;
Total white blood cell count <1000 cells/µL ;
If patients on statin therapy  complain of persistent muscle pain without any obvious cause 
for greater than 3 day s accompanied b y increase in CK levels >10 xULN or persistent 
intolerable muscle pain regardless of the accompany ing CK level ;
If a patient develops a medical conditi on that requires consistent use of prohibited 
treatment as per Section 5.5.9 or if patient exhibits a behavior of non -compliance 
regarding prohibited medication.
The appropriate personnel from the site and Novartis will assess whether investigational 
treatment should be discontinued for any patient whose treatment code has been broken 
inadvertentl y for an y reason. 
Patients who discontinue investigational treatment should NOT be considered withdrawn 
from the study . If premature discontinuation of investigational treatment occurs for any  reason 
the patient should continue attending the remaining study  visits while off investigational 
treatment. The patient should return to the clinic as soon as possible for an investigational 
treatment discontinuation visit (TD). At this visit, the assessments listed under 
UNSCHEDULED -TDin Table 6
-1should be completed and recorded in the eCRF. The 
investigator and study staff must discuss with the patient, the patient’s continued participation 
in the study  and request patients to continue attending study  visits according to the study  visit 
schedule with all assessments (except study  drug related assessments such as comp liance 
checks ) completed up to Visit 299. If the patient cannot or is unwilling to attend any further 
visit(s), the site staff should maintain regular phone contact with the patient, or with a person 
pre-designated by the patient. This phone contact should preferabl y be done according to the 
study  visit schedule. Data will continue to be collected concerning the patients’ condition and 
changes in concomitant medications, surgeries and procedures, serious and non- serious 

Novartis Confidential Page 46
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
adverse events, and asthma exacerbati ons should be recorded in the appropriate eCRF if 
applicable. If necessary  an unscheduled clinical visit may  be arranged.
The investigator must also contact the IRT to register the patient’s discontinuation from 
investigational treatment
5.5.11 Discontinuation fr om study
Patients will only be discontinued from the study if they withdraw consent , die during 
the study or are lost to follow -up (seeSection 5.5.13 ).
5.5.12 Withdrawal of consent
Patients may voluntaril y withdraw consent to participate in the study  for any reason at any 
time. 
Withdrawal of consent occurs onl y when a patient does not want to participate in the study 
anymore and does not want any further visits or assessments and does not want any further 
study  related contacts and does not allow anal ysis of alread y obtained biologic material.
If a patient withdraws consent, the investigator must make every  effort (e.g. telephone, e -mail, 
letter) to determine the primary  reason for this decision and record this information. 
Investigational treatment must be discontinued and no further assessments conducted. All 
biological material that has not been analyzed at the time of withdrawal must not be used. 
Further attempts to contact the patient are not allowed unless safety  findings require 
communicating or follow -up.
The investigator must also contact the IRT to register the patient’s withdrawal from the stud y.
Patients who prematurely discontinue study  treatment or withdraw from the study will not be 
replaced.
5.5.13 Lostto follow -up 
For patients whose status is unclear because they  fail to appear for study  visits without stating 
an intention to withdraw, the investigator should show "due diligence" by contacting the 
patient, family  or family p hysician as agreed in the informed consent and by documenting in 
the source documents steps taken to contact the patient, e.g. dates of telephone calls, 
registered letters, etc. A patient should not be considered lost to follow -up until his/her 
scheduled e nd of study  visit would have occurred.
5.5.14 Emergency  breaking of assigned treatment code 
Emergency  treatment code breaks should only be undertaken when it is essential to treat the 
patient safel y and efficaciously . Most often, study drug discontinuation and knowledge of the 
possible treatment assignments are sufficient to treat a study  patient who presents with an 
emergency  condition. Emergency  treatment code breaks are performed using the IRT. When 
the investigator contacts the system to break a treatment code for a patient, he/she must 
provide the requested patient identify ing information and confirm the necessity  to break the 
treatment code for the patient. The investigator will then receive details of the investigational 
drug treatment for the specified patient and a fax or email confirming this information. The 
system will automatically  inform Novartis that the code has been broken.

Novartis Confidential Page 47
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
It is the investigator’s responsibility  to ensure that there is a dependable, redundant procedure 
in place to allow access to the IRT code break card at any time in case of emergency . The 
investigator will provide the protocol number, investigational treatment name if available, 
patient number as well as oral and written information to the patient on how to contact his/her 
backup in cases of emergency  when he/she is unavailable to ensure that un-blinding can be 
performed at any time in the case of emergency . Study  drug must be discontinued after 
emergency  unblinding. Study  drug must also be discontinued for any patient whose treat ment 
code has been inadvertently  broken or for any  other non -emergency  reason.
5.5.15 Study completion and post- study treatment 
Study  completion for a patient will occur after he/she has completed 52 weeks of treatment 
(through to Visit 299) or they have prematu rely withdrawn. Completion of the study  will be 
when all randomized patients have completed 52 weeks of treatment and the post-treatment 
follow -up visit .
Patients who have been screened when enrolment target has been met will be allowed to 
proceed onto study  participation.
A Safet y Study  of QAW039 is planned. At sites participating in the Safet y Study , patients 
who successfully  complete 52 weeks of treatment in this study  (Study  A2307) may be offered 
participation in the Safety  Study; patient participati on in the Safety  Study will be optional. 
Patients not entering the safet y study  will complete the follow -up epoch and will not be given 
further access to study  drug  because the risk/benefit ratio will not yet have been substantiated 
and there are alread y other marketed therapeutic alternatives available to treat these patients. 
At the time of study  completion or early termination, all patients will be placed on the 
appropriate asthma treatment as prescribed b y the investigator.
The investigator must provi de appropriate advice on the continued use of effective 
contraception for at least one week (at least 5 half-lives of QAW039) after the study 
completion (V299) or premature study  drug discontinuation and follow up with the subject as 
appropriate at least t o the end of this period .
The investigator must provide follow -up medical care for all patients who are prematurely 
withdrawn from the study, or must refer them for appropriate ongoing care. 
5.5.16 Early  study termination 
The study  can be terminated at any  time for any  reason by  Novartis. Should this be necessary, 
the patient should be seen as soon as possible and treated for a prematurely withdrawn patient. 
The investigator may be informed of additional procedures to be followed in order to ensure 
that adequate consideration is given to the protection of the patient’s interests. The 
investigator will be responsible for informing the Institutional Review Board/Independent 
Ethics Committee (I RBs/IECs) of the earl y termination of the trial.
6 Visit schedule and asse ssments
Visits must be scheduled to allow randomized study drug to be taken in the morning 
Table 6 -1lists all of the assessments and indicates with an “x” when the visits are performed. 

Novartis Confidential Page 48
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Patients should be seen for all visits as close as possible to the visit date. In case a treatment 
visit cannot occur as scheduled in the protocol, visits should be scheduled according tothe 
specified visit window in the schedule of assessments. 
Patients ,who discontinue study  treatment before completing the study and will accept to 
remain in the study , will return for study  visits as described in Section 
5.5.10 . If they fail to 
return for these assessments for unknown reasons, every  effort should be made to contact 
them as specified in Section 5.5.10.  At the very least, patients should be asked if they can be 
contacted by phone by study personnel at the date they would have been scheduled to end the 
follow up epoch (4weeks after premature drug discontinuation) to ask about concomitant 
medication use, surgery  and procedures, SAEs, AEs and asthma exacerbations .
Patients will be required to attend the clinic in the morning at approximately the same 
time , so that pre -dose FEV1 assessments can be performed between 6:00 A.M. and 10:00
A.M. (+/- 1 hour) .  
 At certain clinic visits, measurements will be collected 
2 hours post dosing ; these measurements should be accounted for when scheduling clinic 
visits.
When the following assessments are scheduled to be per formed at the same time -point, 
the order of priority will be as follows: 
1)Question on medication withholding for spirometry; 
2)Patient Reported Outcome instruments to be completed in the following order: 
ACQ -5,AQLQ +12, at certain clinic visits ; 
3)Vital signs ;
4)ECG s;
5)Samples for urine/hematology/blood chemistry (At Visit 1 collect samples prior to 
spirometry . At all other visits, c ollect samples prior to the 1stpre-dose spirometry  
[which is the -45 min pre -dose spirometry ]or between the 1stand 2ndpre-dose 
spirometry  measurements. );
6)Samples for RAST /ImmunoCAP test, Total IgE, at certain clinic visit(s) (At Visit 
1 collect samples prior to spirometry . At all other visits, collect samples prior to the 1st
pre-dose spirometry  [which is the -45 min pre -dose spirometry ]or between the 1stand 
2ndpre-dose spirometry  measurements.);
 
 
9)Spirometry assessments should be timed so that the Visit 1 spirometry assessment 
and all pre-dose spirometry assessments (i.e., FEV1 mea surements) during the 
run- in epoch and treatment epoch a reperformed between 6:00 A.M. and 10:00
A.M .(+/-1 hour) . Other tests should be performed as close as possible to those 
spirometry  times. During the run-in epoch and treatment epoch, two pre -dose 
spirometry  assessments sh ould be performed as follows :

Novartis Confidential Page 49
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
First pre -dose spirometry assessment : approximately  45 minutes prior to the 
dosing of study drug at the clinic visit .
Second pre- dose spirometry assessment :approximately  15 min utesprior to the 
dosing of study drug at the clinic visit .
10)Reversibility at certain visits (spirometry  after administration of SABA) may be 
performed after 10:00 A .M.(+/-1 hour) ;
11)In-clinic witnessed dosing of study drug ;
12)ECG s(2hourpost-dose) at certain clinic visits ;

Novartis Confidential Page 50
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Table 6-1 Assessment schedule
Screen Run-in Treatment Follow -up
Visit Number (Site visits)1
1 101 199 201 202 203 204 205 206 207UNSCH
EDULED
-TD299 301
Telephone Call (TC)2
Note: TC in -between site visits TC1 TC2 TC3 TC4 TC5 TC6
Treatment Week -4 -231 1 4 8 12 16 20 24 28 32 36 40 44 48 TD 52 56
Treatment Day
Note: * V199 and 201 will occur on the 
same day if the patient is randomized.-28 -1431* 1* 28 56 84 112 140 168 196 224 252 280 308 336 TD364392
Visit Window (Days) NA +/-7 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 NA +/-5 +/-5
1Scheduled clinic visits (starting at Visit101 and thereafter) are to occur in the morning at approximately the same time, so that the -45 min and -15 min pre-dose FEV1 assessments can be performed between 06:00 
A.M. and 10:00 A.M. (+/-1 hour) .
2Scheduled telephone calls (TCs) will be conducted to check the patients’ condition (Changes in concomitant medications, surge ries and procedures, serious and non -serious adverse events, and asth ma exacerbations 
should be recorded in the appropriate eCRF if applicable). If necessary an unscheduled clinical visit may be arranged.
3For patients experiencing an asthma exacerbation during the run-in epoch , the run -in may be extended upto 6 weeks.
4The follow -up epoch applies to all patients except those patients who enter the safety study directly after Visit 299.
TD = investigational treatment discontinuation (permanent treatment discontinuation but continue with limited assessments; (S) = assessment to be recorded in source documents only; assessment will not be entered 
into the eCRFs; V= Visit
Informed consent and assent (if 
applicable) 
Note: ICF must be obtained within 14 
days prior toor on V1.X
Ask question on withholding of 
medication before clinic visits (for 
details see Section 5.5.8 )
Note: If the patient has not withheld 
medications as specified in the protocol 
before a particular visit, t he visit must be 
rescheduled.X X X X X X X X X X X
Demographics X
Medical history X
Medical History –Protocol solicited 
events for asthmaX
Asthma exacerbation history X
Smoking history X
Prior/concomitant medication 
(asthma and non -asthma 
medications) reviewX X X X X X X X X X X
Inclusion/exclusion criteria X X X

Novartis Confidential Page 51
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Screen Run-in Treatment Follow -up
Visit Number (Site visits)1
1 101 199 201 202 203 204 205 206 207UNSCH
EDULED
-TD299 301
Telephone Call (TC)2
Note: TC in -between site visits TC1 TC2 TC3 TC4 TC5 TC6
Treatment Week -4 -231 1 4 8 12 16 20 24 28 32 36 40 44 48 TD 52 56
Treatment Day
Note: * V199 and 201 will occur on the 
same day if the patient is randomized.-28 -1431* 1* 28 56 84 112 140 168 196 224 252 280 308 336 TD364392
Visit Window (Days) NA +/-7 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 NA +/-5 +/-5
1Scheduled clinic visits (starting at Visit101 and thereafter) are to occur in the morning at approximately the same time, so that the -45 min and -15 min pre-dose FEV1 assessments can be performed between 06:00 
A.M. and 10:00 A.M. (+/-1 hour) .
2Scheduled telephone calls (TCs) will be conducted to check the patients’ condition (Changes in concomitant medications, surge ries and procedures, serious and non -serious adverse events, and asth ma exacerbations 
should be recorded in the appropriate eCRF if applicable). If necessary an unscheduled clinical visit may be arranged.
3For patients experiencing an asthma exacerbation during the run-in epoch , the run -in may be extended upto 6 weeks.
4The follow -up epoch applies to all patients except those patients who enter the safety study directly after Visit 299.
TD = investigational treatment discontinuation (permanent treatment discontinuation but continue with limited assessments; (S) = assessment to be recorded in source documents only; assessment will not be entered 
into the eCRFs; V= Visit
Review and record surgeries and 
proceduresX X X X X X X X X X X X X X X X X
Physical examination (S) X X X
Abbreviated physical examination 
(heart and lung only) (S)X X X X X X X X
Height
Note: Height must be collected using a 
standard measurement device (such as 
a stadiometer)X X
Weight X X X X
Parasitic screening (S)
Note: Only if required by health 
authority and/or ethics 
committee/institutional review board.  
Sites should use local laboratories.X
Vital signs
(systolic/diastolic blood pressure, radial 
pulse (sitting), and body temperature)X X X X X X X X X X X
Electrocardiograms X X
Electrocardiograms (Pre -dose) X X X X X X X X X
Electrocardiograms (2h -post dose) X X X X

Novartis Confidential Page 52
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Screen Run-in Treatment Follow -up
Visit Number (Site visits)1
1 101 199 201 202 203 204 205 206 207UNSCH
EDULED
-TD299 301
Telephone Call (TC)2
Note: TC in -between site visits TC1 TC2 TC3 TC4 TC5 TC6
Treatment Week -4 -231 1 4 8 12 16 20 24 28 32 36 40 44 48 TD 52 56
Treatment Day
Note: * V199 and 201 will occur on the 
same day if the patient is randomized.-28 -1431* 1* 28 56 84 112 140 168 196 224 252 280 308 336 TD364392
Visit Window (Days) NA +/-7 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 NA +/-5 +/-5
1Scheduled clinic visits (starting at Visit101 and thereafter) are to occur in the morning at approximately the same time, so that the -45 min and -15 min pre-dose FEV1 assessments can be performed between 06:00 
A.M. and 10:00 A.M. (+/-1 hour) .
2Scheduled telephone calls (TCs) will be conducted to check the patients’ condition (Changes in concomitant medications, surge ries and procedures, serious and non -serious adverse events, and asth ma exacerbations 
should be recorded in the appropriate eCRF if applicable). If necessary an unscheduled clinical visit may be arranged.
3For patients experiencing an asthma exacerbation during the run-in epoch , the run -in may be extended upto 6 weeks.
4The follow -up epoch applies to all patients except those patients who enter the safety study directly after Visit 299.
TD = investigational treatment discontinuation (permanent treatment discontinuation but continue with limited assessments; (S) = assessment to be recorded in source documents only; assessment will not be entered 
into the eCRFs; V= Visit
Pregnancy test —serum (women of 
child bearing potential)
Note: Pregnancy testing will begin at  
Visit 1 if a patient is identified as being of 
child bearing potentialX
Pregnancy test —urine (women of 
child bearing potential)
Notes:
Pregnancy testing will begin at the visit a 
patient is first identified as being of child 
bearing potential .
A positive urine pregnancy test requires 
immediate interruption of study 
medication until serum β- hCG is 
performed and found t o be negative. If 
positive, the patient must be 
discontinued from study treatment .X X X X X X X X X X X
In countries where monthly 
pregnancy testing is required 
for women of child -bearing 
potential by local laws or 
regulations : Home Pregnancy 
testing - urine 
Note:   at telephone visits (S)X X X X X X
Urinalysisand urine chemistry
(central laboratory) X X X X X X X X X X

Novartis Confidential Page 53
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Screen Run-in Treatment Follow -up
Visit Number (Site visits)1
1 101 199 201 202 203 204 205 206 207UNSCH
EDULED
-TD299 301
Telephone Call (TC)2
Note: TC in -between site visits TC1 TC2 TC3 TC4 TC5 TC6
Treatment Week -4 -231 1 4 8 12 16 20 24 28 32 36 40 44 48 TD 52 56
Treatment Day
Note: * V199 and 201 will occur on the 
same day if the patient is randomized.-28 -1431* 1* 28 56 84 112 140 168 196 224 252 280 308 336 TD364392
Visit Window (Days) NA +/-7 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 NA +/-5 +/-5
1Scheduled clinic visits (starting at Visit101 and thereafter) are to occur in the morning at approximately the same time, so that the -45 min and -15 min pre-dose FEV1 assessments can be performed between 06:00 
A.M. and 10:00 A.M. (+/-1 hour) .
2Scheduled telephone calls (TCs) will be conducted to check the patients’ condition (Changes in concomitant medications, surge ries and procedures, serious and non -serious adverse events, and asth ma exacerbations 
should be recorded in the appropriate eCRF if applicable). If necessary an unscheduled clinical visit may be arranged.
3For patients experiencing an asthma exacerbation during the run-in epoch , the run -in may be extended upto 6 weeks.
4The follow -up epoch applies to all patients except those patients who enter the safety study directly after Visit 299.
TD = investigational treatment discontinuation (permanent treatment discontinuation but continue with limited assessments; (S) = assessment to be recorded in source documents only; assessment will not be entered 
into the eCRFs; V= Visit
Blood for hematology and 
chemistry (central laboratory)
Notes: No fasting requirement prior to 
blood sampling.X X X X X X X X X X
Blood for RAST /ImmunoCAP test 
(central laboratory)X
Blood sample for IgE X X X
Review Visit 1 laboratory results 
(chemistry, hematology, HbA1c , 
RAST/ImmunoCAP, IgE, urine 
chemistry and urinalysis). (S)
Note: If results for chemistry , hematol ogy,  
HbA1c , RAST/ImmunoCAP, IgE, urine 
chemistry  and urinalysis are missing, obtain 
a repeat for the missing result .X
Telephone contact with patient (S) X X X X X X
Serious adverse event recording X X X X X X X X X X X X X X X X X X X
Adverse event recording X X X X X X X X X X X X X X X X X X

Novartis Confidential Page 54
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Screen Run-in Treatment Follow -up
Visit Number (Site visits)1
1 101 199 201 202 203 204 205 206 207UNSCH
EDULED
-TD299 301
Telephone Call (TC)2
Note: TC in -between site visits TC1 TC2 TC3 TC4 TC5 TC6
Treatment Week -4 -231 1 4 8 12 16 20 24 28 32 36 40 44 48 TD 52 56
Treatment Day
Note: * V199 and 201 will occur on the 
same day if the patient is randomized.-28 -1431* 1* 28 56 84 112 140 168 196 224 252 280 308 336 TD364392
Visit Window (Days) NA +/-7 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 NA +/-5 +/-5
1Scheduled clinic visits (starting at Visit101 and thereafter) are to occur in the morning at approximately the same time, so that the -45 min and -15 min pre-dose FEV1 assessments can be performed between 06:00 
A.M. and 10:00 A.M. (+/-1 hour) .
2Scheduled telephone calls (TCs) will be conducted to check the patients’ condition (Changes in concomitant medications, surge ries and procedures, serious and non -serious adverse events, and asth ma exacerbations 
should be recorded in the appropriate eCRF if applicable). If necessary an unscheduled clinical visit may be arranged.
3For patients experiencing an asthma exacerbation during the run-in epoch , the run -in may be extended upto 6 weeks.
4The follow -up epoch applies to all patients except those patients who enter the safety study directly after Visit 299.
TD = investigational treatment discontinuation (permanent treatment discontinuation but continue with limited assessments; (S) = assessment to be recorded in source documents only; assessment will not be entered 
into the eCRFs; V= Visit
Record deaths X X X X X X X X X X X X X X X X X X X
Liver events monitoring X X X X X X X X X X X X
Renal events monitoring X X X X X X X X X X X X
Asthma exacerbation recording
Note: In case of an asthma 
exacerbation, the patient should be 
encouraged by the site to contact it for 
advice. If necessary, an unscheduled 
visit to the site may be organizedX X X X X X X X X X X X X X X X X
Spirometry (centralized)
£To be performed prior to reversibility 
test. X£X
1stPre-dose Spirometry 
(centralized) -45 min pre -dose
Note: To be performed approximately. 
45 min prior to in -clinic witnessed study 
drug administration.X X X X X X X X X
2ndpre-dose Spirometry 
(centralized) -15 min pre -dose
Note: To be performed approx imately . 
15 min prior to in -clinic witnessed study 
drug administration.
£To be performed prior to reversibility 
test. X£X£X£X X X£X X X£

Novartis Confidential Page 55
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Screen Run-in Treatment Follow -up
Visit Number (Site visits)1
1 101 199 201 202 203 204 205 206 207UNSCH
EDULED
-TD299 301
Telephone Call (TC)2
Note: TC in -between site visits TC1 TC2 TC3 TC4 TC5 TC6
Treatment Week -4 -231 1 4 8 12 16 20 24 28 32 36 40 44 48 TD 52 56
Treatment Day
Note: * V199 and 201 will occur on the 
same day if the patient is randomized.-28 -1431* 1* 28 56 84 112 140 168 196 224 252 280 308 336 TD364392
Visit Window (Days) NA +/-7 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 NA +/-5 +/-5
1Scheduled clinic visits (starting at Visit101 and thereafter) are to occur in the morning at approximately the same time, so that the -45 min and -15 min pre-dose FEV1 assessments can be performed between 06:00 
A.M. and 10:00 A.M. (+/-1 hour) .
2Scheduled telephone calls (TCs) will be conducted to check the patients’ condition (Changes in concomitant medications, surge ries and procedures, serious and non -serious adverse events, and asth ma exacerbations 
should be recorded in the appropriate eCRF if applicable). If necessary an unscheduled clinical visit may be arranged.
3For patients experiencing an asthma exacerbation during the run-in epoch , the run -in may be extended upto 6 weeks.
4The follow -up epoch applies to all patients except those patients who enter the safety study directly after Visit 299.
TD = investigational treatment discontinuation (permanent treatment discontinuation but continue with limited assessments; (S) = assessment to be recorded in source documents only; assessment will not be entered 
into the eCRFs; V= Visit
Reversibility test / Post -
bronchodilator FEV1 (spirometry 
after administration of short -acting 
β-agonist [SABA])
Notes:
**If reversibility is not demonstrated at 
Visit 1 and documented evidence for one 
of the other criteria for a clinical 
diagnosis of asthma is not met, then the 
reversibility test m ay be repeated at Visit 
101.
To be performed prior to in- clinic 
witnessed study drug administration.
ßTo be performed after the second pre -
dose spirometry (may be performed after 
10:00 AM (+/-1 hour) ).X X**,,ßX,ßX,ßX,ßX,ß
Airway hyper -reactivity test 
***optional test if reversibility is not met
at V1 .X***

Novartis Confidential Page 56
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Screen Run-in Treatment Follow -up
Visit Number (Site visits)1
1 101 199 201 202 203 204 205 206 207UNSCH
EDULED
-TD299 301
Telephone Call (TC)2
Note: TC in -between site visits TC1 TC2 TC3 TC4 TC5 TC6
Treatment Week -4 -231 1 4 8 12 16 20 24 28 32 36 40 44 48 TD 52 56
Treatment Day
Note: * V199 and 201 will occur on the 
same day if the patient is randomized.-28 -1431* 1* 28 56 84 112 140 168 196 224 252 280 308 336 TD364392
Visit Window (Days) NA +/-7 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 NA +/-5 +/-5
1Scheduled clinic visits (starting at Visit101 and thereafter) are to occur in the morning at approximately the same time, so that the -45 min and -15 min pre-dose FEV1 assessments can be performed between 06:00 
A.M. and 10:00 A.M. (+/-1 hour) .
2Scheduled telephone calls (TCs) will be conducted to check the patients’ condition (Changes in concomitant medications, surge ries and procedures, serious and non -serious adverse events, and asth ma exacerbations 
should be recorded in the appropriate eCRF if applicable). If necessary an unscheduled clinical visit may be arranged.
3For patients experiencing an asthma exacerbation during the run-in epoch , the run -in may be extended upto 6 weeks.
4The follow -up epoch applies to all patients except those patients who enter the safety study directly after Visit 299.
TD = investigational treatment discontinuation (permanent treatment discontinuation but continue with limited assessments; (S) = assessment to be recorded in source documents only; assessment will not be entered 
into the eCRFs; V= Visit
Train and assess patient’s ability to 
use eDiary/  and dispense 
eDiary/  (S)X
Review eDiary/  compliance 
prior to randomizing the patient (S)X X
Review eDiary/  entries (S) X X X X X X X X
Contact IRT (S) X X X X X X X X X X X X X
Randomize patient through IRT (S) X
ACQ -5 in clinic X X X X X X X X X X X
AQLQ+12 in clinic X X X X X X X X X X
Dispense study drug (S)
Note: The patients will be instructed to 
take their investigational treatment in the 
morningX X X X X X X X

Novartis Confidential Page 57
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Screen Run-in Treatment Follow -up
Visit Number (Site visits)1
1 101 199 201 202 203 204 205 206 207UNSCH
EDULED
-TD299 301
Telephone Call (TC)2
Note: TC in -between site visits TC1 TC2 TC3 TC4 TC5 TC6
Treatment Week -4 -231 1 4 8 12 16 20 24 28 32 36 40 44 48 TD 52 56
Treatment Day
Note: * V199 and 201 will occur on the 
same day if the patient is randomized.-28 -1431* 1* 28 56 84 112 140 168 196 224 252 280 308 336 TD364392
Visit Window (Days) NA +/-7 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 NA +/-5 +/-5
1Scheduled clinic visits (starting at Visit101 and thereafter) are to occur in the morning at approximately the same time, so that the -45 min and -15 min pre-dose FEV1 assessments can be performed between 06:00 
A.M. and 10:00 A.M. (+/-1 hour) .
2Scheduled telephone calls (TCs) will be conducted to check the patients’ condition (Changes in concomitant medications, surge ries and procedures, serious and non -serious adverse events, and asth ma exacerbations 
should be recorded in the appropriate eCRF if applicable). If necessary an unscheduled clinical visit may be arranged.
3For patients experiencing an asthma exacerbation during the run-in epoch , the run -in may be extended upto 6 weeks.
4The follow -up epoch applies to all patients except those patients who enter the safety study directly after Visit 299.
TD = investigational treatment discontinuation (permanent treatment discontinuation but continue with limited assessments; (S) = assessment to be recorded in source documents only; assessment will not be entered 
into the eCRFs; V= Visit
Return and assess compliance 
with study drug (count tablets in 
returned bottles) (S)X X X X X X X X X
In-clinic witnessed study drug 
intake
Note Complete Dose administration 
record (DAR) –at site visit X X X X X X X X X
Complete Dose administration 
record -Summary pageX X X X X X X X X
Complete Study Disposition page 
(screening)X
Complete Study Disposition page 
(run-in)
Note:$V101 Disposition is only present 
if patient is a run -in failure.   X$X
Complete Study Disposition page 
(end of treatment )X
Complete Study Disposition page 
(follow -up )X
Withdrawal of informed consent X X X X X X X X X X X X X X X X X X X
Re-screening of patient
Notes: Re-screening of patients is 
permitted once. Once a patient enters 
the run -in epoch, the patient may not be 
re-screened. If a patient is re- screened, 
a new informed consent (and assent if 
applicable) must be obtained for the 
study as outlined in the assessment 
schedule above.X
Appointment for next clinic visit (S) X X X X X X X X X X X X X X X X X

Novartis Confidential Page 58
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Screen Run-in Treatment Follow -up
Visit Number (Site visits)1
1 101 199 201 202 203 204 205 206 207UNSCH
EDULED
-TD299 301
Telephone Call (TC)2
Note: TC in -between site visits TC1 TC2 TC3 TC4 TC5 TC6
Treatment Week -4 -231 1 4 8 12 16 20 24 28 32 36 40 44 48 TD 52 56
Treatment Day
Note: * V199 and 201 will occur on the 
same day if the patient is randomized.-28 -1431* 1* 28 56 84 112 140 168 196 224 252 280 308 336 TD364392
Visit Window (Days) NA +/-7 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 +/-5 NA +/-5 +/-5
1Scheduled clinic visits (starting at Visit101 and thereafter) are to occur in the morning at approximately the same time, so that the -45 min and -15 min pre-dose FEV1 assessments can be performed between 06:00 
A.M. and 10:00 A.M. (+/-1 hour) .
2Scheduled telephone calls (TCs) will be conducted to check the patients’ condition (Changes in concomitant medications, surge ries and procedures, serious and non -serious adverse events, and asth ma exacerbations 
should be recorded in the appropriate eCRF if applicable). If necessary an unscheduled clinical visit may be arranged.
3For patients experiencing an asthma exacerbation during the run-in epoch , the run -in may be extended upto 6 weeks.
4The follow -up epoch applies to all patients except those patients who enter the safety study directly after Visit 299.
TD = investigational treatment discontinuation (permanent treatment discontinuation but continue with limited assessments; (S) = assessment to be recorded in source documents only; assessment will not be entered 
into the eCRFs; V= Visit
Dispense patient card (S) X
Collect patient card (S)X
For 
patients 
participat
ing in the 
safety 
studyX
For sites participating in the Safety 
Study, d iscuss optional patient 
participation in the S afety Study.X

Novartis Confidential Page 59
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
6.1 Information to be collected on screening failures and run -in 
failures
All patients who have signed informed consent but not entered into the next epoch (run-in)
will have the study completion page for the screening epoch, demographics, 
inclusion/exclusion, blood eosinophil counts, and serious adverse event (SAE) data collected. 
Adverse events that are not SAEs will be followed by the investigator and collected only in 
the source data.
All patients who have signed informed consent and have received single -blind study 
medication, but discontinue prior to randomization (run-in failures) should have all data for 
the visits they attended, the summary  pages (Adverse Event, Concomitant Medication, 
Dosage Administrative Record), and screening and run-in disposition pages completed. All 
adverse events occurring after informed consent is signed should berecorded on the 
Adverse Event CRF. 
Investigators will have the discretion to record abnormal test findings on the medical history 
CRF whenever in their judgment, the test abnormality  occurred prior to the informed consent 
signature.
6.2 Patient demographics/other baseline characteristics 
The following demographics and baseline characteristics will be collected on all patients:
Age
Gender
Race and ethnicity
Height
Weight
Body mass index ( BMI )
Duration of asthma
Number of exacerbations in prior y ear
Atopic Y/N (RAST /ImmunoCAP )
Smoking history
Reversibility  (demonstrated or historical)
FEV1
OCS use Y/N
Baseline ACQ

Blood eosinophil counts at Visit 1 and baseline
Relevant medical history/current medical condition present before signing informed 
consent. Where possible, diagnoses and not s ymptoms will be recorded.

Novartis Confidential Page 60
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
6.3 Treatment exposure and compliance 
Study drug compliance will be assessed by the investigator and/or center personnel at 
designated visits by  recording tablet counts from the previousl y dispensed bottles. 
The total number of doses of study  drug administered since the last dispensing visit will be 
recorded in the Dosage Administration Record eCRF.
All doses of study  drug taken at the clinic visits should be from the newl y assigned 
medication packs, except at Visit 299 when the medication returned by the patient should 
be used .
6.4 Efficacy
6.4.1 Asthma exa cerbations
The following definitions of exacerbations are used in this study .
A severe asthma exacerbation is defined as 
treatment with ‘rescue’ sy stemic corticosteroids for greater than or equal to 3 day s 
and hospitalization ; or
treatment with ‘rescue’ systemic corticosteroids for greater than or equal to 3 day s 
andemergency  department visit (greater than 24 hours*) ; or
death due to asthma. 
A moderate asthma exacerbation is defined as treatment with ‘rescue’ s ystemic 
corticosteroids for greater than or equal to 3 day s either as an outpatient or in emergency  
department visits (Emergency  department visit less than or equal to 24 hours).
*An emergency  room visit greater than 24 hours is considered to be a hospitalization
‘Rescue’ systemic corticosteroids are tablets, suspension, or injection, or an increase of a 
patient’s maintenance systemic corticosteroids of greater than 2 fold (i.e., greater than 
doubling the maintenance dose of systemic corticosteroids) . A single depo -injectable dose of 
corticosteroid will be considered the equivalent to a 3 -day course of sy stemic steroids ( Reddel, 
et al 2009 )
. Endotracheal intubations will be captured on the CRF.
Scheduled spirometry  should not be performed during an exacerbat ion until it has completely  
resolved.
If patients experience an asthma attack/exacerbation requiring systemic corticosteroids, 
hospitalization, or emergency  room visit during the screening epoch, they may be re-screened 
once with the re-screening of the patient occurring 6 weeks or more after recovery  from the 
asthma exacerbation. 
6.4.2 Asthma Control Questionnaire (A CQ-5)
In this study , the ACQ -5 will be used to assess improvements in asthma symptom control . 
The ACQ -5 will be collected in an electronic format.
The original ACQ consists of 7 items: 5 items on symptom assessment, 1 item on rescue 
bronchodilator use, and 1 item on airway  caliber (% FEV 1predicted). The rescue 
bronchodilator useand % FEV 1predicted items are not included in the ACQ -5.  The ACQ 
was originally  validated in patients with asthma over aged 17 years (Juniper 1999, 2006 ), and 

Novartis Confidential Page 61
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
is one of several asthma control measures recommended by the GINA Guidelines.  The ACQ 
has been fully  validated, including patients aged from 6to 16years (Juniper 2010) and 
including a minimal important difference (MID) or smallest change that can be considered 
clinically  important (0.5).
The ACQ -
5 (see Appendix 8) will be self-administered at the clinic and only takes a few 
minutes to complete. Patients will be asked to recall how their asthma has been during the 
previous week and to respond to the sy mptom questions on a 7-point scale (0=no impairment, 
6=maximum impairment). The questions are equally  weighted and the ACQ -
5score is the 
mean of the 5questions: therefore, between 0 (totally  controlled) and 6 (severely  uncontrolled) 
(Juniper, et al 1999; Juniper, et al 2005 ;Juniper, et al 2006 ).
The ACQ will be completed by  patients at the visits specified in the table of assessments (See
Table 6 -1). The questionnaire should be completed before the AQLQ +12and before any  other 
assessments (see Section 
6). The appropriate language version(s) of the questionnaire will be 
used in each participating country . The same language version of the questionnaire should be 
used by  a particular patient throughout the study .   
The study  coordinator should be familiar with the instrument and the associated user guides 
and training materials provided.  Patients should complete the questionnaire in a quiet area 
and are allowed to ask questions; however the site staff should take care not to influence the 
patient’s response. In response to a question, patients should be instructed to provide the truest 
or best response for them. 
Missing data should be avoided; therefore, the study  coordinator will check the questionnaire 
for completeness before the patient leaves the clinic, and if necessary , encourage the patient to 
complete any missing responses. At later visits patients are not allowed to review their 
previous responses.
Completed questionnaires will be reviewed by the investigator for responses which may 
indicate potential AEs or SAEs.  The investigator should review not only the responses to the 
questions in the questionnaire but also for any  unsolicited comments written by  the patient.  If 
AEs or SAEs are confirmed then the physician must record the events as per instruct ions 
given in Section 7.1 and Section 7.2 of the protocol. Investigators should not encourage the 
patients to change the responses reported in the complete d questionnaires.
6.4.3 Asthma Quality  of Life Questionnaire for 12 y ears and older 
(AQLQ+12)
In this study , the disease -specific AQLQ+12 will be used to measure health- related qualit y of 
life in patients. The measure was originally  validated for use in patien ts with asthma aged “12 
to 80 y ears ( Juniper, et al 2005 )”. The AQLQ+12 will be collected in an electronic format.
The AQLQ+12 comprise sa total of 32 individual questions that span a total of four domains: 
symptoms, activity  limitation, emotional function, and environmental stimuli. Test-retest 
reliability , construct validity  (cross -sectional and longitudinal), and responsiveness have been 
demonstrated (See Appendix 9 ).
The AQLQ+12 will be self-administered at the clinic. It takes about 4 to 5 minutes to 
complete.  Patients are asked to recall their experiences during the previous 2 weeks and to 

Novartis Confidential Page 62
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
score each item on a 7-point scale (7 = not at all impaired to 1 = severely impaired). The  
AQLQ+12 yields individual domain scores, which is the mean of all items in each domain, 
and an overall score, which is the mean of all 32 individual respo nses. Higher scores indicate 
less impairment in HRQOL .
The questionnaire will be completed by patients at the visits specified in the table of 
assessments (SeeTable 6 -1).
The appropriate language versi on(s) of the questionnaire will be used in each participating 
country . The same language version of the questionnaire should be used by a  p articular 
patient throughout the study .  
The study  coordinator should be familiar with the instrument and the associ ated user guides 
and training materials provided. The patient should complete the questionnaire in a quiet area 
and be allowed to ask questions; however site staff should take care not to influence the 
patient’s responses. The patient will be instructed toprovide the truest and for them best 
response. 
Missing data should be avoided, therefore, the study  coordinator will check the questionnaire 
for completeness before the patient leaves the clinic, and if necessary , encourage the patient to 
complete any missing responses. At later visits patients are not allowed to review their 
previous responses. 
Completed questionnaires will be reviewed by the investigator for responses which may 
indicate potential AEs or SAEs.  The investigator should review not only the responses to the 
questions in the questionnaire but also for any  unsolicited comments written by  the patient.  If 
AEs or SAEs are confirmed then the physician must record the events as per instructions 
given in Section 7.1 and Section 7.2 of the protocol. Investigators should not encourage the 
patients to change the responses reported in the completed questionnaires.
The PROs ACQ, AQLQ+12,  questionnaires should alway s be completed before 
any other assessments and in the above order (see Section 6).

Novartis Confidential Page 63
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
 

Novartis Confidential Page 64
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14

Novartis Confidential Page 65
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
6.4.8 Spirometry (FEV1 )
All clinic visits must occur in the morning. Please refer to Section 6 and Table 6-1for full 
details of the scheduling of spirometry  measurements.
Equipment for spirometry  assessments will be provided to all study  sites by a  C entral 
Spirometry  vendor, and all measurements will be reviewed by trained spirometry  overreaders
at the central vendor. The final spirometry  assessments will be those provided by the 
spirometry  overreaders of the central spirometry  vendor.
Please refer to the Spirometry  Guidance, in Appendix 5, for full details on scheduling and 
performing spirometry . Reversibility  testing must be conducted in the morning.
6.4.9 Appropriateness of efficacy  assessments 
The measures described above are standard outcome measures in asthma trials.
6.5 Safet y
The following safet y assessments as delineated in Table 6-1 will be performed :
History  and ph ysical examination
Vital signs
Hematology
Blood chemistry  including but not limited to 

Novartis Confidential Page 66
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Liver function tests: ALT, AST, total bilirubin
Metabolic panel: sodium, potassium, chloride, bicarbonate, BUN/urea, creatinine, 
glucose, calcium, phosphorus, magnesium, total protein, albumin, γ- GT, alkaline 
phosphatase, LDH, CK, iron, uric acid, cholesterol, trigl ycerides
amylase, lipase
hsCRP
CK-MB and Troponin -I (in respons e to CK results outside of the normal range)
HbA1c (collected at Visit 1 only )
Urinaly sisand urine chemistry .
Pregnancy  test (females of childbearing potential)
ECG
Adverse events including serious adverse events
Spirometry  will also be used to monitor the safety of patients during the study . Patients will 
also be provided with an eDiary / . The data captured in the eDiary /  will be used to 
alert the patient and/or investigator to possible signs of worsening asthma 
A central laboratory  will be used to analy ze and report blood chemistry /hematology /urinal ysis 
and urine chemistries . A central ECG vendor will be used to collect, assess and report ECGs.
A Data Monitoring Committee will be set up to overview safet y. See Section 8.3 for details.
6.5.1 Physical examination 
A complete physical examination will be performed at Visits 1 and 299 ( and 
UNSECHEDULED -TD if a patient discontinues investigational treatment but continue s with 
study participation) .  It will include the examination of general appearance, skin, neck 
(including thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph nodes, 
extremities, vascular and neurological. If indicated based on medical history  and/or sy mptoms, 
rectal, external genitalia, breast, and pelvic exams will be performed .
Abbreviated physical examinations will be performed at visits 101 to 207 (except Visit 201, 
since Visit 199 and 201 should occur on the same day). It will include the examination of the 
lungs and heart.
Information for all phy sical examinations must be included in the source documentation at the 
study  site. Significant findings that are present prior to informed consent being granted must 
be included in the Relevant Medical History /Current Medical Conditions screen on the 
patient’s eCRF. Significant findings made after informed consent is given which meet the 
definition of an Adverse Event must be recorded on the Adverse Event screen of the patient’s 
eCRF.
6.5.2 Vital signs 
Vital signs will be assessed at every  visit(except Visit 201, since Visit 199 and 201 should 
occur on the same day). Measurements will include blood pressure, pulse rate, and body 
temperature. 
After the patient has been sitting for ten minutes, with back supported and both f eet placed on 
the floor, systolic and diastolic blood pressure will be measured three times using an 

Novartis Confidential Page 67
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
automated validated device, e.g. OMRON, with an appropriately  sized cuff. The repeat sitting 
measurements will be made at 1 to 2 minute intervals and the m ean of the three measurements 
will be used. In case the cuff sizes available are not large enough for the patient's arm 
circumference, a sph ygmomanometer with an appropriatel y sized cuff may be used.
The patient’s condition must be monitored to rule out any clinicall y relevant arrhy thmia or 
tachycardia.
Clinically  notable vital signs are defined in Appendix 1 .
6.5.3 Height and weight 
Height in centimeters (cm) will be measured at the visits specified in the table of assessments 
(See Table 6 -1).
Body weight 
(to the nearest 0.1 kilogram [kg] in indoor clothing, but without shoes) will be 
measured at the visits specified in the table of assessments (See Table 6-1 ).
Body Mass Index (BM I)will be calculated as the weight in kg divided by  the height in meters 
squared. 
6.5.4 Laboratory  evaluations 
A central laboratory  will be used for analysis of all specimens detailed in this section. Details 
on the collections, shipment of samples and reporting of results by the central laboratory  are 
provided to investigators in the laboratory  manual.
Details on c linically  notable laboratory  findings are defined in Appendix 1 .
6.5.4.1 Hematology
Hemoglobin, hematocrit, red blood cell count, white blood cell count with differential, and 
platelet count will be measured according to the assessment schedule in Table 6-1. Other 
reflex testing will be performed as outlined in the lab oratorymanual.
6.5.4.2 Clinical chemistry
BUN/ urea, creatinine, creatine kinase , total 
bilirubin, AST, ALT, alkaline phosphatase, 
gamma -glutamy l transpeptidase, lactate dehydrogenase, sodium, potassium, chloride, calcium, 
magnesium, iron, bicarbonate, cholesterol, triglycerides, high-sensitivity  C-reactive protein, 
phosphorus, total protein, albumin, glucose, uric acid , amy lase, lipase, CK-MB and Troponin -
I (in response to CK results outside of the normal range) , HbA1c (collected at Visit 1 only)
and immunoglobulins (IgE, RAST/ImmunoCAP test), will be measured according to the 
assessment schedule inTable 6-1. Other reflex testing will be performed as outlined in the 
lab
oratory manual.
If the total bilirubin concentration is increased above 1.5 times the upper limit of normal range, 
the total bilirubin will differentiated into the direct and indirect reacting b ilirubin. 
All patients with laboratory  tests containing clinically  significant abnormalities should be 
followed until the values return to within the normal ranges or until a clinical explanation is 
identified, even after study  medication has discontinued.

Novartis Confidential Page 68
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
6.5.4.3 Urinaly sis
Urine for urinal ysis and urine chemistry will be collected according to the collection schedule 
in Table 6-1.  All samples for urinalysis and urine chemistr ywill be sent to the central 
laboratory for analysis .  The urinal ysis evaluation by the central laboratory  will include a 
urine dipstick for specific gravit y, protein, glucose, leukocy tes and blood and, if required ,a 
microscopic examination. Urine chemist r
yand microscopic examination of the urine will be 
performed by the central laboratory  as delineated inTable 7-1“Specific Renal Alert Criteria 
and Actions ” in Section 
7.4“Renal Safety  Monitoring” of this protocol ”.Other reflex testing 
will be performed as outlined in the lab oratory manual.
6.5.5 Electrocardiogram (ECG) 
ECGs will be measured according to the assessment schedule in Table 6-1. At Visits 1 and 
101 an ECG will be measured to test for eligibility  for trial inclusion.
ECGs must be recorded after 10 minutes of rest in the supine position to ensure a stable 
baseline. The preferred sequence of cardiovascular data collection during study  visits is PRO 
collection first, followed by ECG, and then other study  procedures (see Section 
6). The 
Fridericia QT correction formula (QTcF) should be use d for clinical decisions.
Triplicate 12 lead ECGs are to be collected with ECG machines supplied by the core 
laboratory .  Full details of all procedures relating to the ECG collection and reporting will be 
contained in an investigator manual to be provided
to each investigator site.
The original trace will be sent electronicall y for central review directly  from the ECG 
machine. Two ‘identical’ duplicate print -outs will be generated and kept at the investigator 
site as source documentation and as back -up forsubmission to the central laboratory  in case 
of problems with the electronic transmission.  Each page of the ECG tracing should be labeled 
with study  number (CQAW039A2307), subject initials (where this is allowed according to 
local regulations), subject n umber, date and time, and filed in the study  site source documents.
For any ECGs with subject safet y concerns, two additional ECGs should be performed to 
confirm the safet y finding and copies forwarded to the central ECG laboratory  for assessment. 
The final ECG assessments will be those provided by the central cardiologist ECG 
overreaders of the central vendor. Clinically  significant ECG findings prior to dosing with 
investigational treatment must be discussed with the Novartis responsible person or designe e.
Clinically  significant abnormalities should be recorded on the relevant section of the medical 
history /Current medical conditions/AE CRF /e CRF page as appropriate.
In the event that the central cardiologist reports that an ECG is abnormal, then the inve stigator 
must comment as to whether the ECG abnormality is either clinically  significant or clinically 
insignificant. If necessary a cardiologist may  be consulted.
6.5.6 Pregnancy  and assessments of fertility  
All women of child bearing potential will have a serum pregnancy  test at Visits 1 and a urine 
pregnancy  test at all other site visits (except visit 201, since Visit 199 and 201 should occur on 
the same 
day). 
Pregnancy  testing will begin at the visit a patient is first identified as being of child bearing 
potential.

Novartis Confidential Page 69
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
In countries where monthly  pregnancy  testing is required for women of child- bearin g 
potential by local lawsor regulation s, these patients will perform home urine pregnancy 
testing on the day of all telephone visits. These female patients will report the results of their 
home urine pregnancy  test as “positive” or “negative” to study  site staff as part of the 
telephone visit and the results will be recorded in source documents.
A positive urine pregnancy test requires immediate interruption of study medication until 
serum β-hCG is performed and found to be negative. If positive, the patient must be 
discontinued from the study  treatment .
6.5.7 Appropriateness of safety  measurements 
The safet y assessments selected are standard for this indication/patien t population.
6.6 Other assessments 

Novartis Confidential Page 70
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
6.6.4 Airway s hyper-reactivity test
Anairway s hyper-reactivity  (AHR) test should be performe d at Visit 101 if reversibility  is not 
demonstrated at screening (Visit 1) and documented evidence for one of the other criteria for a 
clinical diagnosis of asthma is not met (see Section 4.1). A positive result is defined as a 
provoked fall in FEV 1of 20% (PC20) by  methacholine  at ≤8 mg/ml (or histamine ≤10 mg/ml 
or acetylcholine <20 mg/mL ) when not on ICS or ≤16 mg/ml or histamine ≤20 mg/ml or 
acetylcholine <40 mg/mL) on ICS therapy  performed according to ATS/ERS guidelines.
7 Safety  monitoring
7.1 Adverse events
An adverse event (AE) is any untoward medical occurrence (i.e., any unfavorable and 
unintended sign [including abnormal laboratory  findings], sy mptom or disease) in a subject or 
clinical investigation subject after providing written informed consent for participation in the 

Novartis Confidential Page 71
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
study . Therefore, an AE may  or may  not be temporally  or causall y associated with the use of a 
medicinal (investigational) product.
The occurrence of adverse events should be sought by non-directive questioning of the patient 
at each visit during the study . Adverse events also may  be detected when they  are volunteered 
by the patient during or between visits or through physical examination, laboratory  test, or 
other assessments.
Abnormal laboratory  values or test results constitute adverse events only if they fulfill at least 
one of the following criteria:
they induce clinical signs or sy mptoms
they are considered clinically  significant
they require therapy
Clinically  significant abnormal laboratory  values or test results should be identified through a 
review of values outside of normal ranges/clinically  notable ranges, significant changes from 
baseline or the previous visit, or values which are considered to be non-typical in patient with
underly ing disease. Investigators have the responsibility  for managing the safet y of individual 
patient and identify ing adverse events. Alert ranges for labs and other test abnormalities are 
included in Appendix 1.
Adverse events should be recorded in 
theAdverse Events CRF under the signs, symptoms or 
diagnosis associated with them accompanied by  the following information:
the severit y grade: 
mild: usually  transient in nature and generally  not interfering with normal activities
moderate: sufficiently  discomforting to interfere with normal activities
severe: prevents normal activities
its relationship to the study  treatment :
Yes
No
its duration (start and end dates) or if the event is ongoing an outcome of not 
recovered/not resolved should be reported.
whether it constitutes a serious adverse event ( SAE -See Section 7.2 for definition of 
SAE )
and which seriousness criteria have been met.
action taken regarding study treatment
All adverse events should be treated appropriately . Treatment may include one or more of the 
following: 
no action taken (i.e. further observation only ) 
study  treatment dosage increased/reduced
study  treatment interrupted/withdrawn
concomitant medicatio n or non
-drug therap y given 
non-drug therap y given 
patient hospitalized/patient’s hospitalization prolonged 

Novartis Confidential Page 72
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
its outcome (not recovered/not resolved; recovered/resolved; recovering/resolving, 
recovered/resolved with sequelae; fatal; or unknown)
Once an adverse event is detected, it should be followed until its resolution or until it is 
judged to be permanent, and assessment should be made at each visit (or more frequently , if 
necessary ) of any changes in severit y, the suspected relationship to the study  drug, the 
interventions required to treat it, and the outcome.
Information about common side effects alread y known about the investigational drug can be 
found in the Investigator Brochure (IB) or will be communicated between IB updates in the 
form of Inves tigator Notifications. This information will be included in the patient informed 
consent and should be discussed with the patient during the stud y as needed.
The investigator should also instruct each patient to report any  new adverse event (bey ond the 
protocol observation period) that the patient, or the patient’s personal physician, believes 
might reasonabl y be related to study  treatment. This information should be recorded in the 
investigator’s source documents, however, if the AE meets the criteria of an SAE, it must be 
reported to Novartis.
Adverse events of special interest are being evaluated inthis study  population. Definitions of 
IDRs are provided in Appendix 3 .
7.2 Serious adverse events
7.2.1 Definitio n of SA E
An SAE is defined as any adverse event (appearance of (or worsening of any pre-existing) 
undesirable sign(s), symptom(s) or medical conditions(s) which meets any one of the 
following criteria:
is fatal or life -threatening 
results in persistent or significant disability /incapacity
constitutes a congenital anomaly /birth defect
requires inpatient hospitalization or prolongation of existing hospitalization, unless 
hospitalization is for:
routine treatment or monitoring of the studied indication, not a ssociated with any  
deterioration in condition under study
elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed consent
treatment on an emergency  outp atient basis for an event not fulfilling an y of the 
definitions of a SAE given above and not resulting in hospital admission 
social reasons and respite care in the absence of any  deterioration in the patient’s 
general condition
is medically  significant, i .e. defined as an event that jeopardizes the patient or may  require 
medical or surgical intervention.
All malignant neoplasms will be assessed as serious under “medically  significant” if other 
seriousness criteria are not met.

Novartis Confidential Page 73
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Life-threatening in the conte xt of a SAE refers to a reaction in which the patient was at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically  might have 
caused death if more severe (see Annex I V, ICH-E2D Guideline).
Medical and scientific judgment should be exercised in deciding whether other situations 
should be considered serious reactions, such as important medical events that might not be 
immediately  life threatening or result in death or hospitalization but might jeopardize the 
patient ormight require intervention to prevent one of the other outcomes listed above. 
Examples of such events are intensive treatment in an emergency  room or at home for allergic 
bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization or 
development of dependency or abuse (see Annex IV, ICH-E2D Guideline).
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.
All AEs (serious and non-serious) are captured on the CRF, SAE s also require individual 
reporting to DS&E as per Section 7.2.2.
7.2.2 SAE reporting
To ensure patient safet y, every SAE, regardless of causalit y, occurring after the patient has 
provided informed consent and until 30 days after the last study  visitmust be reported to 
Novartis within 24 hours of learning of its occurrence. Any SAEs experienced after the 30 
days period should only be reported to Novartis if the investigator suspects a causal 
relationship to study  treatment. 
Recurrent episodes, compli cations, or progression of the initial SAE must be reported as 
follow -
up to the original episode, regardless of when the event occurs. This report must be 
submitted within 24 hours of the investigator receiving the follow -up information. An SAE 
that is considered completely  unrelated to a previously  reported one should be reported 
separately  as a new event.
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicable sections of the form must be completed in order to provide a clinically 
thorough report. The investigator must assess the relationship of each SAE to each specific 
component of study treatment, (if study treatment consists of several components) complete 
the SAE Report Form in English, and submit the completed form within 24 hours to Novartis. 
Detailed instructions regarding the submission process and requirements for signature are to 
be found in the investigator folder provided to each site. 
Follow -up information is submitted as instructed in the investigator folder. Each re-
occurrence, complication, or progression of the original event must be rep orted as a follow -up 
to that event regardless of when it occurs.  The follow -up information should describe 
whether the event has resolved or continues, if and how it was treated, whether the blind was 
broken or not, and whether the patient continued or wi thdrew from study  participation.
If the SAE is not previously  documented in the Investigator’s Brochure or Package Insert 
(new occurrence) and is thought to be related to the investigational treatment a Drug Safet y 
and Epidemiology  Department associate may urgentl y require further information from the 
investigator for Health Authority  reporting. Novartis may need to issue an Investigator 
Notification (IN) to inform all investigators involved in any study with the same 

Novartis Confidential Page 74
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
investigational treatment that this SAE has been reported. Suspected Unexpected Serious 
Adverse Reactions (SUSARs) will be collected and reported to the competent authorities and 
relevant ethics committees in accordance with EU Guidance 2011/C 172/01 or as per national 
regulatory  requirements i n participating countries.
7.3 Liver safety  monitoring
To ensure patient safet y and enhance reliability  in determining the hepatotoxic potential of an 
investigational drug, a standardized process for identification, monitoring and evaluation of 
liver events ha s to be followed. 
The following two categories of abnormalities / adverse events have to be considered during 
the course of the study :
Liver laboratory  triggers, which will require repeated assessments of the abnormal 
laboratory  parameter
Liver events, which will require close observation, follow -up monitoring and completion 
of the standard base liver CRF pages
Please refer to Table 14-1 in Appendix 2for complete definitions of liver laboratory  triggers 
and liver events. 
Every  liver laboratory  trigger or liver event as defined in Table 14-1 of Appendix 2should be 
followed up by the investigator or designated personal at the trial site as summarized below. 
Detailed information is outlined in Table 14
-2in Appendix 2 .
For the liver laboratory  trigger:
Repeating the LFT within the next week to confirm elevation.
These LFT repeats should be performed using the central laboratory  if possible. If this is not 
possible, then the repeats can be performed at a local laboratory  to monitor the safet y of the 
patient. Repeats laboratory  should then be performed at central laboratory as soon as possible. 
If a liver event is subsequently  reported, any local LFTs previousl y conducted that are 
associated wi th this event should be reported on the L iver CRF pages.
If the elevation is confirmed, close observation of the patient will be initiated, including 
consideration of treatment interruption if deemed appropriate.
For the liver events:
Repeating the LFT to confirm elevation as appropriate
Discontinuation of the investigational drug if appropriate
Hospitalization of the patient if appropriate
A causalit y assessment of the liver event via exclusion of alternative causes (e.g., disease, 
co-medications)
An inves tigation of the liver event which needs to be followed until resolution. 
These investigations can include serology  tests, imaging and pathology  assessments, 
hepatologist’s consultancy , based on investigator’s discretion. All follow -up information, and 
theprocedures performed should be recorded on appropriate CRF pages, including the liver 
event overview CRF pages.

Novartis Confidential Page 75
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
7.4 Renal safety  monitoring 
To ensure patient safety  and enhance reliability  in determining the nephrotoxic potential of an 
investigational drug, a standardized process for identification, monitoring and evaluation of 
renal events has to be followed. 
The following two categories of abnormal renal laboratory  values have to be considered 
during the course of the study :
1. Serum event:
confirmed (after ≥ 24h) increase in serum creatinine of ≥ 25% compared to baseline 
during normal hy dration status
2. Urine event :
urinary  albumin -creatinine ratio (ACR) ≥ 1g/g or ≥ 100 mg/mmol
urinary  protein- creatinine ratio (PCR ) ≥ 1g/g or ≥ 100 mg/mmol
Every  renal laboratory  trigger or renal event as defined in Table 7-1should be f ollowed up by 
the investigator or designated personnel at the trial site as s
ummarized below. 
Table 7-1 Specific Renal A lert Criteria and A ctions
Serum Event
Serum creatinine increase
25 –49% compared to baselineConfirm 25% increase after 24- 48h 
Follow up within 2 -5 days
Acute Kidney Injury: Serum creatinine 
increase   50 % compared to baselineFollow up within 24 -48h if possible
Consider drug interruption 
Consider patient hospitalization /specialized treatment
Urine Event
Albumin -creatinine ratio (ACR) ≥1g/g or 
≥100 mg/mmol;
Protein -creatinine ratio (PCR ) ≥1g/g or 
≥100 mg/mmolConfirm value after 24- 48h
Perform urine microscopy
Consider drug interruption / discontinuation 
For all renal events:
1.Document contributing factors in the CRF : co-medication, other co -morbid conditions, and 
additional diagnostic procedures performed 
2.Monitor patient regularly (frequency at investigator’s discretion) until either: 
Event resolution : sCr within 10% of baseline or protein -creatinine ratio within 50% of 
baseline, or
Event stabilization : sCr level with ±10% variability over last 6 months or protein-
creatinine ratio stabilization at a new level with ±50% variability over last 6 months.

Novartis Confidential Page 76
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
7.5 Idiosy ncratic drug reactions monitoring
IDRs are adverse drug reactions that do not occur in most patients (i.e., they are rare, 
occurring 1 in 10,000 to 1 in 100,000 patients) and do not result from known pharmacological 
effects of a drug. Their onset is unpredictable and they may involve one or more organ 
systems, most notably  the immune sy stem, liver and blood cells.  
The invest igator should pay special attention to any adverse events which may be a potential 
IDR reported by a patient. If such an event occurs, the investigator should report the event as 
per standard adverse event reporting procedures (i.e., serious adverse events for those meeting 
serious criteria and non-serious adverse events for those meeting non-serious adverse event 
criteria as defined in the protocol). 
The investigator may be also be contacted by Novartis regarding AEs that may resemble an 
IDR. A list of terms considered IDRs are provided in Appendix 3 
Events with potential to be IDRs will be identified thorough a prespecified search algorithm 
based on 
the Standardised MedDRA Queries as described in the study  analysis plan. These 
events will be reviewed by  the DMC on a regular basis.
7.6 Pregnancy  reporting
To ensure patient safet y, each pregnancy  occurring while the patient is on study  treatment 
must be reported to Novartis within 24 hours of learning of its occurrence. The pregnancy 
should be followed up to determine outcome, including spontaneous or voluntary  termination, 
details of the birth, and the presence or absence of any  birth defects, congenital ab normalities, 
or maternal and/or newborn complications.
Pregnancy  should be recorded on the Pharmacovigilance Pregnancy  Form and reported by the 
investigator to the local Novartis Drug Safet y and Epidemiology  Department. Pregnancy 
follow -up should be record ed on the same form and should include an assessment of the 
possible relationship to the investigational treatment.
Any SAE experienced during the pregnancy  and unrelated to the pregnancy  must be reported 
on a SAE form.
8 Data revie w and database management
8.1 Site monitoring 
Before study  initiation, at a site initiation visit or at an investigator’s meeting, a Novartis 
representative will review the protocol and CRFs with the investigators and their staff. During 
the study , Novartis employ s several methods of ensuring protocol and GCP compliance and 
the quality /integrity  of the sites’ data. The field monitor will visit the site to check the 
completeness of patient records, the accuracy  of entries on the (e)CRFs, the adherence to the 
protocol and to Good Clinica l Practice, the progress of enrollment, and to ensure that study 
treatment is being stored, dispensed, and accounted for according to specifications. Key study 
personnel must be available to assist the 
field monitor during these visits.  Continuous remote 
monitoring of each site’s data may  be performed by a centralized Novartis CRA organization .   
Additionally , a central analy tics organization may analyze data & identify  risks & trends for 

Novartis Confidential Page 77
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
site operational parameters, and provide reports to Novartis Clinica l Teams to assist with trial 
oversight.
The investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospital or clinic medical records) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information on CRFs must be traceable to these source documents in the 
patient's file. The investigator must also keep the original informed consent form signed by 
the patient (a si gned copy is given to the patient).
The investigator must give the monitor access to all relevant source documents to confirm 
their consistency  with the CRF entries. Novartis monitoring standards require full verification 
for the presence of informed consent, adherence to the inclusion/exclusion criteria, 
documentation of SAEs, and of data that will be used for all primary  variables. Additional 
checks of the consistency  of the source data with the CRFs are performed according to the 
study -specific moni toring plan. No information in source documents about the identity  of the 
patients will be disclosed.
8.2 Database management and quality  control 
Novartis staff , or a CRO working on behalf of Novartis ,review the data entered into the CRFs 
by investigational staff for completeness and accuracy  and instruct the site personnel to make 
any required corrections or additions. Queries are sent to the investigational site using an 
electronic data query . Designated investigator site staff is required to respond to the query  and 
confirm or correct the data. If the electronic query  system is not used, a paper Data Query 
Form will be faxed to the site. Site personnel will complete and sign the faxed copy  and fax it 
back to Novartis staff that will make the correction to the database. The signed copy of the 
Data Query  Form is kept at the investigator site.
Concomitant medications entered into the database will be coded using the WHO Drug 
Reference List, which employ s the Anatomical Therapeutic Chemical classification system . 
Concomitant procedures, non-drug therapies and adverse events will be coded using the 
Medical dictionary  for regulatory  activities (MedDRA) terminology .
Laboratory  samples will be processed centrall y and the results will be sent electronicall y to 
Novarti s (or a designated CRO).
ECG readings will be processed centrally  and the results will be sent electronically  to 
Novartis (or a designated CRO).
Centralized spirometry  readings will be processed centrall y and the results will be sent 
electronically  to Nova rtis(or a designated CRO).
Diary  data will be entered 
into an electronic diary by the patient. The system will be supplied 
by a vendor(s), who will also manage the database. The database will be sent electronically  to 
Novartis (or a designated CRO).
Randomization codes and data about all study  drug(s) dispensed to the patient and all dosage 
changes will be tracked using an Interactive Response Technology  (IRT). The system will be 
supplied by a  v endor, who will also manage the database. The database will besent 
electronically  to Novartis (or a designated CRO).

Novartis Confidential Page 78
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Each occurrence of a code break via IRT will be reported to the clinical team and monitor.  
The code break functionality  will remain available until study  shut down or upon request of 
Novartis. 
The occurrence of relevant protocol deviations will be determined. After these actions have 
been completed and the database has been declared to be complete and accurate, it will be 
locked and the treatment codes will be unblinded and made available for data an
alysis. Any 
changes to the database after that time can only be made after written agreement by Novartis 
Development management.
8.3 Data Monitoring Committee 
An independent, external data monitoring committee (DMC) will be set up to review safet y 
data (including specific safet y summaries for adolescent participants) from this trial and other 
Phase III trials in the QAW039 asthma development program, as well as to conduct the 
planned single interim analy sis for futility  as described in Section 3.5and Section 9.6. The 
DMC will consist of a group of experts independent of the sponsor, analy ses for the DMC 
will be prepared by individuals independent of the sponsor and sponsor personnel will remain 
fully  blinded to the interim results until the final clinical database lock as described in Section 
5.4. Based on the safet y implications of the data, the DMC may recommend modification or 
termination of the study. There will be no stopping for demonstrated efficacy  prior to the 
completion of the study  at either the unblinded safet y reviews or the futility  interim analysis, 
because a sufficientl y large safet y datas et is needed in addition to efficacy  data.  Therefore, no 
statistical adjustment will be made to the final analy sis.Full details 
on procedures, the DMC 
and futility  criteria will be specified in a DMC charter.
A charter for the Data Monitoring Committee (DMC) will be developed in a separate 
document. The DMC is the autonomous data and safety  advisory  group for Novartis. Novartis 
will be described as the “Sponsor” in the charter, though the Sponsor of the trial in any 
particular country  may  in fact be an af filiate of this entity . 
The purpose of the DMC charter is to define: 
1. the membership of the DMC 
2.responsibilities of the DMC and Novartis 
3.responsibilities of independent biostatistician and programmer 
4. the relationship of the DMC with other trial compone nts and data flow 
5.the purpose and timing of DMC meetings 
6.procedures for ensuring proper confidentiality , addressing conflict of interest, and 
ensuring proper communication 
The charter will compl ywith Novartis standard operating procedures and is in accordance 
with the FDA guidance (FDA 2006) and CHMP guidelines (CHMP 2006 )on DMCs. If 
significant safet y issues arise in between scheduled meetings, ad-hoc meetings will be 
scheduled to review the data.

Novartis Confidential Page 79
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
8.4 Data collection 
Designated investigator staff will enter the data required by the protocol into the OC/RDC 
system. Designated investigator site staff will not be given access to the system until they 
have been trained. 
Automatic validation procedures within the system check for data discrepancies during and 
after data entry  and, by generating appropriate error messages, allow the data to be confirmed 
or corrected online by the designated investigator site staff. The Investigator must certify  that 
the data entered into the electronic Case Report Forms are complete and accurate. After 
database lock, the investigator will receive copies of the patient data for archiving at the 
investigational site. 
8.5 Adjudication Committee 
Not required.
9 Data analy sis 
9.1 Analysis sets 
The screened set (SCR) will include all patients who provided informed consent.
The Randomized Set (RAN) will include all patients that were randomized. Data from these 
patients will be analyzed according to the treatment to which the patient was assigned at 
randomization.
The full anal ysis set (FAS) will include all randomized patients who received at least one dose 
of study  drug. It was considered reasonable to limit the FAS topatients who took trial 
medication, because the decision on whether or not treatment is started will not be influenced 
by the treatment group assignment due to the effective treatment blinding procedures 
described in Section 5.4 . Following the intent -to-treat principle, patients will be analy zed 
according to the treatment they  were assigned to at randomization.
The per-protocol set (PPS) will include all patients in the FAS without any major protocol 
deviat ions such as violation of major entry  criteria. Patients may also be considered censored 
for the PPS analy sis at the time of major post-baseline protocol deviations. Major protocol 
deviations will be defined in the data handling plan prior to database lock and the un-blinding 
of the study . Patients will be anal yzed according to the treatment they  received.
The safet y set (SAF) will include all patients who received at least one dose of study  drug. 
Patients will be analy zed according to the treatment they  received.
 
The analy sis of the primary  objective will be performed on the FAS. The PPS will be used for 
the supportive analysis of the primary  and the key secondary  variables. The FAS will be used 
for theanalysis of all other efficacy  variables. The SAF will be used in the analysis of all 
safet y variables.

Novartis Confidential Page 80
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Note that the set of patients included in the FAS and SAF are the same except that the SAF 
allows the inclusion of non -randomized patients who receive stud y drug in error.
9.2 Patient demographics and other baseline characteristics 
Patient demographics and baseline characteristics measured before randomization including 
age (calc ulated from date of birth to date of Visit 1), sex, race, ethnicit y, height, weight, body 
mass index (BMI), relevant medical history ,  including smoking history , asthma duration, use 
of long-acting beta -agonists, use of oral corticosteroids, pre-  FEV1, 
percent predicted FEV1, ACQ score, blood eosinophil count, number of exacerbations in the 
previous year will be summarized by  treatment group for the FAS. Categorizations 
of age will include at least the categories of <18, 18 to <65, 65 -74, 75- 84 and ≥85 y ears of age.
Blood eosinophil counts will also be summarized for the SCR.
9.3 Treatments 
The duration of exposure, the number of patients randomized who completed the foreseen 
course of study  medication and the number of patients who discontinued from the study 
medication will be summarized.
Medications started and stopped prior to study drug, taken concomitantly , and started 
following last study  drug dose (if applicable) will be summarized by treatment group in 
separate tables inthe SAF. Concomitant therapies will be 
recorded, listed and summarized 
separately  for asthma related medications / non-drug therapies and other medications.  
Concomitant asthma related medications will be summarized by pre-defined category .
  
Concomitant m edications not related to asthma will be summarized by  pharmacological (ATC) 
class and preferred term.  More than one ATC class per medication is possible and the 
medication will be reported under all applicable classes.
Short acting β2-agonist usage (number of puffs) during the screening epoch will be 
summarized. 
Usage of asthma medication (e.g. LABA, ICS) at baseline will be summarized. Usage of oral 
corticosteroids (OCS) including dose will also be summarized. Patients taking prohibited 
concomitant medications will be noted in the summary  of protocol deviations.
Compliance with study  medication over the entire study  will be summarized as the percentage 
of day s with study  medication intake during the period from first intake to last intake.
9.4 Analysis of the primary  variable(s)
The primary  analysis for this study  will be conducted according the intention to treat principle.
9.4.1 Variable(s)
The primary  variable for this study  is the number of moderate -to-severe asthma exacerbations 
as defined in Section 6.4.1 experienced by  each patient per patient y ear of follow -up. The start 
date of a moderate -to-severe asthma exacerbation recorded in the CRF is defined as the first 
day of ‘rescue’ systemic corticosteroid use, or the date of death if no rescue corticosteroids 
were taken prior to an asthma related death. Further asthma exacerbations will only be 
considered additional events, if the start date of the next episode is at least 7 day s after the end 

Novartis Confidential Page 81
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
of the previou s exacerbation episode. The end of an exacerbation is defined as the last day of 
systemic corticosteroid use.
The key secondary  variables are AQLQ+12, ACQ -5 and pre-dose FEV1 at the end of the 52 
week treatment period. Their definition and analy sis is desc ribed in Section 9.5.
9.4.2 Statistical model, hypothesis, and method of analy sis
Primary  null hypotheses
The trial will be considered positive, if one or more of the two QAW039 doses demonstrate a 
statistica lly significant reduction in the rate of moderate -to-severe asthma exacerbations. As 
described below, the two doses will be tested in parallel and each dose may achieve 
statistically  significant results irrespective of the results achieved b y the other dos e. 
The p rimary  null hy potheses are:
H0 450 eosinophil subgroup : relative risk ratio for the QAW039 450 mg QD group versus placebo 
in patients with eosinophil count 
≥ 250 cells/µl = 1, 
H0 150 eosinophil subgroup : relative risk ratio for the QAW039 150 mg QD versus placebo in 
patients with eosinophil count ≥ 250 cells/µl = 1,
H0 450 overall : relative risk ratio for the QAW039 450 mg QD versus placebo in the overall 
study  population = 1 and
H0 150 overall : relative risk ratio for the QAW039 150 mg QD versus placebo in the overall 
study  population = 1 .
The primary  alternate hypotheses are:
HA 450 eosinophil subgroup : relative risk ratio for the QAW039 450 mg QD group versus placebo 
in patients with eosinophil count ≥ 250 cells/µl ≠ 1,
HA 150 eosinophil subgrou p: relative risk ratio for the QAW039 150 mg QD group versus placebo 
in patients with eosinophil count ≥ 250 cells/µl ≠ 1,
HA 450 overall : relative risk ratio for the QAW039 450 mg QD group versus placebo in the 
overall study  population ≠1 and
HA 150 over all: relative risk ratio for the QAW039 150 mg QD group versus placebo in the 
overall study  population ≠1.
The superiority  of QAW039 over placebo will be considered confirmed if at least one of the 
four primary  null hypotheses is rejected in favor of the respective two-sided alternative 
hypotheses.
Family wise ty pe I error rate control
The famil ywise type I error rate will be controlled at the two-sided 5% level across the 
primary  and key secondary  null hypotheses using the closed testing procedure specifie d by 
Figure 9-1using the graphical method of  Bretz, et al 2009 . In this closed testing procedure 
the primary  null hy pothesis about exacerbations in the subset of patients with eosinophil count 
≥ 250 cells/µl for each dose acts as a gatekeeper for the other null hypotheses for the same 
dose. 

Novartis Confidential Page 82
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Figure 9-1 Closed testing procedure for primary  and key  secondary  objectives
Vertices with associated weights denote the individual null hypotheses and their local significance 
levels (initially α is split 50%:50% across the primary null hypotheses regarding the subgroup with 
blood eosinophils ≥ 250 cells/ μl for the 2 QAW 039 doses). Directed edges between the vertices 
specify how the local significance levels are propagated in case of significant results. Dotted Dashed 
edges with a weight of ε indicate that the local significance level from the key  secondary null 
hypotheses of a dose will only be propagated to the other population for the same dose, once all key  
secondar y null hypotheses for a dose and population have been rejected. Dotted edges with a weight 
of ε2(much smaller th an ε) indicate that the local significance level from the key  secondary null 
hypotheses of a dose will only be propagated to the other dose, once all key secondary null 
hypotheses for a dose have been rejected.
Initiall y, 50% of the alpha is assigned to each of the primary  null hypotheses regarding the 
subgroup with blood eosinophils ≥ 250 cells/ μl for the QAW039 450 mg QD and QAW039 
150 mg QD doses, respectively . 
Once this first primary null hypothesis for a dose has been rejected, the alpha will be 
distributed to the other primary  null hypothesis regarding the overall population for the same 
dose and the key secondary  null hypotheses regarding the subgroup with blood eosinophils ≥ 
250 cells/μl for that same dose. If the null hypothesis regarding the prima ry endpoint for the 
overall population is rejected for a dose, then alpha is reassigned to the key secondary  null 
hypotheses regarding the overall population for that dose. Alpha will only be reassigned from 
the set of null hypotheses for a dose to the null hypotheses for the other dose once all null 
hypotheses for the dose to which the alpha was originall y assigned have been rejected. 
Once the primary  null hypothesis for a dose and population has been rejected, all key 
secondary  null hypothesis for that dose and population are tested and can be rejected 
irrespective of whether the other key secondary  null hypotheses for that dose and population 
can be rejected. However, FEV1 will be initiall y given the highest local significance level due 
to its regulatory importance.

Novartis Confidential Page 83
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Statistical model for primary  variable
These hypothesis tests, as well as point estimates and confidence intervals will be based on a 
negative binomial regression model  with the natural logarithm of the duration of follow -up in 
years as an offset variable (Keene, et al 2007 ; Keene, et al 2008 ), treatment group, 
randomization stratum (use or non-use of oral corticosteroids as part of SoC asthma therapy , 
patient age at Visit 1 [<18 years or ≥18 years], and when analy zing the overall population ,
peripheral blood eosinophil counts at Visit 1 
[<250 cells/l or ≥250 cells/l]) and region as a 
fixed class effects, the natural logarithm of the number of asthma exacerbations (requiring 
treatment with oral or systemic corticosteroids) in the 12 months prior to screening and the 
baseline pre-dose FEV1 as a continuous linear covaria te. Note that the duration of follow -up 
will be the planned duration of follow -up for all patients, because any missing data will be 
imputed as described in Section 9.4.3. The inclusion of the offset isnevertheless useful to 
make regression coefficients easier to interpret. Should despite the inclusion criteria a patient 
with no exacerbations requiring 
treatment with oral or systemic corticosteroids in the 12 
months prior to screening be included in the trial, such a patient will be considered to have 
had 0.5 such exacerbations.
A negative binomial model will be used, because patient heterogeneit y beyond that captured 
by the available patient -level covariates is expected. This can lead to over dispersed 
cumulative counts and zero inflation. A negative binomial model can better capture such 
heterogeneity  than a Poisson model and can be seen as a Poisson model with the intensity 
distributed across patients according to a Gamma distribution (Keene, et al 2007 ).
Summary  statistics for the primary  variable
The primary  variable will be summarized by  treatment group in terms of the mean rate (events 
per patient year of follow -up) overall and for different time intervals, the distribution of 
patients by number of exacerbations and using plots of Nelson's (1995) nonparametric 
estimate of the mean cumulative function. The components of the
 composite primary  endpoint 
will be summarized .
9.4.3 Handling of missing values/censoring/discontinuations
Despite all attempt to ensure complete follow -up for all patients, some patients may not be 
followed for exacerbations for the whole planned study  duration. Missing data will be 
imputed using a multip le imputation approach similar to the “missing at random and jump to 
reference” approach described by  Keene et al. (2014) . 
The first step in implementing this approach is fitting a Bayesian negative multinomial model 
with non -informative priors to the data. This model will distinguish on -and off -treatment data 
for the QAW039 group and assume that the same event rate as in the placebo group applies 
after QAW039 discontinuation. The model will include the same covar iates as the primar y 
model, as well as a log length of follow -up offset variable. Missing data on exacerbations in 
both treatment groups will then be imputed by simulation using independent pseudorandom 
draws from the posterior for the parameters of this m odel in the conditional distribution of the 
missing data given the observed data as described by  Keene et al. (2014) . The imputation will 
use a mixture of the jump to reference and the missing at random approaches (Keene et al. 
2014) andwill distinguish the following two cases:

Novartis Confidential Page 84
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
1.No further treatment effect versus placebo will be imputed for QAW039 patients that 
discontinue treatment and are lost to follow- up due to (or following a treatment 
discontinuation due to) lack of efficacy , adverse events or death. 
2. A continued treatment effect for QAW039 patients being lost to follow- up for reasons 
likely  to be unrelated to study  treatment (e.g. lost to follow -up, withdrew consent) w ill be 
assumed.
A large number of imputed datasets will be created, with their number chosen based on 
computational feasibility, but at least 1,000 based on the recommendation of Keene et al. 
(2014) . Each dataset will be analy zed using the model described in Section 9.4.2 and the 
results will be combined on the log-scale using Rubin’s rule (Barnard and Rubin 1999) . 
Regression 
coefficients and their confidence intervals will then be exponentiated to obtain 
rates and risk ratios.
9.4.4 Supportive analy ses
The primary  and the key  secondary  anal yses will be repeated for the PPS.
The analysis results and the imputed data for d ifferent methods for imputing missing data will 
be compared.
If feasible retrieved data after the discontinuation of treatment (retrieved drop-out) will be 
used to impute missing post-treatment discontinuation data as a sensitivity  analysis. While 
retrieve d drop-outs may be a particularl y suitable basis for imputing data for non-retrieved 
drop-outs, this analysis may not be feasible or may require simplification of the imputation 
model, because observed post
-treatment discontinuation data may  be sparse.
An on-treatment analysis will also be conducted. In this analy sis all moderate -to-severe 
asthma exacerbations as defined in Section 
6.4.1 will be counted, if the start date of the 
exacerbation is on or aft
er the first day of treatment with double -blind study  medication, but 
before or on the day  after the last day  of treatment with double -blind study  medication. In this 
analysis a negative binomial regression model with the natural logarithm of the duration of 
on-treatment follow - up in years as an offset variable will be used. The duration of on-
treatment follow -
up in years will be calculated for each patient as (treatment end date -
treatment start date + 1 day)/365.25 without taking into account treatment interruptions. Such 
a negative binomial model assumes that missing data after censoring either due to losses to 
follow -up or the end of treatment are missing at random conditional on the baseline covariates 
and the preceding data on events per follow -up time included in the analysis (Cook and 
Lawless 2007) . Under this assumption the model implicitly  imputes the missing data and the 
data censored at the end of treatment assuming a hypothetical situation of continued t
reatment 
with an unchanged on-treatment event rate for the patient (Committee for Medicinal Products 
for Human Use 2010
). This analysis and missing data handling approach is in-line with the 
recentl y completed MENS A exacerbation trial for the monoclonal anti-interleukin -5 antibod y 
mepolizumab in a similar population (Ortega, et al 2014). It is therefore the most appropriate 
analysis for a comparison of the results of the pre sent trial to the MENSA trial.
In a tipping point analy sis it will be explored by  how much the event rate post -discontinuation 
would have had to increase (or continuous outcomes to worsen) in the primary  and key 
secondary  anal ysesin order to change the tr ial conclusions. 

Novartis Confidential Page 85
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
As a worst reasonable case analysis a disappearing treatment effect for all patients that are 
lost-to-follow -up will be used (jump- to-reference). This is a sensitivity  analysis for the effect 
of assuming a continued treatment effect for patients withdrawing from the study  for reasons 
considered to be likel y unrelated to stud y therap y (see Section 9.4.3)
In a
 further rank-based sensitivity  analysis for the primary  endpoint withdrawal from the trial 
and death will be directly  treated as negative trial outcomes for patients. Patients that 
completed the trial will be ranked as having had a more favorable outcome than patients that 
withdrew from the trial, who will in turn be ranked as having had a more favorable outcome 
than patients that died. Within each of these categories patients will be ranked according to 
(number of exacerbations + 0.5)/patient years of follow -up. Compared to solely  ranking 
patients according to the number of exacerbations or solely  according to the duration of 
follow -up, this ensures that patients lost to follow -up very early in the trial without 
experiencing any exacerbations will not be ranked more favorabl y than patients that nearl y 
completed the trial and only had 1, or 2 exacerba tions, while also ensuring that a patient with 
10 exacerbations that was lost to follow -up after 11 months and 1 day is not ranked as havin g 
a more favorable outcome than a patient with 0 exacerbations that was lost to follow -up after 
11 months. A Wilcoxon rank-sum test stratified by randomization stratum will be used to 
analyze the ranked data.
Supportive analyses will also explore whether allowing the possibility  of declining or 
increasing exacerbation rates over time affects study  conclusions.
Time to first asthma exacerbation and mean duration of asthma exacerbations will also be 
analyzed.
The absolute difference in the rates of moderate to severe asthma exacerbation rates per 
patient year and resulting number of patients that needs to be treated for 1 year to prevent one 
exacerbation will also be reported with confidence intervals.
For comparison to historical study  results, data for the key secondary  endpoints using last-
observation -carried -forward will also be provided.
Subgroups
The primary  and key secondary  analyses will also be conducted by subgroup including for 
key demographic (e.g. age, sex, race, BMI , geographic region ) and disease related subgroups 
(e.g. number of exacerbations in the previous year, OCS use/GINA step, baseline FEV1 
tertiles, ACQ tertiles, as well as blood eosinophil counts).
Relationship of efficacy and baseline eosinophil levels
In addition to subgroup analyses with different baseline eosinophil levels, the functional 
relationship between the treatment effect and baseline blood eosinophil levels as a continuous 
covariate will be investigated for the primary  and key  secondary  variables.
9.5 Analysis of secondary  variables
9.5.1 Efficacy  variables 
The key secondary  variables of this trial are the mean of the two pre-dose FEV1 assessments 
atthe week 52 visit, AQLQ+12 and ACQ -5 at the end of the 52 week treatment period. Data 

Novartis Confidential Page 86
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
from the preceding visits will be used primarily to describe the onset of action and for missing 
data imputation.
The key  secondary  variables of AQL Q+12, ACQ -5 and pre -dose FEV1 will be analy zed using 
an analysis of covariance (ANCOVA) model with factors for treatment group, randomization 
stratum andregion, as well as the baseline AQLQ+12, baseline ACQ -5 and baseline  pre-
bronchodilator FEV1 as continuous linear covariat es.
The null hypothesis will be tested for each dose group, each population (subgroup with 
peripheral blood eosinophil counts at Visit 1 ≥250 cells/ l or overall population) and each key  
secondary  variable using this model versus the two
-sided alternative hypotheses
For each key secondary  endpoint, each QAW039 dose and each population the null 
hypothesis is that the treatment difference compared to placebo at the week 52 visit = 0, while 
the alternative h ypothesis is that the treatment difference to placebo at the week 52 visit ≠0.
This model will be fitted to each of multiple imputations generated using the jump -to-
reference approach described by Carpenter et al. (2013) . In a similar manner to the primary 
analysis a continued treatment effect will be imputed for QAW039 patients with intermittent 
missing data and those QAW039 patients discontinuing double -blind study medication due to 
reasons likely to be unrelated to study  medication (see Section 9.4.3). For all other QAW039 
patients with missing data and placebo patients with missing data imputation will be based on 
the placebo group. The average of the two FEV1 assessments will only be formed after 
multiple impu tations so that if one of the two FEV1 assessments at a visit is missing, the 
average will be between the one available assessment and a second imputed assessment.
The test for the key secondary  variables AQLQ+12, ACQ -
5 and pre-dose FEV1 in patients 
with eosinophil count ≥ 250 cells/µl and for the overall population for each dose will be 
performed, i f the primary null hy pothesis has been rejected for the same dose for patients with 
eosinophil count ≥ 250 cells/µl and for the overall population, respectively . The local 
significance level for each secondary  null hypothesis will be determined based on the closed 
testing procedure specified by  Figure 9-1.
Sensitivity analy ses for the key  secondary endpoints
Arange of sensitivity  analyses for the key secondary  endpoints similar to those described in 
Section 9.4.3 and Section 9.4.4 will be conducted. Further supportive analy ses will look at the 
treatment effect separately  for each visit. 
Additionally , a mixed model for repeated measures ( MMRM) with an unstructured covariance 
structure will be fitted for secondary  variables to evaluate the average treatmen t effect during 
weeks 12 to 52 of the trial. These MMRMs will include treatment group, visit, randomization 
stratum and region as fixed class effects, and the baseline AQLQ+12, baseline ACQ -5 and 
baseline pre- bronchodilator FEV1 as continuous linear covari ates. Treatment group by  week 4 
visit and baseline value by visit interactions will also be included in the model. This average 
effect will be both investigated using the main data imputation approach, as well as in an on-
treatment analy sis. Note that the supportive on-treatment analy sis for the on-treatment values 
(from start of double -blind study  medication to the day  after the last day  of treatment) will use 
a MMRM with an unstructured covariance structure. This model implicitly  imputes 
unrecorded values and the data censored at the end of treatment assuming a hypothetical 
situation of continued treatment with an unchanged on-treatment effect that is constant across 

Novartis Confidential Page 87
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
the week 12 to 52 visits for patients in a similar manner as the on-treatment analysis using a 
negative binomial model described in Section 9.4.4 . 
An analysis of percent change from baseline in pre-dose FEV1 will also be performed. For 
this analy sis pre-dose FEV1 and its baseline will be log
-transformed for analysis and results 
will be back -transformed to obtain geometric means and ratios of geometric means to allow 
an interpretation as percent change from baseline. 
9.5.1.1 Asthma Quality  of Life Questionnaire for 12 y ears and older 
(AQLQ+12)
The 32 items in the AQLQ+12 are divided into 4 domain -specific scores and a total score as 
follows: 
Symptoms = Mean of I tems 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 29, 30 (12 items) 
Activity  limitation  = Mean of Items 1, 2, 3, 4, 5, 11, 19, 25, 28, 31, 3 2 (11 items) 
Emotional function  = Mean of Items 7, 13, 15, 21, 27 (5 items) 
Environmental Stimuli = Mean of Items 9, 17, 23, 26 (4 items) 
Overall Score = Mean of Items 1 to 32 (32 items) 
Each item of the AQLQ+12 is equally  weighted and scored along a 7-point scale, where 1 
indicates maximal impairment and 7 indicates no 
impairment. Thus, higher scores indicate 
better asthma -related HRQOL. There is a mean score calculated for each of the four domains, 
as well as an overall quality -of-life score, which is the mean score of all 32 items. The 
resultant overall scores will be between 1 and 7.
The developer suggests no more than 10% of missing data. This means no more than 3 
missing responses for the overall score and no more than 1 missing response per domai n.  For 
the symptoms and activity  domain scores, one missing value per domain is allowed.  For the 
emotional function and environmental stimuli domain scores, no missing values are allowed .
If these limits for missing questions are exceeded, the variable w ill be considered missing and 
will be imputed as described in S ection 9.5.1 .
The minimal important difference (MID), defined as “the smallest difference in score which 
patients perceive as beneficial and would mandate, in the absence of troublesome side effects 
and excessive cost, a change in the patient’s management,” of 0.5 has been established for this 
questionnaire as clinically significant (Juniper, et al 19 94).
9.5.1.2 Pre-dose FEV1
The baseline measurement is defined as the mean of the pre-bronchodilator FEV1 value s
taken 
at the last visit in the clinic prior to first dose of study  drug. 
If the pre-dose FEV1 is taken within 6 hours of SABA use,or within 12 hours of twice -daily 
LABA (including fixed dose combinations of LABA and ICS) use,or 24 hours ofonce -daily 
LABA (including fixed dose combinations of LABA and ICS) use,or 24 hours ofonce -daily 
LAMA use , then the individual FEV1 value is set to missing. 
9.5.1.3 Asthma Control Questio nnaire (A CQ-
5)
The ACQ measures asthma symptom control and consists of 7 items. It includes the 5 most 
important symptoms, 1 about rescue bronchodilator use and 1 about airway  calibre (FEV1 % 

Novartis Confidential Page 88
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
predicted pre -bronchodilator). Patients wi ll be asked to recall their experiences during the past 
one week and to response items 1-6 (night -time waking, symptoms on waking, activit y 
limitation, shortness of breath, wheeze, and rescue short -acting β2-agonist use) on a 7-point 
scale (0 –totally  controlled, 6 – extremely  poorly  controlled). The ACQ -5 score calculated 
based on the 5 questions of the 5 most important sy mptoms. The5 questions of the ACQ -5 are 
equally  weighted. The ACQ -5 score is the mean of the responses to the 5 questions. The 
resultant score will be between 0 and 6.
A score of 1.5 at baseline indicates patients who entered the study  had inadequatel y controlled 
asthma (Juniper 2006). In addition, the minimal important difference (MID) or smallest 
change that can be considered clinically  important is 0.5. 
9.5.2 Safety  
variables
All safet y data will be summarized for the safety set.
Safety  summaries will be primarily  based on on- treatment data with selected tables also 
presented for the all data after the first intake of study  drug, while all databased safety  data 
will be listed. 
Unless otherwise specified, all safet y summaries will be provided for patients with eosinophil 
count ≥ 250 cells/µl, for patients with eosinophil count < 250 cells/µl and for the overall study 
population.
Adverse events
Adverse events after informed consent including asthma exacerbations will be summarized 
and listed.
Adverse events starting 
on or after the time of the first intake of study  drug and until the day 
after the last intake of study  drug will be classified as a treatment emergent adverse events. 
Any adverse events that started during the study  after informed consent before the time of the 
first intake of study  drug will be classified as a prior adverse events and not included in 
tabulations of tre atment emergent adverse events. 
The following treatment emergent adverse event summaries will be produced, overall by 
system organ class and preferred term, overall by system organ class, preferred term and 
maximum severity , suspected drug -related adverse events by  system organ class and preferred 
term, serious adverse events by system organ class and preferred term, and adverse events 
leading to permanent discontinuation of study -drug by system organ class and preferred term.
Additionally , summaries including both treatment emergent and post-treatment 

Novartis Confidential Page 89
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
discontinuation events will be produced for adverse events and serious adverse events by 
system organ class and preferred term.
The number and percentage of patients with treatment emergent adverse events of special 
interest (e.g. IDRs), as well as cardiac events  will be summarized for each type of event with 
a break -down for each type of event by SMQ (when applicable) and preferred term. Time -to-
first-event analyses using Kaplan -Meier plots and Cox regressio n with the same model terms 
as the primary  efficacy  analysis model will be reported for each type of event, as well as 
incidence for recurrent events per patient -year of follow -up. The strategy  for identify ing these 
events will be defined in the detailed s tatistical analy sis plan for this trial.
Vital signs
On-treatment data from the vital signs (systolic blood pressure, diastolic blood pressure, and 
pulse rate) will be summarized by  treatment and scheduled visit. The maximum and minimum 
on-treatment systolic blood pressure, diastolic blood pressure, and pulse rate post-baseline 
(including values from post-baseline unscheduled and premature discontinuation visits) can 
also be summarized by treatment. Absolute on-treatment body  weight will be summarized by 
scheduled visit. The on-treatment change from baseline to each scheduled post-baseline visit 
will be summarized by vital sign parameter, scheduled visit and treatment with standard 
descriptive statistics.
Notable on-treatment values and notable on-treatment changes from baseline in vital signs 
will be summarized.
Electrocardiogram (ECG) 
The on-treatment changes from baseline will be summarized by ECG parameter, schedule 
visit where baseline and post baseline values are both available. 
The following quantita tive on-treatment variables will be summarized by treatment at each 
scheduled post-baseline visit: ventricular rate, QT interval, RR interval, PR interval, QRS 
duration, heart rate, and Fridericia’s QTc. The maximum on-treatment QTc (including values 
from post-baseline unscheduled and premature discontinuation visits) will also be summarized. 
Notable on-treatment values and notable on-treatment changes from baseline in quantitative 
ECG variables will be summarized.
Laboratory  data
All laboratory  data will be listed with abnormal values flagged. The laboratory  on-treatment 
values and the on
-treatment change from baseline for continuous laboratory  parameters will 
be summarized at each visit. A frequency  table of results for categorical on-treatment 
laboratory parameters will be produced for the whole study  duration. 
Shift tables relative to the normal reference ranges will be used to summarize the on -treatment 
change from baseline to post-baseline for each laboratory  parameter. For each on-treatment 
laborator y parameter, the patients will be classified into one of the four mutually  exclusive 
groups (low, normal, high, and low + high).
For selected laboratory parameter s, the number and percentage of patients with newly 
occurring or worsening on-treatment labora tory abnormalities meeting the clinicall y notable 

Novartis Confidential Page 90
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
criteria will be summarized by laboratory  parameter at any time-point over the treatment 
period, considering all post-baseline data from scheduled, unscheduled and premature 
discontinuation visits. Patients with any newly occurring or worsening on-treatment value 
meeting the clinically  notable criteria will be counted under the applicable criteria. 
9.6 Interim analy ses 
As described in Section 
3.5, a single futility  interim analy sis will be conducted in addition to 
periodic unblinded safet y reviews by  the DMC (see Section 8.3 ) using data (including specific 
safet y summaries for adoles
cent participants) from this trial and other Phase III trials in the 
QAW039 asthma development program. No stopping for demonstrated efficacy  prior to the 
completion of the study is foreseen at either the unblinded safet y reviews or the futility 
interim analysis, because a sufficientl y large safety  dataset is needed in addition to efficacy 
data and thus, no statistical adjustment will be made to the final anal ysis.
9.7 Sample size calculation
To be conservative a mean placebo event rate of 1.5 events per patient year of follow -up has 
been assumed for this study ; this is a slightly  lower rate than the 1.75 events per patient- year 
observed in the placebo group of the MENSA trial (Ortega, et al 2014 ) and the same event 
rate as assumed for the DREAM trial, although the actual DREAM placebo event rate was 2.4 
events per patient year of follow -
up (Pavord, et al 2012 ). A 40% reduction in the rate of 
asthma exacerbations per year in the QAW039 treatment compared to placebo has been 
assumed for the subgroup with high eosinophils ≥ 250 cells/ μl for this study ; this is 
considered to be highl y clinically  relevant and at the same time realistic based on the DREAM 
and MENSA trials conducted in similar patient populations. In the DREAM trial 75 mg 
mepolizumab reduced the number of asthma exacerbations per patient per year by 48%, 

Novartis Confidential Page 91
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
250mg mepolizumab by 39% and 750mg mepolizumab by 52% compared with placebo. In 
the MENSA trial intravenous mepolizumab reduced the number of asthma exacerbations per 
patient per year by 47% and subcutaneous mepolizumab by 53% compared with placebo. 
These relative risk reductions were taken into account, because the observed reduction in 
sputum eosinophils with QAW039 in Study CQAW039A2208 were similar to those observed 
with mepolizumab (Haldar, et al 2009; Pavord, et al 2012). On this basis it is postulated 
QAW039 may reduce the rate of asthma exacerbations to a similar extent as mepolizumab. 
For the subgroup with eosinophils < 250 cells/μl a lesser relative risk reduction of 30% was 
assumed. However, it 
should be noted that the trial may produce a significant result with a 
smaller reduction in exacerbations than that assumed for power calculations and that such a 
reduction could still be considered clinicall y relevant.
As reported in online supplementary  material for the MENS A publication the negative 
binomial dispersion parameter for the exacerbation rates was estimated to be 0.8 in the 
DREAM trial. In the DREAM trial approximately  15% of patients in the mepolizumab arms 
and 20% of patients in the placebo arm were lost to follow- up by the end of the 1-year trial, 
while in the 32 week MENSA trial only  6 to 8% of patients were lost across groups . Therefore, 
a constant exponential hazard rate over time for treatment discontinuation is assumed with 
15% of patients off treatment by1 year in the active treatment groups and the placebo group.
No further treatment effect versus placebo has been assumed during the off-treatment, i.e. a 
mean event rate of 1.5 events per patient year has been assumed for patients after treatment 
disconti nuation in both the QAW039 and placebo groups .
A 1:1:1 randomization was used, even though the power to demonstrate the 
superiorit y of at 
least one arm versus placebo would likely  have been higher with an increased assignment to 
the placebo group, in order to not reduce the amount of efficacy  and safety  information for 
each QAW039 dose group. 
Negative binomial counts were simulated based on the assumptions above and the testing 
procedure in Figure 9-1was applied to each simulation result. For the purpose of evaluating 
the power for the primary  trial objectives, it was assumed that none of the key secondary  null 
hypotheses would be rejected.
For this study  a two-sided significance level of 5% is used fortesting. As shown in Table 9-1
188 
patients per arm in the subpopulation with blood eosinophils ≥ 250 cells/ μl and 282
patients per arm in the overall population corresponding to a total sample size of 846 patients 
provide greater than 80% power for demonstrating the superiorit y of each dose of QAW039 
compared to placebo in the subpopulation with blood eosinophils ≥ 250 cells/ μl and overall 
population under the des cribed assumptions .

Novartis Confidential Page 92
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Table 9-1 Power for the primary  variable
True relative risk reduction
Upper row: Subpopulation
Lower row: Other populationPower (%)
Upper row: Subpopul ation
Lower row: Overall population
450 mg 150 mg At least one All doses
(%) (%) 450 mg 150 mg dose significant Significant
40
3040
3089%
84%89%
84%96%
93%82%
75%
40
2040
2089%
76%89%
76%96%
88%82%
64%
40
040
089%
49%89%
49%96%
66%82%
32%
Subpopulation means the subpopulation with blood eosinophils ≥ 250 cells/ μl, while other 
population refers to the subpopulation with blood eosinophils < 250 cells/μl. Power results 
are based on 100,000simulated trials per scenario. Only results for primary  endpoints were 
simulated . For the purpose of evaluating the power for the primary  trial objectives, it was 
assumed that none of the key secondar y null hypotheses would be rejected. All simulations 
were performed in SAS 9. 4.
If statistical signific ance is achieved in the primary  test,the test for the key secondary 
variables pre-dose FEV1 ,AQLQ+12 andACQ -5 will be performed. The local significance 
level for each secondary  null hypothesis will be determined based on the closed testing 
procedure show n in Figure 9-1. For the power for each key secondary  variable in the 
subpopulation with blood eosinophils ≥250 cells/ μland overall population, it was 
conservativel y assumed that only the null hypothesis for the primary endpoint for the 
respective dose in the subpopulation and overall population would be rejected. For AQLQ+12 
and ACQ5 the power was additionally  calculated conditional 
on both the null hypothesis for 
the primary  endpoint and pre-dose FEV1 for the respective dose in the subpopulation and 
overall population having been rejected. The power for each key  secondary  endpoint is shown 
in Table 9-2. However, note that the power for the key secondary  endpoints will be higher 
once the null hypotheses relating to other key secondary  variables or other doses have been 
rejected. For the power calculation of secondary  endpoints no further treatment effect versus 
placebo has been assumed for patients with treatment discontinuation.
It was assumed that QAW039 achieves a difference of 150 mLagainst placebo in FEV1 after 
52weeks for patients that remain on treatment
. ASD of 380 mL was assumed for the anal ysis 
in FEV1 . Given a 15% treatment discontinuation rate by week 52,the planned sample size
will give 80% power for each dose in the subpopulation at theresulting local two-sided 
significance level of 1.625 % and 90% power for each dose in the overall population at the
resulting local two -sided significance level of 0.698 %.
Assuming a clinicall y important true improvement of at least 0.5 in AQL Q+12 after 52weeks 
treatment for patients that remain on treatment, a standard deviation (SD) of 1and 15% 
treatment discontinuation rateby week 52, the planned sample sizeper armwill provide 76% 
power for each dose in the subpopulation with blood eosinophils ≥ 250 cells/
μlat the resulting 
local two sided significance level of 0.075 % and 93% power for each dose in the overall 

Novartis Confidential Page 93
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
population at the resulting local two-sided significance level of 0.038 %after the respective 
primary  null hy pothesis has been rejected . 
Assuming a difference of 0.5against placebo in ACQ -5after 52weeks for patients without 
treatment discontinuation, a SD of 1.1, and a 15% treatment discontinuation rate by week 52, 
the planned sample size will give 59% power for each dose in the subpopulation at the
resulting local two
-sided significance level of 0.05% and 78% power for each dose in the 
overall population at theresulting two-sided local significance level of 0.015 %after the 
respective primary  null hy pothesis has been rejected .
Table 9-2 Power of each dose for the analy ses of key  secondary  variables 
Pre-dose FEV1 AQLQ+12 ACQ -5
Difference of effect ( δ) for patients 
without treatment discontinuation150 mL 0.5 0.5
SD (σ) 380 mL 1 1.1
Treatment discontinuation rate 15% 15% 15%
Subpopulation Local two-sided 
significance level1.625%0.075% *
1.294%†0.05% *
0.456%†
Power80%76%*
95%†59%*
81%†
Overall population Local two-sided 
significance level0.698%0.038% *
0.561%†0.015% *
0.189%†
Power90%93%*
99%†78%*
93%†
Subpopulation means the subpopulation with blood eosinophils ≥ 250 cells/ μl.
* For local two -sided significance level and power in AQLQ+12 and ACQ5 the upper row shows the 
value when only the null hypothesis for the primary  endpoint for the respective dose in the 
subpopulation and overall population have been rejected. 
† The lower row shows the value when both the null hypothesis for the primary  endpoint and pre -dose 
FEV1 for the respective dose in the subpopulation and overall population have been rejecte d.
10 Ethical considerations 
10.1 Regulatory  and ethical compliance 
This clinical study  was designed and shall be implemented and reported in accordance with 
the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC, US CFR 21, and Japanese Ministry  of 
Health, Labor, and Welfare), and with the ethical principles laid down in the Declaration of 
Helsinki.
10.2 Informed consent procedures 
Eligible patients may only be included in the study  after providing written (witnessed, where 
required by law or regulation), IRB/IEC -approved informed consent, or, if incapable of doing 
so, after such consent has been provided by a  legally  acceptable representative(s) of the 
patient. In cases where the patient’s representative gives consent, the patient should be 

Novartis Confidential Page 94
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
informed about the study  to the extent possible given his/her understanding. If the patient is 
capable of doing so, he/she should indicate assent by personally  signing and dating the written 
informed consent document or a separate assent form. Informed consent must be obtained 
before conducting any study -specific procedures (i.e. all of the procedures described in the 
protocol). The process of obtaining informed consent should be documented in the patient 
source documents. 
Novartis will provide to investigators in a separate document a proposed informed consent 
form that complies with the ICH GCP guideline and regulatory  requirements and is 
conside red appropriate for this study . Any  changes to the proposed consent form suggested by  
the investigator must be agreed to by Novartis before submission to the IRB/IEC, and a copy 
of the approved version must be provided to the Novartis monitor after IRB/IEC approval.
Women of child bearing potential should be informed that taking the study  treatment may 
involve unknown risks to the fetus if pregnancy  were to occur during the study  and agree that 
in order to participate in the study  they must adhere to the contraception requirement for the 
duration of the study . If there is any question that the patient will not reliably compl y, they 
should not be entered in the study .
In the event that Novartis wants to perform testing on the samples that are not described in
this protocol, additional Institutional Review Board and/or Ethics Committee approval will be 
obtained.
10.3 Responsibilities of the investigator and IRB/IEC 
Before initiating a trial, the investigator/institution should obtain approval/favorable opinion 
from the Institutional Review Board/Independent Ethics Committee (IRB/IEC) for the trial 
protocol, written informed consent form, consent form updates, subject recruitment 
procedures (e.g., advertisements) and any other written information to be provided to pa tients. 
Prior to study  start, the investigator is required to sign a protocol signature page confirming 
his/her agreement to conduct the study  in accordance with these documents and all of the 
instructions and procedures found in this protocol and to give access to all relevant data and 
records to Novartis monitors, auditors, Novartis Quality  Assurance representatives, designated 
agents of Novartis, IRBs/I ECs, and regulatory  authorities as required. If an inspection of the 
clinical site is requested by a regulatory  authority , the investigator must inform Novartis 
immediately  that this request has been made.
10.4 Publication of study  protocol and results 
Novartis assures that the key design elements of this protocol will be posted in a publicl y 
accessible databas e such as clinicaltrials.gov. In addition, upon study  completion and 
finalization of the study  report the results of this trial will be either submitted for publication 
and/or posted in a publicly  accessible database of clinical trial results.
10.5 Qualit y Control and Quality  
Novartis maintains a robust Quality  Management (QM) system that includes all activities 
involved in quality  assurance and qualit y control, including the assignment of roles and 
responsibilities, the reporting of results, and the documentat ion of actions and escalation of 
issues identified during the review of qualit y metrics, incidents, audits and inspections.

Novartis Confidential Page 95
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Audits of investigator sites, vendors, and Novartis sy stems are performed by  Novartis Pharma 
Auditing and Compliance Qualit y Assurance (CQA), a group independent from those 
involved in conducting, monitoring or performing quality  control of the clinical trial. The 
clinical audit process uses a knowledge/risk based approach.
Audits are conducted to assess GCP compliance with global and local regulatory  requirements, 
protocols and internal SOPs, and are performed according to written Novartis processes.
11 Protocol adherence 
This protocol defines the study  objectives, the study  procedures and the data to be collected 
on study  participants. Additional assessments required to ensure safet y of patients should be 
administered as deemed necessary  on a case by case basis. Under no circumstances should an 
investigator collect additional data or conduct any additional procedures for any research 
related purpose involving any  investigational drugs.
Investigators ascertain they will apply due diligence to avoid protocol deviations. If an 
investigator feels a protocol deviation would improve the conduct of the study  this must be 
considered a protocol amendment, and unless such an amendment is agreed upon by Novartis 
and approved by the IRB/IEC and health authorities, where required, it cannot be 
implemented. All significant protocol deviations will be recorded and reported in the CSR.
11.1 Protocol A mendments
Any change or addition to the protocol can onl y be made in a written protocol amendment that 
must be approved by Novartis, Health Authorities where required, and the IRB/IEC prior to 
implementation. Only  amendments that are intended to eliminate an appar ent immediate 
hazard to patients may be implemented immediately  provided the Health Authorities are 
subsequently  notified by protocol amendment and the reviewing IRB/IEC is notified. 
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expected to take any immediate action required for the safet y of any patient included in this 
study , even if this action represents a deviation from the protocol. In such cases, the report ing 
requirements identified in Section 7 Safety  Monitoring should be followed.
12 References 
References are available upon request.
ATS/ERS (2005) Recommendations for Standardized Procedures for Online and Offline 
Measurement of Exhaled L ower Respiratory  Nitric Oxide and Nasal Nitric Oxide. AJRCCM; 
171: 912
-930.
Barnard J, Rubin D (1999) Small- sample degrees of freedom with multiple imputation. 
Biometrika; 86:948 –955.
Bretz F, Maurer W, Brannath W et al
.(2009) A graphical approach to sequentially  rejectiv e 
multiple test procedures. Statistics in Medicine; 28(4): 586 -604.
Carpenter JR, Roger JH and Kenward MG (2013) Analy sis of Longitudinal Trials with 
Protocol Deviation: A Framework for Relevant, Accessible Assumptions, and I nference via 
Multiple I mputatio n. Journal of Biopharmaceutical Statistics, 23:6, 1352- 1371

Novartis Confidential Page 96
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Castro M, Mathur S, Hargreave F et al (2011) Reslizumab for poorly  controlled, eosinophilic 
asthma. Am J Resp Crit Care Med; 184: 1125 -1132.
Castro M, Zangrilli J, Wechsler ME et al. (2015) Reslizumab for inadequately  controlled 
asthma with blood eosinophil counts from two, multicentre, parallel, double -blind, 
randomised, placebo -controlled, phase 3 trials. Lancet Respir Med ; Published Online: 23 
February  2015.
Center for Disease Control and Prevention (Cdc.gov) (2000). Growth Charts -Homepage. 
Available from :http://www.cdc.gov/growthcharts/ .
Chevalier E, Stock J, Fisher T et al. (2005 ) Cutting edge: chemoattractant receptor -
homologous molecule expressed on Th2 cells plays a restricting role on IL-5 production and 
eosinophil recruitment. J Immunol ; 175: 2056 –2060.
Chung KF , Wenzel S, Brozek J et al. (2014) International ERS/ATS guidelin es on definition, 
evaluation and treatment of severe asthma. Eur Respir J; 43:343 .
Cook, Richard J., and Jerald F. Lawless. The statistical anal ysis of recurrent events. Springer, 
2007.
Deng JW, Song I S, Shin HJ et al (2008) The effect of SL C01B1*15 in the disposition of 
pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity  
changes b y SLC01B1*15.  Pharmacogenetics and Genomics; 18(5): 424 -433.
Elsby  R, Hilgendorf C, and Fenner K (2012) Understanding the critical disp osition pathway s 
of statins to assess drug
-drug interaction risk during drug development: it’s not just about 
OATP1B1. Clin Pharmacol and Ther; 92: 585 -598.
Global Strategy  for Asthma Management and Prevention, Global I nitiative for Asthma 
(GINA) 201 6.  Available from http://www.ginasthma.org/. 
Haldar P, Brightling CE, Hargadon B et al. (
2009) Mepolizumab and exacerbations of 
refractory  eosinophilic asthma. N Engl J Med.; 360(10):973 -
84.
Hurst H, Bolton  J.  (2004) Assessing the clinical significance of change  scores  recorded  on 
subjective outcome  measures. J Manipulative Physiol Ther ;27:26 -35.
Jacobson TA (2008) Toward “pain- fee” statin prescribing: clinical algorithm for diagnosis 
and management of my algia. May o Clin Proc ;83: 687-700.
Juniper EF, O'By rne PM, Guy att GH et al. (1999) Development and validation of the 
questionnaire to measure asthma control. Eur Resp J, 14: 902-907.
Juniper EF, Svensson K, Moerk AC, Ståhl E (2005) Modification of the Asthma Quality  of 
Life Questionnaire (standardised) in patients 12 y ears and older. Health and Quality  of Life 
Outcomes. Health Qual of L ife Outcomes; 3: 58.
Juniper EF, Bousquet J, Abetz L et al., GOAL Committee (2006) Identifying ‘well -controlled’ 
and ‘not well -controlled’ asthma using the Asthma Control Questionnaire. Respir Med ;100: 
616- 621.
Juniper EF, Gruffy dd
-Jones K, Ward S, Svensson K (2010) Validation, measurement 
properties and interpretation of the Asthma Control Questionnaire in children. Eur Respir J ;
36: 1410-1416.
Kalliokoski A and Niemi M (2009)  Impact of OATP transporters on pharmacokinetics.  B J 
P; 158: 693-705.

Novartis Confidential Page 97
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Keene, O. N., Jones, M. R., Lane, P. W., & Anderson, J. (2007) Analy sis of exacerbation rates 
in asthma and chronic obstructive pulmonary  disease: example from the TRI STAN stud y. 
Pharmaceutical statistics; 6(2): 89 -97.
Keene ON, Calverley  PM, Jones PW, Vestbo J, Anderson JA (2008) Statistical analy sis of 
exacerbation rates in COPD: TRI STAN and ISOLDE revisited. Eur Respir J ;32: 17 –24.
Keene ON, Roger JH, Hartley  BF and Kenward MG (2014) Missing data sensitivity  analy sis 
for recurrent event data using controlled imputation. Pharmaceut. Statist.; 13: 258 –264
Masoli M, Fabian D, Holt S et al. (2004) Th e global burden of asthma: executive summary  of 
the GINA Dissemination Committee Report. Allergy ;59: 469
-478.
Nair P , Pizzichini MM, Kjarsgaard M et al (2009) Mepolizumab for prednisone -dependent 
asthma with sputum eosinophilia. N Engl J Med; 360(10):985-93.
Nelson, W (1995) Confidence Limits for Recurrence Data —Applied to Cost or Nu mber of 
Product Repairs. 
Technometrics ; 37: 147 –157.
Noe J, Portmann R, Brun ME et al (2007) Substrate
-dependent drug -drug interactions 
between gemfibrozil, fluvastatin, and other organic anion -transporting peptide (OATP) 
substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos 35(8): 1308 -1314.
Nowak RM, Parker JM, Silverman RA et al (2015) A randomized trial of benralizumab, an 
antiinterleukin 5 receptor α monoclonal antibod y, after acute asthma. Am J Emergency Med; 
33:14 -20.
Ortega H , Liu MC, Pavord ID et al. (2014) Mepolizumab treatment in patients with severe 
eosinophilic asthma. N Engl J Med; 371(13) : 1198 - 1207.
Pavord ID, Korn S, Howarth P et al. (2012) Mepolizumab for severe eosinophilic asthma 
(DREAM): a multicenter, double- blind, placebo -controlled trial. Lancet ;380: 651 -659.
Reddel HK, Tay lor DR, Bateman ED et al. (2009) An official American Thoracic 
Society /European Respiratory  Society  statement: asthma control and exacerbations: 
standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care 
Med;180: 59-99.
Regan SL, Maggs JL , Hammond TG et al (2010) Acy l glucuronides: the good, the bad and the 
ugly. Biopharm Drug Dispos; 31:367 -95.
Santanello NC, Barber BL, Reiss TF et al (1997) Measurement characteris tics of two asthma 
symptom diary  scales for use in clinical trials.  Eur Resp J ;10: 646-651.
Takaku Y, Soma T, Nishihara F et al. (2013) Omalizumab attenuates airway  inflammation 
and interleukin -5production by  mononuclear cells in patients with severe allergic asthma. Int 
Arch Allergy  Immunol; 161 Suppl 2:107 -17.
Wenzel S (2005) Severe asthma in adults. Am J Respir Crit Care Med ; 172(2):149 -60. Epub 
2005 Apr 22.
Wenzel S, Ford L , Pearlman D (2013) Dupilumab in persistent asthma with elevated 
eosinophil levels. N Engl J Med; 368(26): 2455-66.
Woodruff PG, Modrek B, Choy  DF et al. (2009) T
-helper t ype 2 -driven inflammation defines 
major subphenoty pes of asthma. Am J Respir Crit Care Med; 180(5):388 -95.

Novartis Confidential Page 98
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
13 Appendix 1: Clinically  notable laboratory  values and vital 
signs
Thecentral laboratory  will flag laboratory  values falling outside of the normal ranges on the 
central laboratory  report s.  Investigators are responsible for reviewing these abnormal values 
for clinical significance, signing the laboratory  reports to indicate their review, and reporting 
values considered clinically  significant in the appropriate eCRF.
Any clinicall y significant abnormal laboratory value should be evaluated and followed-up by 
the investigator until normal or a cause for the abnormality  is determined.
See Appendix 2 for specific liver event and laboratory test trigger definitions and follow -
up requirements.
ForECGs, a notable QTc value is defined as a QTcF(Fridericia) interval of ≥450 msec for 
males or ≥460 msec for females –all such ECGs will be flagged by the Central CRO and 
require assessment for clinical relevance and continuance of the patient by the Inv estigator.   

Novartis Confidential Page 99
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
14 Appendix 2: Liver event and Laborator y trigger Definitions 
and Follo w-up Requirements
Table 14-1 Liver Event and Laboratory  Trigger Definitions
Definition/ th reshold
LIVER LABORATORY 
TRIGGERS3 x ULN < ALT / AST 5 x ULN
1.5 x ULN < TBL 2 x ULN
LIVER EVENTS ALT or AST > 5 × ULN
ALP > 2 × ULN (in the absence of known bone pathology)
TBL > 2 × ULN (in the absence of known Gilbert syndrome)
ALT or AST > 3 × ULN and INR > 1.5 
Potential Hy’s Law cases (defined as ALT or AST > 3 × ULN 
and TBL > 2 × ULN [mainly conjugated fraction] without 
notable increase in ALP to > 2 × ULN)
Any clinical event of jaundice (or equivalent term)
ALT or AST > 3 × ULN accompanied by (general) malaise, 
fatigue, abdominal pain, nausea, or vomiting, or rash with 
eosinophilia
Any adverse event potentially indicative of a liver toxicity * 
*These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage -
related conditions; the non -infectious hepatitis; the benign, malignant and unspecified liver 
neopl asms
TBL: total bilirubin; ULN: upper limit of normal
Table 14-2 Follo w Up Requirements for Liver Events and Laboratory  Triggers
Criteria Actions required Follow -up monitoring
Potential Hy’s 
Law caseaDiscontinue the study drug 
immediately
Hospitalize, if clinically appropriate
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc
(frequency at investigator 
discretion)
ALT or A ST
> 8 × ULN Discontinue the study drug 
immediately
Hospitalize if clinically appropriate
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc
(frequency at investigator 
discretion)
> 3 × ULN and 
INR > 1.5Discontinue the study drug 
immediately
Hospitalize, if clinically appropriate
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc
(frequency at investigator 
discretion)
> 5 to ≤ 8 × ULN Repeat LFT within 48 hours
If elevation persists, continue 
follow -up monitoringALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc
(frequency at investigator 

Novartis Confidential Page 100
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Criteria Actions required Follow -up monitoring
If elevation persists for more than 2 
weeks , discontinue the study drug
Establish causality
Complete liver CRFdiscretion)
> 3 ×ULN 
accompanied by 
symptomsbDiscontinue the study drug 
immediately
Hospitalize if clinically appropriate
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc
(frequency at investigator 
discretion)
> 3 to ≤ 5 × ULN 
(patient is 
asymptomatic)Repeat LF T within the next week
If elevation is confirmed, initiate 
close observation of the patientALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc
(frequency at investigator 
discretion)
ALP (isolated)
> 2 ×ULN (in the 
absence of 
known bone 
pathology)Repeat LFT within 48 hours
If elevation persists, establish 
causality
Complete liver CRFInvestigator discretion
Monitor LFT within 1 to 4 weeks 
or at next visit
TBL (isolated)
> 2 × ULN (in the 
absence of 
known Gilbert 
syndrome)Repeat LFT within 48 hours
If elevation persists, discontinue 
the study drug immediately
Hospitalize if clinically appropriate
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc
(frequen cy at investigator 
discretion)
Test for hemoly sis (e.g., 
reticulocytes, haptoglobin, 
unconjugated [indirect] bilirubin)
> 1.5 to ≤ 2 × 
ULN
(patient is 
asymptomatic)Repeat LFT within the next week
If elevation is confirmed, initiate 
close observation of the patientInvestigator discretion
Monitor LFT within 1 to 4 weeks 
or at next visit
Jaundice Discontinue the study drug 
immediately
Hospitalize the patient
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc
(frequency at investigator 
discretion)
Any AE 
potentially 
indicative of a 
liver toxicity*Consider study drug interruption or 
discontinuation 
Hospitalization if clinically 
appropriate
Establish causality
Complete liver CRFInvestigator discretion
aElevated ALT/AST > 3 × ULN and TBL > 2 × ULN but without notable increase in ALP to > 2 × 
ULN
b(General) malaise, fatigue, abdominal pain, nausea, or vomiting, or rash with eosinophilia 
cResolution is defined as an outcome of one of the following: (1) ret urn to baseline values, (2) 
stable values at three subsequent monitoring visits at least 2 weeks apart, (3) remain at 
elevated level after a maximum of 6 months, (4) liver transplantation, and (5) death.

Novartis Confidential Page 101
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Refer to Section 5.5.10 for additional guidance on study  treatment discontinuation due to liver 
laboratory  abnorma lity / liver event, and to Section 7.3 for guidance on liver safet y 
monitoring.

Novartis Confidential Page 102
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
15 Appendix 3: List of IDRs for investigators
Table 15-1 Definition of potential idiosy ncratic drug reactions 
Type of reaction Possible eve nts diagnoses and signs/sy mptoms
Anaphylaxis Anaphylactic/anaphylactoid reactions 
Angioedema: diagnosis 
and/or signs and s ymptomsAngioed ema, site specific angioedema  urticaria, 
anisarca/generalized edema urticaria
Severe skin reactions Acute generalised exanthematous pustulosis, Cutaneous 
vasculitis, Drug reaction with eosinophilia and systemic 
symptoms (DRESS), Epidermal necrosis, Toxic skin eruption , 
Oculomucocutaneous s yndrome, Skin necrosis, Stevens -
Johnson s yndrom e (SJS), Toxic epidermal necrolysis (TENS)
Agranulocytosis and other 
cytopenic eventsAgranulocytosis, aplastic anemia, panc ytopenia
Other hypersensitivity 
reactionsOther suspected hypersensitivity to suspected drug  
Liver reactions Any event that qualifies as a liver laboratory trigger or event as 
defined in Appendix 2
While this list is intended as a guide to the investigator, other potential IDRs may arise. 

Novartis Confidential Page 103
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
16 Appendix 4: Blood collection logs
Table 16-1 Time schedule for blood sampling for safety , Total IgE and 
RAST/Immuno CAPtest
*For patients who discontinue study drug early and remain in the study (see Section 5.5.10 ), extra 
blood samples must be taken at the UNSCHEDULED -TD visit.

Novartis Confidential Page 104
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14

Novartis Confidential Page 105
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
17 Appendix 5: Spirometry  Guidance
Equipment
Spirometers must meet the specifications and performance criteria recommended in the 
American Thoracic Society  (ATS)/European Respiratory  Societ y (ERS) Standardization of 
Spirometry1. Spirometers must have the capacit y to print  tracings.  All spirometry  values 
should be reported at BTPS by  the method established by  the manufacturer.
Calibration
The spirometer should be calibrated every  morning before any spirometric measurements for 
the study  are performed. Calibration reports should be printe d and stored as source data at the 
site. 
Preparing the test subject
On study  days when spirometry  will be performed, patients should refrain from the following:
Coffee, tea, chocolate, cola and other caffeine -containing beverages and foods and ice -
cold be verages  for 4 hours prior to spirometry
Alcohol for 4 hours prior to spirometry
Strenuous activity  for 12 hours prior to spirometry 
Exposure to environmental smoke, dust or areas with strong odors 
Every  effort should be made to assure consistent testing conditions throughout the study .  A 
seated position with nose clips is recommended to reduce risks related to dizziness or sy ncope.  
When possible, spirometry  should be conducted by the same technician using the same 
spirometer.  To minimize the effects of diurnal variation on lung function, spirometry  visits 
should start at approximately  the same time of day at each visit.  
Performing Spirometry
The subject’s age, height and gender will be entered into the spirometer.  It is important that 
the height is measured accuratel y at the study  site. Spirometry , an effort-dependent test, 
requires careful instruction and cooperation of the subject.  The technician should ensure a 
good seal around the mouthpiece, and confirm that the subject’s posture is correct. The 
subject should be instructed to perform a maximal inspiration, followed by maximum forced 
expiration until no more air can be exhaled or for at least 6 seconds. Expiration must be rapid 
with exertion of maximal effort. The results of spirometry  should meet the ATS/ERS criteria 
for acceptability  and repeatability . Acceptability  criteria should be applied before repeatability 
is determined.  
 
 

Novartis Confidential Page 106
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
Acceptability
An acceptable maneuver has the following characteristics: 
No hesitation or false start;
A rapid start;
No cough, especially  during the first second of the maneuver;
No glottic closure or obstruction by tongue or dentures
No earl y termination of exhalation (minimum exhalation time of 6 sec onds is 
recommended, or no volume change for at least 1 second) or the subject cannot continue 
to exhale further
Repeatability
The 2 largest  FEV 1values from 3 acceptable maneuvers should not vary by more 
than 0.150 L.
If patient does not meet the repeatabilit y or acceptability  criteria during the screening epoch , 
patient may  be rescreened once or allow one spirometry  retest.
Recording of data
The greatest FEV1  from any of the acceptable curves are recorded. (The greatest 
FEV1  may  not necessarily  result from the same acceptable curve).  
Predicted normal
For all subjects, this study  will utilize the global lung function 2012 equations (GLI2012) 
published by  Quanjer et al 20122or Japanese Respiratory  Societ y3.
Reversibility
All rever sibility  evaluations should follow the recommendations of the ATS/ERS Task force: 
Standardization of Lung Function Testing1. A pre-bronchodilator spirometry *assessment 
should be performed after 
withholding of specified medications as specified in Table 5-2
“Medications to be withheld prior to spirometry ”.
Administer 400µg of salbutamol/albuterol (or equivalent) following the completion of the pre -
bronchodilator assessment *.  
Subjects will be considered reversible if an increase of at least 12% (and 200 ml) is
demonstrated after administration of the salbutamol/albuterol.
*NOTE : At visits with two pre-dose spirometry  assessments (please see Table 6-1for 
schedule of assessments) the FEV 1from the 2ndpre-dose spirometry assessment (performed 

Novartis Confidential Page 107
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
approximately  15 min prior to in-clinic witnessed study  drug administration) should be used
forFEV1 (pre -bronchodilator) .
17.1 References for appendix
1Miller MR et al (2005) Standardization of L ung Function Testing . Eur Resp J ; 26:153 -161.
2Quanjer PH, Stanojevic S, Cole TJ, Baur X, L  Hall GL , Culver B, Enright PL , Hankinson J L, 
Zheng J, Stocks J and the E RS Global L ung Function I nitiative (2012) Multi ethnic reference 
values for spirometry  for the 3 -95 year age range: the global lung function 2012 equations. 
Report of the Global Lung Function Initiative (GLI), ERS Task Force to establish improved 
Lung Func tion Reference Values. Eur Resp J; 40:1324-1343.
3 Kubota, Kobayashi, Quanjer PH, et al. Reference values for spirometry, including vital 
capacity , in Japanese adults calculated with the LMS method and compared with previous 
values. Clinical Pulmonary  Functions Committee of the Japanese Respiratory  
Society .Respiratory  Investigations 2014, 242
-250.

Novartis Confidential Page 108
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14

Novartis Confidential Page 109
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
19 Appendix 7: Estimated Equivalence of Inhaled 
Corticosteroids
From the Global Strategy for Asthma Management and Prevention 2016, © Global I nitiative 
forAsthma (GINA) all rights reserved. Available from http://www.ginasthma.org
.
For the purposes of calculating total daily  dose for the study , if the table has the medi cation 
dose listed by  DPI, but not 
by MDI ,then use the DPI  classification as thereference and vice 
versa (i.e., if the table has the medication dose listed by  MDI, but not by DPI, then use the 
MDI  classification) .

Novartis Confidential Page 110
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
20 Appendix 8: A sthma Control Questionna ire
A SAMPLE of the Asthma Control Questionnaire – 5 is included below.  The format of the 
administered test may  vary .

Novartis Confidential Page 111
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14

Novartis Confidential Page 112
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
21 Appendix 9: Asthma Quality  of Life Questionnaire for 12 
years and older (A QLQ+12)
A SAMPLE of the Asthma Quality  of Life Questionnaire for 12 years and older is included 
below.  The format of the administered test may  vary .

Novartis Confidential Page 113
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14

Novartis Confidential Page 114
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14

Novartis Confidential Page 115
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14

Novartis Confidential Page 116
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14

Novartis Confidential Page 117
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14

Novartis Confidential Page 118
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14

Novartis Confidential Page 119
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14

Novartis Confidential Page 120
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14

Novartis Confidential Page 121
Amended Protocol Version v03 –Clean Protocol No. CQAW 039A23 14
